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Resumo
O Rabdomiosarcoma (RMS) e˜ o sarcoma mais comum em crianças e carac-
teriza-se pela expressão de proteínas de músculo esquelético, como os fatores
de transcrição miogénicos (MYF5, MYOD1, MYOG e MRF4/MYF6) e as proteí-
nas estruturais Desmina e Miosina. O tratamento agressivo é eficaz em eliminar
células com capacidade de auto-renovação, mas conduz frequentemente a ele-
vada toxicidade. As células com capacidade de auto-renovação que evadem o
tratamento conduzem a recidivas. É portanto importante investigar os mecan-
ismos que regulam estas células em Rabdomiosarcomas, para que se possam
desenvolver tratamentos direcionados e menos tóxicos que efetivamente elim-
inem estas células, prevenindo recidivas.
Foi desenvolvido previamente um modelo de peixe-zebra que recapitula mor-
fologicamente e em termos moleculares o subtipo histológico Rabdomiosarcoma
embrionário (ERMS). Através da análise molecular das células destes tumores
identificou-se uma sub-população de células com capacidade de auto-renovação
que expressa o fator de transcrição miogénico MYF5 e um conjunto de genes car-
acterísticos de células satélite do músculo ativadas. Dado que MYF5 e MYOD1
são necessários para o desenvolvimento embrionário de músculo, e aos papéis
que desempenham na auto-renovação de células satélite no processo regener-
ativo, nós postulámos que estes genes e os seus genes-alvo podem ser respon-
sáveis por induzir programas de auto-renovação numa sub-população de células
destes tumores. Através da utilização de uma série de peixes-zebra transgénicos
multi-coloridos, em que diferentes sub-populações de células do tumor são distin-
guidas com base na expressão de genes de diferentes estádios de diferenciação,
visuaizámos populações distintas de células em proliferação e com capacidade
de auto-renovação que expressam MYF5 e células migratórias que expressam
MYOG, in vivo. Adicionalmente, mostrámos funcionalmente que MYF5 é um
marcador destas células propagadoras de tumores ou TPCs em RMS.
Para além de ser um marcador, mostramos ainda que MYF5 é capaz de in-
duzir esta capacidade de auto-renovação a células diferenciadas contidas nos
RMSs no modelo de peixe-zebra. Estes tumores surgem mais cedo, com maior
v
penetrância e são tendencialmente maiores do que os tumores-controlo. Con-
sistentemente com os papéis redundantes de MYF5 e MYOD1 nos processos de
desenvolvimento, regeneração e auto-renovação de células estaminais de mús-
culo, indentificámos a existência de duas classes de ERMS em células humanas,
expressando níveis mais elevados de um ou outro destes fatores. Ambos os fa-
tores são necessários para progressão no ciclo celular, viabilidade e crescimento
in vitro e/ou in vivo. Através da técnica ChIP-seq, observámos ainda que MYF5
e MYOD1 se ligam a elementos regulatórios comuns no ADN relacionados com
estados de diferenciação muscular e progressão no ciclo celular.
Propomos assim um modelo em que MYF5 e MYOD1 regulam programas
moleculares comuns de auto-renovação e crescimento em Rabdomiosarcoma, à
semelhança da redundância dos seus papéis no desenvolvimento e regeneração
de músculo. Em suma, os nosso dados são consistentes com a ideia de que
vias de auto-renovação em tumores são semelhantes às de células estaminais
do tecido não-maligno e de que estes processos são ativados aberrantemente
durante a transformação maligna, um conceito emergente na biologia do cancro.
Palavras Chave
Rabdomiosarcoma; MYF5; MYOD; Músculo; Cancro; Células Estaminais;
Peixe-zebra
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Abstract
Rhabdomyosarcoma (RMS) is the most common pediatric sarcoma with skele-
tal muscle differentiation features, such as the expression of Myogenic Regulatory
Factors (MRFs) (MYF5, MYOD1, MYOG, MRF4/MYF6) and skeletal muscle struc-
tural proteins (Desmin and Myosin). The aggressive treatment regimen eliminates
self-renewing cells, but often leads to toxicity. Remaining self-renewing cells can
evade treatment and lead to relapse. Understanding the molecular mechanisms
of self-renewing cells in these cancers is thus paramount for the development
of less toxic, targeted treatments that effectively eliminate these cells to prevent
relapse.
A transgenic zebrafish model that is morphologically and molecularly similar
to the human ERMS subtype was developed previously. Molecular analysis of
mononuclear ERMS cells identified a sub-population of self-renewing tumor cells
that is most similar to a MYF5-expressing, activated satellite cell. Given that
MYF5 and MYOD1 are required for normal muscle development, are involved in
muscle regeneration, and have roles in satellite cell self-renewal, we hypothe-
sized that these genes and their transcriptional targets are responsible for elicit-
ing stem cell self-renewal programs in a subset of ERMS cells. Through a series
of transgenic multi-colour zebrafish, where sub-populations of RMS cells are la-
belled based on the expression of muscle differentiation markers, we were able to
image discrete populations of proliferating MYF5-positive self-renewing cells and
migratory MYOG-positive cells within RMS in live animals. Furthermore, we show
that MYF5 is a marker of functionally-defined ERMS Tumor Propagating Cells.
Additionally to being a marker of these cells, we show that MYF5 is sufficient
to confer self-renewal to differentiated zebrafish ERMS cells. These tumors ini-
tiate earlier, have higher penetrance and a tendency to be larger than control
tumors. Consistent with redundant roles for MYF5 and MYOD1 in muscle de-
velopment, regeneration and stem cell self-renewal, we identified two classes of
human ERMS that express either high levels of MYF5 or MYOD1, with either MRF
being required for sustained tumor growth in vitro and/or in vivo. ChIP-seq exper-
iments went on to reveal that MYF5 and MYOD1 bind common DNA regulatory
ix
elements likely to arrest human ERMS in early stages of muscle development
while simultaneously promoting cell cycle progression.
We suggest a model where MYF5 and MYOD1 converge on common molec-
ular pathways to regulate human RMS growth and self-renewal, similar to their
overlapping roles in muscle development and regeneration. Taken together, we
show that cancer self-renewal pathways are likely shared with their non-malignant
counterparts and that these processes are aberrantly activated during malignant
transformation, an emerging concept in cancer biology.
Keywords
Rhabdomyosarcoma; MYF5; MYOD; Muscle; Cancer; Stem Cells; Zebrafish
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General Introduction
"We are drowning in information while
starving for wisdom. The world henceforth
will be run by synthesizers, people able to
put together the right information, think
critically about it, and make important
choices wisely."
Edward O. Wilson
Consilience: the Unity of Knowledge (1998)
1.1 Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue sar-
coma, with an incidence of 4 to 7 cases per million children in the United States of
America (USA) (Ognjanovic et al., 2009; Perez et al., 2011). This corresponds to
a conservative estimate of an average of 300 children per year in North America,
with similar numbers reported in Europe (Weihkopf et al., 2008). As all pediatric
malignancies it is thus a rare disease, a fact that has contributed to the relatively
slow progress in our understanding of its basic molecular mechanisms and toward
better and targeted treatments on the clinical front (Sokolowski et al., 2014).
RMSs comprise heterogeneous tumors with common features of skeletal mus-
cle differentiation, including muscle striations by electron microscopy and pro-
tein expression of key factors involved in skeletal muscle differentiation (such as
1
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MYOD1, MYOG and Desmin) (Sebire and Malone, 2003). The anatomical loca-
tion of primary tumors is fairly diverse, with a predominance for the regions of
the head and neck, extremities and genitourinary tract (reviewed in Kikuchi et al.,
2011).
Treatment includes intensive, multi-agent chemotherapy, radiation therapy and
surgical resection (reviewed in Hawkins et al., 2014). Risk stratification and the
employment of aggressive therapy regimens has provided relatively high survival
rates (ranging from 70% to 95% in low-risk, 35% in intermediate-risk and 15% in
high-risk groups), which have remained relatively constant over the last 25 years
(Ognjanovic et al., 2009; Perez et al., 2011; Weihkopf et al., 2008). Moreover, the
current treatment modality often leads to high levels of short-term or long-term
toxicity (reviewed in Hawkins et al., 2014). Importantly, survival upon relapse re-
mains one of the major clinical challenges in treating this disease (Hettmer et
al., 2014). Several initiatives have been developed toward promoting drug de-
velopment for rare pediatric cancers. These include patent protection policies,
alleviated numbers in clinical trial design and a shorter review process from regu-
latory agencies (FDA and EMA) (Sokolowski et al., 2014). However, despite such
efforts, treatment options for RMS have largely remained unchanged (Malempati
and Hawkins, 2012).
RMSs can be subdivided into two most common RMS subtypes - Embryonal
RMS (ERMS) and Alveolar RMS (ARMS) - which differ in histology, genetics,
clinical presentation and outcome (Kikuchi et al., 2011; Saab et al., 2011) (see
Figure 1.1).
ARMS comprises approximately 25 to 30% of the RMS cases in the USA
and affects older children and adolescents. It generally arises in the trunk and
extremities and is associated with poorer outcome (Ognjanovic et al., 2009; Perez
et al., 2011).
The majority of ARMS is accompanied by recurrent reciprocal chromosomal
translocations that fuse PAX3 or PAX7 with FOXO1 to generate hyper-stable
chimeric PAX3 or PAX7-FOXO1 oncogenes (therefore designated Fusion Posi-
tive RMS (FP-RMS)) (Barr et al., 1993; Shapiro et al., 1993). Several affected
downstream pathways include IGF1R, FGFR4 and MET. Fusion Negative RMS
(FN-RMS) ARMS cases are often accompanied by ALK overexpression, which is
also common to the ERMS subtype (Hawkins et al., 2014).
ERMS is the most common RMS subtype (60 to 70% of the cases), has an
earlier onset and includes most of the head and neck cases (Ognjanovic et al.,
2009; Perez et al., 2011). It is associated with better prognosis under current
2
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Figure 1.1: Representative hematoxylin- and eosin-stained sections of ERMS
and ARMS rhabdomyosarcoma. The insets show typical immuno-histochemical
staining for MYOG in each subtype (reproduced with permission from Saab et al.,
2011).
treatment but in recurring and/or metastatic cases the survival rates decrease
drastically to less than 25% (Breneman et al., 2003).
The genomic landscape of ERMS is more complex with no fusion events
(solely comprising FN-RMS) but a recurrent chromosomal alteration (Loss of
Heterozygozity (LOH) of 11p15.5) and specific mutations including members of
the TP53 pathway (TP53 or CDKN2A loss, MDM2 overexpression), RAS path-
way (comprising HRASG12V, KRASG12D, or NRAS mutations) and deletions of
NF1, FGFR4 pathway, IGF2 and CDKN1C. Other cases include dysfunctional
SHH signaling (PTCH1 and GLI loss), RB1 loss or PI3K and CTNNB1 activation
(Sokolowski et al., 2014).
Recent genomic studies have provided a more complete description of the
molecular alterations in RMS. Through a series of whole-genome, whole-exome,
and transcriptome sequencing of primary and recurrent rhabdomyosarcoma sam-
ples, Chen et al., 2013 have confirmed the existence of a common set of Copy
Number Variations (CNVs) (more significant in FN-RMS) and fusion events (such
as PAX3- or PAX7- FOXO1) in RMSs. The most common consensus gene mu-
tations in ERMS were on the Rat Sarcoma Viral Oncogene Family (RAS) path-
way and were particularly prevalent in high and intermediate risk clinical groups.
Additional common mutations were found in TP53 and FGFR pathways. Addi-
tionally, by analyzing pre- ad post- treatment matched samples, the authors were
also able to describe the disappearance and emergence of specific mutations
during the process of tumor evolution (for example, in ALK). This is explained
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at least partially by the existence of intra-tumor heterogeneous clones that har-
bor specific LOH and CNV mutations. Also, arising from Ribonucleic Acid (RNA)
sequencing (RNA-seq) and methylation analyses, this study confirmed several
reports pointing to an enrichment of WNT and SHH signalling pathway genes
and/or mutations in FN-RMS tumors (Annavarapu et al., 2013; Chen et al., 2014;
Zibat et al., 2010) . Finally, this study points to the MAPK pathway and functional
sensitivity to oxidative stress-inducing drugs as a potential actionable hallmark of
FN-RMS tumors.
Figure 1.2: The genomic landscape of pediatric RMS highlighting candidate al-
terations. Demographic characteristics, histologic subtypes, and selected genes
with copy-number alterations or somatic mutations across 147 rhabdomyosar-
coma cases. Unique sample identifier and sequencing platform. Sex: males in
blue, females in pink. Age: years at diagnosis divided into fewer than 5 years and
greater than 5 years. Histologic diagnosis: red, ARMS; blue, ERMS including
spindle and botryoid subtypes; gray, RMS NOS. Mixed alveolar and embryonal
histology in green. Copy-number gains and losses for selected genes. Blue,
losses; red, gains; green, LOH. Selected genes with somatic mutations. Pur-
ple, fusion protein; black, missense; orange, nonsense/splice site/indel mutations
(reproduced with permission from Shern et al., 2014).
The largest-scale study to date was reported by Shern et al., 2014 (see Fig-
ure 1.2). Similar to what was reported by Chen et al., 2013, PAX3- and PAX7-
FOXO1 fusions were found in a majority of ARMS FP-RMSs. Mutations in the
RAS pathway, TP53 cell cycle regulators plus other Receptor Tyrosine Kinases
4
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(RTKs) such as FGFR4 were found in FN-RMS. Additionally, mutations were
found in genes involved in DNA damage (ex: ATM), muscle cell differentiation
(MET, MYOD1), MAPK, chromatin modification, induction of apoptosis and in-
sulin receptor signaling (IGF1R and IGF2) predominantly in FN-RMS and MYCN
in FP-RMS. Importantly, several altered genes in FN-RMS (such as MET and
MYOD1) were known downstream PAX3 and PAX3-FOXO1 targets, suggesting
common mechanisms underlying cancer processes in both groups.
Taken together, these reports highlight common mutations of the RTK, RAS,
and PI3K axis in 93% of the FN-RMS cases, providing a framework for genomics-
directed therapies that might improve outcomes for patients with RMS.
Given the heterogeneous molecular presentation of the classical histological
subtypes, including ARMS, ERMS and also the less common Undifferentiated
Pleomorphic Sarcoma (UPS), stratification based on presence or absence of
FOXO1 fusions was shown to be preferable, by dividing RMS simply into FP-RMS
and FN-RMS (Williamson et al., 2010). Additionally, within each clinical subgroup,
several molecular marker signatures have emerged that provide a better predic-
tive and prognostic alternative (Davicioni et al., 2010; Hingorani et al., 2015).
Moving forward, a better mechanistic understanding of the involvement of
these pathways in tumor growth, metastasis and especially relapse may help to
establish more prognostic markers and educate the development of new, efficient
and less toxic therapies. The recent emergence of novel genomic and transcrip-
tomic analysis studies (mentioned above) as well as the establishment and ex-
ploitation of diverse animal models that recapitulate this heterogeneous disease
(discussed below, and the purpose of this work) should contribute to a better
understanding of the biology of these tumors in the near future.
5
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1.2 RMS as an aberrant skeletal muscle differentia-
tion tissue
In spite of all differences between RMS cases, they share the inability to
achieve terminal myogenic differentiation.
During embryonic skeletal muscle development, lineage-specific basic Helix-
loop-Helix (bHLH) Myogenic Regulatory Factors (MRFs) act as competing bind-
ing partners of the Transcription Factor 3/ E2A (TCF3), Transcription Factor 4/
E2-2 (TCF4) and Transcription Factor 12/ HEB (TCF12) and orchestrate a faith-
ful succession of cellular states that ultimately leads to the formation of skeletal
muscle fibers (Figure 1.3) (Buckingham and Rigby, 2014; Tapscott, 2005). These
events are similarly recapitulated in response to injury in the adult tissue (Taj-
bakhsh, 2009).
In RMS, albeit the characteristic expression of these markers (PAX3, PAX7,
MYF5, MYOD1, MRF4/MYF6 and MYOG) (Barr, 2001; Sebire and Malone, 2003),
the tissue acts as dysfunctional developing muscle that is locked in incomplete
stages of the myogenic differentiation cascade by several mechanisms. In recent
years, great effort has been placed toward understanding these mechanisms, so
that a differentiation strategy by means of overcoming those constrains could act
as a promising therapeutic avenue for the treatment of RMS.
A non-exhaustive but comprehensive overview of current knowledge on the
role of MRFs in muscle development and regeneration and on mechanisms that
are aberrantly operating in RMS tumors is provided below.
1.2.1 Myogenic Regulatory Factors and their role in muscle
development and regeneration
The role of MRFs in muscle specification has been long appreciated, since the
first reports of the capacity of MYOD1 (Tapscott et al., 1988) and MYF5 (Braun
et al., 1989) to specify skeletal muscle cells in vitro in fibroblast to myoblast con-
version assays.
From the very beginning, the complex redundancy and interactions between
these MRFs was evident. While single MYOD1 (Rudnicki et al., 1992) and MYF5
(Braun et al., 1992, 1994) knock-out mice develop with minor defects, double
MYF5/MYOD1 knock-out animals are born immobile and die soon after birth
(Rudnicki et al., 1993). However, different muscle populations were later shown to
be more reliant on the action of one of these factors. For example, limb muscles,
6
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Figure 1.3: Epistatic relations among myogenic bHLH factors. Figure shows
acting MRF networks and main signaling operating during trunk skeletal muscle
specification in mammalian organisms (reprinted with permission from Tapscott,
2005)
originated from the hypaxial somite, were shown to be mostly MYOD1-dependent
and MYF5-independent (Tajbakhsh and Buckingham, 1994) and the esophagus
muscle seems to be more reliant on MYF5 in both mouse (Kablar et al., 2000)
and zebrafish (Minchin et al., 2013). This differential requirement is at least par-
tially due to the signaling pathways established in the developing embryo and
emanating from the neural tube, influencing the epaxial myotome, and the dorsal
ectoderm, influencing the hypaxial myotome (see Figure 1.3) (Cossu et al., 1996;
Kablar et al., 1997; Tajbakhsh et al., 1998; Tapscott, 2005).
In addition to this spatial heterogeneity in MRF requirement, there is also dif-
ferential temporal regulation throughout the cell cycle, with MYF5 protein being
degraded at Mitosis while MYOD1 is still present (Doucet et al., 2005; Lindon et
al., 1998; Lindon et al., 2000; Singh and Dilworth, 2013), and in order of emer-
gence, with MYF5 being firstly expressed in vivo (Buckingham, 1992).
A more recent report shined new light on the specific roles of these factors
in the induction of myogenic programs. Through Chromatin Immunoprecipita-
tion Sequencing (ChIP-seq) studies in mouse embryonic fibroblasts expressing
physiologically-relevant levels of MYF5 and/or MYOD1, Conerly et al., 2016 show
that they have overlapping binding sites but distinct roles. On one hand, MYF5
is proficient in inducing histone acetylation but fails to recruit RNA polymerase II
to elicit robust gene activation, whereas MYOD1 induces histone acetylation, re-
cruits Pol II, and robustly activates transcription at these physiological expression
levels, in a protein domain-dependent manner. Furthermore, when MYF5 levels
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are expressed to higher levels, it is capable of activating transcription of down-
stream targets with similar efficiency. This observation provides an explanation
for the higher efficiency of MYOD1 in pushing precursor cells toward myogenic
differentiation in conversion assays (Ishibashi et al., 2005).
Besides the role of MYF5 and MYOD1 in embryonic development, these fac-
tors are also needed for the process of muscle regeneration from satellite cells,
the resident stem cells of adult skeletal muscle. Initial findings that MYOD1
knock-out mice have delayed regeneration were later explained by the obser-
vation that the compensating MYF5-positive, MYOD1-negative cells isolated from
mature muscle are less proficient in inducing MYOG expression and myotube
formation (Yablonka-Reuveni et al., 1999). MYF5 null mice also show aberrant
muscle regeneration with a progressive muscle fibre hypertrophy, delayed differ-
entiation, adipocyte accumulation, and fibrosis after freeze-injury (Gayraud-Morel
et al., 2007). The functional redundancy and divergence of specific roles of these
factors is thus also evident in post-natal myogenesis. Additionally, the existence
of defined heterogeneous populations of muscle satellite cells, that express MYF5
or not, is still a matter of active research. Reports of this heterogeneity, initially
reported by Gensch et al., 2008, Haldar et al., 2008 and Gayraud-Morel et al.,
2012 are currently under active debate (Comai et al., 2014; Haldar et al., 2014).
MRFs are therefore crucial determinants of skeletal muscle tissue during embry-
onic development and post-natal myogenesis.
Other bHLH proteins are also crucial in the specification and differentiation of
other tissues with related embryo origins. The most classical examples are the
neurogenic/glial factors Neuronal Differentiation 1 (NEUROD1), Oligodendrocyte
Transcription Factor 1 (OLIG1/2) and Achaete-Scute Family bHLH Transcription
Factor 1 (ASCL1) that are specified within the neural tube (Imayoshi and Kageyama,
2014). Interestingly, MYF5-expressing cells have been detected in the develop-
ing neural tube, most likely due to failure in responding to positional cues in the
developing embryo (Tajbakhsh and Buckingham, 1995; Tajbakhsh et al., 1996;
Tajbakhsh et al., 1994). This myogenic to neuronal plasticity was recently further
explored by Fong et al., 2015, which demonstrated that MYOD1 can be converted
to NEUROD1 simply by replacing its DNA binding domain to induce neuronal dif-
ferentiation from fibroblasts. Additionally, MYF5 was also recently shown to be ex-
pressed in myo-adipogenic precursors (Sanchez-Gurmaches and Guertin, 2014;
Sanchez-Gurmaches et al., 2012).
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1.2.2 Mechanisms of impaired skeletal muscle differentiation
in RMS
Given that MRFs expression is a common feature of all RMSs, a major effort
has been put toward understanding the epigenetic and transcriptionally elicited
mechanisms that prevent complete muscle differentiation. This knowledge could
in turn translate into the exploitation of those mechanisms to improve tumor dif-
ferentiation ultimately exhausting self-renewing cells - a therapeutic approach re-
ferred to as differentiation therapy.
Differentiation therapy has been successful in treating other malignancies.
The most striking example is in Acute Promyelocytic Leukemia (APL) treatments,
which benefited immensely from introduction of Retinoic Acid-induced differentia-
tion therapy to cure rates of approximating 80% (Stone et al., 1988) . Also in other
sarcomas, some compounds have been shown to effectively induce differentiation
in the clinical setting (in liposarcomas) (Demetri et al., 1999).
Below is an overview of the current knowledge on mechanisms of impaired
differentiation in RMS.
In the case of FP-RMS, the PAX3- and PAX7-FOXO1 fusions were shown to
directly increase the stability of MRFs, desensitize them to cytoplasmic accumu-
lation and foster the over-activation, or de novo activation of genes involved in
cell cycle regulation, growth and apoptosis resistance, while suppressing down-
stream pro-differentiation genes (Jothi et al., 2012). Surprisingly, PAX3-FOXO1
does not impair the Myogenic Differentiation 1 (MYOD1) pro-differentiation activity
by directly inhibiting its transcription, localization, phosphorilation or subsequent
interaction with its binding partners. It appears instead to directly affect the chro-
matin state around MYOD1 target genes (such as the MYOG locus), as assessed
by in vitro studies using well-established PAX3-FOXO1 positive ARMS cell lines
(reviewed in Keller and Guttridge, 2013).
Interestingly, in FN-RMS, MYOD1 function is impaired by similar mechanisms,
despite the absence of the fusions. In the ERMS cell line RD, MYOD1 activity
is inhibited partially due to an increased expression of Musculin (MSC) and of a
spliced form of TCF3, competing for binding to E-box motifs at the target genes
(Yang et al., 2009). Additionally, MYOD1-target microRNAs miR-133, miR-1 and
miR-206 are also deregulated (MacQuarrie et al., 2012; Rota et al., 2011; Sweet-
man et al., 2008) and expression levels positively correlate with clinical outcome
(Missiaglia et al., 2010). Chromatin-associated factors like the Histone Deacethy-
lase3 (HDAC3) and the Histone Methyl-Transferase (HMT) SUV39H1 add a layer
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of complexity to the differentiation cascade pathway and are deregulated in RMS
(Albacker et al., 2013; Demmerle et al., 2013; Mal, 2006; Storer et al., 2013).
Importantly, several reports have identified mutations in MYOD1 in primary RMS
samples (Agaram et al., 2014; Kohsaka et al., 2014; Szuhai et al., 2014).
The role of MYOD1 has been the central focus of mechanistic studies on RMS
differentiation. However, other parallel and cooperating pathways important for
skeletal muscle differentiation have also been implicated in recent years. MET
proto-oncogene, receptor tyrosine kinase (MET) is the receptor of the Hepatocyte
growth Factor (HGF). This pathway is over-activated in a variety of human can-
cers (Graveel et al., 2013) and drives tumor growth and metastasis. It is also rel-
evant to the muscle tissue as it is expressed in muscle precursors, inducing cell
proliferation and migration to their proper sites during development (Buckingham
and Montarras, 2008) and muscle regeneration (reviewed in Wagers and Conboy,
2005). MET over-activation occurs in some RMS cases (see Section 1.1) and
there is functional evidence for its implication in RMS tumor growth in xenograft
mouse models (Yan et al., 2009). Other muscle differentiation pathways that are
deregulated and implicated in RMS tumorigenesis include IL4R (Hosoyama et al.,
2011), TP53/MDM2 (Fiddler et al., 1996; Yang et al., 2009), WNT (Annavarapu
et al., 2013; Chen et al., 2014) and genes from the NOTCH family (Belyea et al.,
2011; Raimondi et al., 2012; Roma et al., 2011).
The increasing accessibility of ChIP-seq, RNA-seq and Whole Genome Se-
quencing (WGS) technologies has opened doors in recent years for a more com-
plete picture of the differentiation blockade in RMS. These include the above-
mentioned (Section 1.1) WGS studies of multiple, sometimes paired, patient-
derived samples (Chen et al., 2013; Shern et al., 2014) and the description of
the chromatin environment of muscle specific promoters in greater detail through
ChIP-seq (Cao et al., 2010a; Cao et al., 2010b; Conerly et al., 2016; Dilworth and
Blais, 2011; MacQuarrie et al., 2013a,b; Roy et al., 2002).
Toward the goal of finding novel therapeutic options to differentiate RMSs,
Chen et al., 2014 have screened for several drugs that would both differentiate
RMS cell lines in vitro, as assessed high throughput Immunofluorescence (IF)
for Myosin Heavy Chain (MyHC), and tumors in vivo in a zebrafish RAS-driven
ERMS model (see Subsection 1.4.1 below). The most relevant compounds
emerging are Glycogen Synthase Kinase 3 beta (GSK3b) inhibitors, a negative
regulator of the beta-catenin-dependent WNT pathway, thus conforming with con-
comitant genomics reports of WNT pathway de-regulation in RMS (Chen et al.,
2013; Shern et al., 2014). Also, Tremblay et al., 2014 showed that Yes Associated
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Protein 1 (YAP1) plays a role in the differentiation blockade by upregulating pro-
proliferative genes and interfering with MYOD1 and the pro-differentiation factor
Myocyte Enhancer Factor-2 (MEF2).
However, it is important to continue to explore these differentiation blockade
mechanisms before effective therapies can be translated into the clinic. It is pos-
sible that, due to the known plasticity of these cells toward different fates (See
Section 1.3) (Abraham et al., 2014; Rubin et al., 2011), incomplete differentia-
tion could push cells toward perhaps more aggressive cell states (Svalina and
Keller, 2014). Understanding intra- and inter-tumor heterogeneity and selection
and evolution processes in these tumors is thus paramount.
1.3 Tumor heterogeneity in Rhabdomyosarcoma
1.3.1 Inter-tumor heterogeneity and the RMS cell-of-origin
The precise cell-of-origin of RMS is currently controversial. It is possible that
the existence of several diverging reports and proposed cells-of-origin for RMS
simply reflects the biological heterogeneity of different tumors in different patients
and between animal models (reviewed in Kashi et al., 2015).
The question of the cell-of-origin and inter-tumor heterogeneity seems to be
biologically and clinically relevant, as shown by Abraham et al., 2014, whom re-
ported a trend for different sensitivities and response to pharmacological com-
pounds depending on the cell-of-origin of the ERMS tumor model deployed.
Rhabdomyosarcomas seem therefore to still encompass a heterogeneous
group of tumors. Recent discoveries of novel biomarkers and molecular strat-
ification (see Section 1.1), allied to a recent explosion in the cellular (Hinson
et al., 2013) and animal models available (Kashi et al., 2015) are furthering our
understanding of this heterogeneity and pave the way for better and tailored pre-
clinical studies (Langenau et al., 2015) and personalized care for RMS patients.
Mouse models of FP-RMS were first generated by Keller C. and colleagues
(Keller et al., 2004a,b). Importantly, PAX3-FOXO1 ARMS can arise from Myogenic
Regulatory Factor 4 (MRF4/MYF6)-expressing myoblast cells but not dermamy-
otome or satellite cells that express Paired box 7 (PAX7) (Keller and Capecchi,
2005). In contrast, tumors with ERMS histology are formed from either satellite
cells or myoblasts that eventually reinitiate molecular programs found in satellite
cells (Rubin et al., 2011). This and a similar study by Blum et al., 2013, where
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different oncogenic drivers are directed toward different cells of origin, point to
a model where RMS and UPS lie in a "continuum", with distinct but overlapping
cells-of-origin. Another model of ARMS histology PAX3-FOXO1 FP-RMS is ob-
tained by expressing the fusion protein in human skeletal muscle progenitor cells
in vitro and transplanting into immune-deficient mice (Linardic et al., 2007). When
the same cells are transformed with T/t-Ag, Telomerase Reverse Transcriptase
Catalytic Unit (TERT) and oncogenic Harvey RAS Homolog (HRAS)G12V, the tu-
mors generated have a ERMS or UPS histology, depending on the progenitor cell
subtype utilized (Linardic et al., 2007). Similarly, targeting Cyclin-Dependent Ki-
nase Inhibitor 2A (CDKN2A) and Kirsten RAS Homolog (KRAS)G12V mutations to
isolated mouse muscle progenitor cells leads to RMS of pleomorphic histology,
that are molecularly similar to both ERMS and ARMS (Hettmer et al., 2011). Ge-
netic alterations also seem to influence the site of RMS emergence. The Tumor
Protein p53 (TP53)/c-FOS double mutant mouse develops ERMS with high pene-
trance in the face and orbit (Fleischmann et al., 2003), while TP53/ERBB2 mutant
animals have a later onset of RMS in the genitourinary tract (Nanni et al., 2003).
More recently, Hettmer et al., 2015 also reported different metastatic behaviors
and histology for FN-RMS arising from different oncogenic lesions with KRAS and
p16/19 null tumors being more metastatic than Hedgehog-activated associated
tumors in mice.
These reports suggest that pathology and histological presentation can be
determined by the combination of cell-of-origin and oncogenic mutations that are
drivers of disease.
Another important theme underlying the question of the cell-of-origin and RMS
heterogeneity is the link between skeletal muscle regeneration and RMS. By
combining TP53 knock-out mice with the Duchenne Muscle Dystrophy mouse
model (mdx), Camboni et al., 2012 show that the presence of a regenerative
microenvironment collaborates with TP53 deficiency to induce ERMS in young
mice. Similarly, Tremblay et al., 2014 report that targeting YAP1 to activated,
but not quiescent satellite cells of muscle (through injury or through targeting to
MYF5-expressing cells in post-natal muscle), also leads to robust development of
ERMS. These reports provide a mechanistic explanation for reports of RMS in
patients (Rossbach et al., 1999) and mouse models (Chamberlain et al., 2007) of
muscle dystrophies.
Rhabdomyosarcomas were also shown to arise from non-myogenic precursor
cells. Intriguing reports of myosin-expressing RMS tumors in non-myogenic loca-
tions, such as in the bone marrow with no other primary location, have long led
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to speculation that these tumors could originate from Mesenchymal Stem Cells
(MSCells) (Charytonowicz et al., 2009; Lisboa et al., 2008; Shinkoda et al., 2009).
Additionally, Nitzki et al., 2011, 2015 have shown that RMS tumors can arise
from uncommited mesodermal progenitor cells in the context of Sonic Hedge-
hog (SHH)-driven FN-RMS. Consistent with the existence of MYF5-positive myo-
adipogenic precursors (see Section 1.2) (Sanchez-Gurmaches and Guertin, 2014;
Sanchez-Gurmaches et al., 2012), Hatley et al., 2012 have also derived RMS
from the adipogenic lineage. Given the plasticity of MSCells toward differenti-
ation of several mesenchymal lineages in vitro and the fact that MSCells have
been identified as the cell-of-origin of other sarcomas (Riggi et al., 2005, 2008)
it is possible that the origin of sarcomas is more closely linked than what was
previously appreciated.
1.3.2 Intra-tumor heterogeneity, tumor-propagating cells and
self-renewal in RMS
In 1976, Peter Nowell proposed a novel view of cancer as a dynamic process
of evolution of cell populations through selection of clones with diverse molecular
and functional properties (Nowell, 1976). This intra-tumor heterogeneity can be
accompanied by an increased capacity of some clones to self-renew as assessed
by transplantation assays into immune-compromised mice and, more recently,
through in vivo lineage tracing strategies (Beck and Blanpain, 2013; Driessens
et al., 2012). Whether tumor cell heterogeneity follows a hierarchical stem cell
model or a more stochastic model, or a combination of both (Magee et al., 2012;
Meacham and Morrison, 2013), it has been suggested that these self-renewing
clones, or Tumor Propagating Cells (TPCs), can be the ones escaping common
therapies and that are responsible for relapsed disease (Bedard et al., 2013).
Moreover, this clonal heterogeneity and tumor evolution processes pose a prob-
lem for clinical biopsy-based molecular diagnosis and stratification of treatment,
since sampling of a particular region of a tumor may not represent the full range
of cellular hierarchies and molecular alterations or be predictive of the emergence
of dominant or de novo dominant clones(Bedard et al., 2013).
Important steps toward resolving the issue of intra-tumor heterogeneity involve
the development of single-cell genomic technologies (Patel et al., 2014), the char-
acterization of isolated liquid biopsies from the blood (Alix-Panabieres and Pantel,
2016), active research in animal models to visualize and test self-renewal during
tumor initiation and progression in vivo (Beck and Blanpain, 2013) and the char-
acterization of self-renewing cell typesin vitro (Suva et al., 2014). Self-renewing
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TPCs have been already characterized in many malignancies. A molecularly-
defined cell population that can be enriched by cell surface markers has been
defined in breast cancer, acute myeloid leukemia and glioblastoma (Beck and
Blanpain, 2013; Dalerba et al., 2007; Eyler et al., 2011; Rheinbay et al., 2013).
However, a RMS-propagating cell that is required for continued tumor growth
has not yet been described in vivo in mice or humans. Komuro et al., 2007 iden-
tified a stem-like cell population in RMS cell lines, based on the exclusion of the
DNA binding dye, Hoechst 33342 and Flow Cytometry analysis. More recently,
Walter et al., 2011 found that ERMS form spheres (rhabdospheres) in a stem cell
medium containing defined growth factors over several passages. These spheres
have increased growth ability and express stem cell markers, including CD133,
that can select for subcultures with increased tumor-formation ability. The SHH
pathway, upregulated in these cells, has then been shown to play a role on self-
renewal in ERMS (Satheesha et al., 2015). Important findings toward RMS intra-
tumor heterogeneity have emerged from a zebrafish model of ERMS and will be
discussed in detail in Subsection 1.4.1, below.
1.4 Zebrafish models of cancer
Existing zebrafish cancer models were shown to mimic human disease and
were developed for diverse cancer types including T- and B-cell leukemia/lymphoma
(Langenau et al., 2003; Sabaawy et al., 2006), acute myeloid leukemia (Zhu-
ravleva et al., 2008), melanoma (Patton et al., 2005), pancreatic neuroendocrine
carcinoma (Yang et al., 2004), pancreatic adenocarcinoma (Park et al., 2008),
intestinal hyperplasia and fibrosarcoma (Le et al., 2007) and embryonal rhab-
domyosarcoma (Langenau et al., 2007) (see Subsection 1.4.1, below).
Zebrafish have many attributes that provide an advantage over other verte-
brate model systems to act as complementary models in studying cancer pro-
cesses. These include:
1. Fecundity : each female can produce 100-200 eggs per week and can mate
weekly;
2. Small size, which facilitates husbandry: many animals can be utilized to
increase statistic power of experiments;
3. External development : animals can be experimentally manipulated from the
one-cell stage through adulthood;
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4. Transgenesis: simple and mosaic transgenic approaches can create robust
cancer models and easily deliver fluorescent proteins to tissues of interest,
enabling in vivo cell tracking and imaging of tumor development;
5. Conserved molecular pathways in development and disease: zebrafish and
human malignancies share similar oncogenes and molecular pathway acti-
vation;
6. Cell transplantation: muscle, hematopoietic, and cancer cells can be en-
grafted into irradiated or syngeneic recipients allowing direct assessment of
self-renewal in vivo.
These advantages, recently reviewed in detail by White et al., 2013, make
zebrafish increasingly useful for studying cancer.
1.4.1 The RAS-driven zebrafish RMS model
Zebrafish rhabdomyosarcomas can be generated by injecting one cell-stage
embryos with linearized DNA containing a minimal rag2 promoter driving the ex-
pression of the human KRASG12D oncogene in the mononuclear component of
muscle (Langenau et al., 2007, 2008). RMS tumors develop with approximately
40% incidence at 40 days post fertilization (dpf) and are histologically and molec-
ularly similar to human ERMS as assessed by Immunohistochemistry (IHC) and
gene-expression analysis through Microarray.
Bioinformatics analyses of these tumors show two major molecular signa-
tures: one RAS-pathway-related, and one ERMS-specific, that includes the over-
expression of the MRF MYF5 (Langenau et al., 2007). A dual-fluorescence trans-
genic approach was used to label less differentiated mononuclear cells, including
satellite cells and myoblasts (using the rag2 promoter), and differentiated cells
(using the alpha-actin promoter). Subsequent cell transplantation and limiting
dilution analysis demonstrated the existence of a prospectively definable TPC
that is rag2-DsRed positive and alpha-actin-GFP negative and molecular analy-
sis showed that it resembles a muscle activated satellite cell signature with ex-
pression of myf5, m-cadherin and met, but not pax3 or pax7 or mature muscle
markers (Langenau et al., 2007).
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Importantly, co-injection of up to three linear DNA fragments was shown to co-
integrate in genomic Deoxyribonucleic Acid (DNA) and to be inherited equally and
co-expressed by daughter cells throughout the zebrafish embryonic development
(Langenau et al., 2008). This co-injection strategy allows for rapid and efficient
assessment of a modifying or oncogenic effect of an over expressed gene or the
multi-colour labelling of cell populations within tumors (see Figure 1.4).
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Figure 1.4: Coinjection strategies can be used to label distinct cell populations
within zebrafish RMS. (A) GFP fluorescent image of RMS developing in a rag2-
DsRED2+/alpha-actin-GFP+-injected animal. (B) GFP fluorescence in cryostat
section. (C) DsRED2 fluorescence image of injected fish shown in A. (D) DsRED2
fluorescence in cryostat section. (E,F) Merged images. Bars: B,D,F, 20um. (G)
FACS profile of a-actin-GFP transgenic animal injected at the one-cell stage with
rag2-DsRED2 and rag2-kRASG12D. (H-K) The four cell populations can be iso-
lated to relative purity by FACS. (L) Semiquantitative RT-PCR analysis confirms
that expression of DsRED2+ and GFP+ can be used to identify discrete popula-
tions of tumor cells based on their stage of muscle differentiation. (M) Microarray
analysis of sorted cell populations from three tumors (numbered 1-3 at top of heat
map) (reproduced with permission from Langenau et al., 2007)
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Novel Zebrafish Transplantation
Tools
"The art of research [is] the art of making
difficult problems soluble by devising means
of getting at them."
Sir Peter B. Medawar
Pluto’s Republic (1982)
2.1 Chapter 2 - Preamble
Allograft transplantation, from a tissue of a donor animal to another of the
same species, is the hallmark functional assay to assess tumor-propagating abil-
ity and self-renewal properties of stem cells and cancers. In zebrafish, this can
be achieved through the utilization of a unique syngeneic, genetically identical,
zebrafish line (Blackburn et al., 2011; Mizgirev and Revskoy, 2006; Smith et al.,
2010), by suppression of the immune system through dexamethasone treatments
(Stoletov et al., 2007) or sublethal irradiation (Smith et al., 2010), or by transplan-
tation into developing zebrafish larvae, prior to the emergence of a competent
immune system (reviewed in Stoletov and Klemke, 2008).
However, despite the widely recognized advantage of the utilization of immune-
compromised animals in mouse model studies (reviewed in Zhou et al., 2014),
similar immune-compromised zebrafish models were not available to date.
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In order to be able to perform experiments described in Chapter 4, and others,
I was involved in a team effort to develop a suite of these lines, particularly of the
ragE450fs mutant zebrafish.
2.2 Chapter 2 - Contribution
My contribution to this work:
• Maintenance of several transgenic zebrafish lines, including AB/a-actin-RFP,
TuAB/myf5-GFP, AB/myogenin-H2B-mRFP, AB/mylpfa-lyn-cyan, AB/mylpfa-
mCherry, AB/mylpfa-GFP, casper/myf5-GFP and generation by multiple ge-
netic crosses and maintenance of triple-colour myf5-GFP; myogenin-H2B-
mRFP; mylpfa-lyn-cyan zebrafish from previously-generated single trans-
genic lines;
• Generation of zebrafish Embryonal RMS (ERMS) primary and secondary
tumors from a variety of transgenic lines and genetic backgrounds;
• Optimization of protocols for efficient transplantation of normal and malig-
nant skeletal muscle cells into these immune-compromized zebrafish recip-
ients;
• Confocal microscopy imaging support;
• Performance of all experiments and writing of the publication Tenente et al.,
2014 to serve as a detailed methodology resource for the field.
2.3 Chapter 2 - Publications
These collaborations resulted in:
• A first-authored publication, reprinted in full in this Chapter
Tenente, I. M. et al. (2014). “Normal and Malignant Muscle Cell Transplanta-
tion into Immune Compromised Adult Zebrafish”. In: J. Vis. Exp. 94. ISSN: 1940-
087X. DOI: 10.3791/52597
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• Two co-authored publications, reprinted in full in Apendix A
Tang, Q. et al. (2014). “Optimized cell transplantation using adult rag2 mutant
zebrafish.” In: Nat. Methods 11, pp. 821–824. ISSN: 1548-7105. DOI: 10.1038/nm
eth.3031
Tang, Q. et al. (2016). “Imaging tumour cell heterogeneity following cell trans-
plantation into optically clear immune-deficient zebrafish”. In: Nat. Commun. 7,
p. 10358. ISSN: 2041-1723. DOI: 10.1038/ncomms10358. URL: http://www.natur
e.com/doifinder/10.1038/ncomms10358
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Abstract
Zebrafish have become a powerful tool for assessing development, regeneration, and cancer. More recently, allograft cell transplantation
protocols have been developed that permit engraftment of normal and malignant cells into irradiated, syngeneic, and immune compromised
adult zebrafish. These models when coupled with optimized cell transplantation protocols allow for the rapid assessment of stem cell function,
regeneration following injury, and cancer. Here, we present a method for cell transplantation of zebrafish adult skeletal muscle and embryonal
rhabdomyosarcoma (ERMS), a pediatric sarcoma that shares features with embryonic muscle, into immune compromised adult rag2E450fs
homozygous mutant zebrafish. Importantly, these animals lack T cells and have reduced B cell function, facilitating engraftment of a wide
range of tissues from unrelated donor animals. Our optimized protocols show that fluorescently labeled muscle cell preparations from α-actin-
RFP transgenic zebrafish engraft robustly when implanted into the dorsal musculature of rag2 homozygous mutant fish. We also demonstrate
engraftment of fluorescent-transgenic ERMS where fluorescence is confined to cells based on differentiation status. Specifically, ERMS
were created in AB-strain myf5-GFP; mylpfa-mCherry double transgenic animals and tumors injected into the peritoneum of adult immune
compromised fish. The utility of these protocols extends to engraftment of a wide range of normal and malignant donor cells that can be
implanted into dorsal musculature or peritoneum of adult zebrafish.
Video Link
The video component of this article can be found at http://www.jove.com/video/52597/
Introduction
Zebrafish are an excellent model for regenerative studies because they can regenerate amputated fins, as well as a damaged brain, retina,
spinal cord, heart, skeletal muscle and other tissues1. Stem cell and regenerative studies in adult zebrafish have largely focused on the
characterization of regeneration in response to injury, while identification of stem and progenitor cells from various tissues by cell transplantation
has only recently been explored2. Zebrafish have also become increasingly used for the study of cancer through the generation of transgenic
cancer models that mimic human disease3–10.
In the setting of cancer, cell transplantation approaches have become widely adopted and permit the dynamic assessment of important cancer
processes including self-renewal11, functional heterogeneity12,13, neovascularization14, proliferation, therapy responses15, and invasion16,17.
However, engrafted cells are often rejected from recipient fish due to host immune defenses that attack and kill the graft18. Several methods
have been used to overcome rejection of engrafted cells. For example, the recipient animals immune system can be transiently ablated by
low dose gamma-irradiation prior to transplantation18,19. However, the recipient immune system will recover by 20 days post-irradiation and kill
donor cells18. Alternatively, dexamethasone treatment has been used to suppress T and B cell function, providing longer immune suppressive
conditioning and facilitating engraftment of a wide range of human tumors for up to 30 days14. These experiments require constant drug dosing
and are limited to study of solid tumors. Long-term engraftment assays have used genetically-identical syngeneic lines20–22, where the donor and
recipient cells are immune matched. However, these models require transgenic lines of interest to be crossed into the syngeneic background
for more than four generations to produce fully syngeneic lines. To obviate issues of immune rejection in recipient fish, our group has recently
developed an immune compromised rag2E450fs homozygous mutant (ZFIN allele designation rag2fb101) line that have reduced T and B cell
function and which permit engraftment of a wide range of tissues23. Similar immune compromised mouse models have been used extensively for
cell transplantation of mouse and human tissues24.
Here, we present methods for transplantation of skeletal muscle and embryonal rhabdomyosarcoma (ERMS), a pediatric sarcoma that shares
features with skeletal muscle, into the newly described rag2 homozygous mutant zebrafish. The availability of an immune compromised adult
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zebrafish expands our ability to perform large-scale cell transplantation studies to directly visualize and assess stem cell self-renewal within
normal and malignant tissues. With this method, fluorescently labeled muscle cell preparations from adult α-actin-RFP25 transgenic zebrafish
robustly engraft in rag2 homozygous mutant zebrafish following injection into the dorsal musculature. Moreover, we demonstrate engraftment
and expansion of primary myf5-GFP; mylpfa-mCherry transgenic ERMS following intraperitoneal injection into rag2E450fs homozygous mutant
zebrafish. The utility of these protocols goes beyond the examples shown and can be easily applied to additional zebrafish regenerative tissues
and cancers.
Protocol
All animal procedures were approved by Massachusetts General Hospital Subcommittee on Research Animal Care, under protocol
#2011N000127.
Section 1. Skeletal Muscle Cell Transplantation into Adult rag2E450fs Homozygous Mutant
Zebrafish
1. Preparation of Adult Zebrafish Donor Skeletal Muscle Cells
1. Obtain transgenic adult zebrafish that have fluorescently labeled muscle. In this experiment, 30 α-actin-RFP donor fish25 were utilized to
transplant 1 x 106 cells per recipient fish.
2. Sacrifice donor zebrafish in 1.6 mg/ml tricaine methanesulfonate (MS222) for 10 min or until no operculum movement is evident.
3. Place donor fish on an absorbent paper towel and excise the dorsal muscle using a clean razor blade. The cut should be made near the anus
at a 45° angle to maximize tissue collection (as noted in Figure 1A). Place dissected tissue into a clean 10 cm Petri dish.
4. Add 500 μl suspension buffer (pre-chilled 0.9x Phosphate Buffer Saline (PBS) supplemented with 5% Fetal Bovine Serum (FBS)) to the
dissected tissue. Up to 10 donor zebrafish can be placed together in this volume.
5. Mince the tissue with a razor blade >20 times until cells are in a uniform suspension. The entire dorsal musculature is homogenized including
skin, bones and fins. Add 2 ml of suspension buffer. Using a 5 ml pipette, triturate the cell suspension ≥20 times to dissociate cells.
6. Filter the cell suspension through a 40 μm mesh strainer into a 50 ml conical tube placed on ice.
7. Wash the Petri dish with an additional 2.5 ml of suspension buffer to collect remaining tissue and filter through the same strainer and conical
tube, to a final volume of 5 ml (10 donor fish can be used per isolate).
 
NOTE: Skin, bones and fins will be excluded following filtration.
8. If applicable, combine similar suspensions into the same conical tube.
9. Count the total number of viable cells using trypan blue dye and a hemocytometer.
10. Reserve 500 μl for flow cytometry, if desired (optional, step 2).
11. Centrifuge cell suspension at 1,000 x g, for 10 min, at 4 °C.
12. Discard supernatant and resuspend cells at 3.33 x 105 cells/μl (0.9x PBS + 5% FBS). In total, 3 μl will be injected per recipient fish for a total
of 1 x 106 cells per recipient (step 3).
 
NOTE: Less than 3 μl of cell suspension should be transplanted into the recipient fish. If cell number is limiting, as low as 5 x 104 cells per
recipient can lead to successful engraftment (Table 1).
2. Flow Cytometry Analysis of Donor Skeletal Muscle Cell Preparation (Optional)
1. Isolate muscle from a wild type, non-transgenic fish as outlined in step 1.1. This sample serves as the negative control and is useful for
setting Flow Cytometry gates.
2. Add an appropriate viability dye. For example, add 5 μl of stock DAPI solution (500 ng/μl) to 500 μl of muscle preparation. Vortex slightly
prior to analysis. Acquire 5 x 103 to 1 x 104 events. Analyze wild type control samples first to place gates followed by analysis of muscle cells
isolated from transgenic fish.
 
NOTE: Flow cytometry analysis is usually performed within 1 hr after muscle tissue dissection, during which time the dissected cells retain
more than 60% viability (Figure 2). Cells should be kept on ice at all times. Total cell viability can be re-assessed prior to transplantation
using trypan blue dye and a hemocytometer.
3. Intramuscular Transplantation of Skeletal Muscle Cells into Adult rag2 Homozygous
Mutant Zebrafish
1. Clean a 10 μl 26S G micro-syringe by drawing in and expelling 10% bleach solution (5 times), followed by 70% ethanol (5 times), and then
followed by suspension buffer (0.9x PBS + 5% FBS, 10 times).
2. Anesthetize 2-4 month old homozygous rag2 mutant fish or wild type recipient fish (as controls) by adding single drops of tricaine
methanesulfonate (MS222, 4 mg/ml stock solution) into a Petri dish containing the fish in system water until operculum movements slow and
fish are still.
 
NOTE: Dose of tricaine anesthesia will depend on age and size of recipient zebrafish.
3. Place anesthetized recipient zebrafish on a damp paper towel or sponge, with the left side facing up.
4. Insert the syringe needle into the latero-dorsal musculature (refer to Figure 1A). Ensure that injections are performed at a 45° angle. Inject 3
μl of the cell suspension (prepared in step 1.12) per fish for a total of 1 x 106 cells per recipient.
5. Carefully transfer injected zebrafish into a clean tank using a plastic spoon to recover.
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6. Assess recipient zebrafish for engraftment rates at 10, 20, 30 days post-transplantation by imaging anesthetized fish under bright field and
epifluorescence microscopy.
Section 2. Embryonal Rhabdomyosarcoma (ERMS) Transplantation into Adult Homozygous
rag2 Mutant Zebrafish
4. DNA Microinjection of Zebrafish Embryos
1. Linearize the rag2-kRASG12D plasmid7 by digesting 10 μg of DNA with XhoI, at 37 °C for 6 hr or O/N.
2. Purify DNA by standard phenol:chloroform extraction and precipitate with ethanol. Resuspend in 20 μl of deionized water (alternatively,
commercial DNA fragment purification columns can be used).
3. Run the undigested and digested DNA on a 1% agarose gel and determine the concentration of DNA by spectrometer reading. Alternatively,
run samples at 1:1, 1:5, and 1:10 dilutions on a 1% agarose gel and quantify compared to a DNA ladder.
4. Prepare an injection mix at a final concentration of 15 ng/μl of digested rag2-kRASG12D DNA in 0.1 M KCl and 0.5x Tris-EDTA. The final
DNA amount injected in 2 nl of injection volume will be 30 pg.
 
NOTE: Up to three different DNA constructs can be efficiently co-injected in a maximum of 60 pg of DNA per embryo. These transgenes
become integrated into the genome and co-expressed within the developing tumor26.
5. Inject linearized rag2-kRASG12D into one-cell stage embryos essentially as described27 into a zebrafish strain of interest (Figure 1B).
Injections should be performed in the cell and not in the yolk for higher efficiency. In this experiment, a double transgenic AB-strain; myf5-
GFP, mylpfa-mCherry was used. Raise zebrafish using standard rearing protocols28.
 
NOTE: Injection survival is often dependent upon the zebrafish strain used. On average, 30% of injected embryos will develop ERMS.
300-600 embryos should be injected per experiment in order to ensure that enough GFP-positive and mCherry-positive primary tumors are
generated for transplantation and analysis.
5. Screening for Primary ERMS in Zebrafish Larvae
1. Observe injected zebrafish from 10 to 30 days post injection for the emergence of externally visible primary ERMS.
2. At 30 days post injection, anesthetize recipient zebrafish by adding single drops of tricaine methanesulfonate (MS222 4 mg/ml stock solution)
into a Petri dish containing fish system water until operculum movements slow and fish are still.
 
NOTE: Dose of tricaine anesthesia will depend on the age and size of recipient zebrafish. Primary tumor-bearing zebrafish require lower
doses of tricaine.
3. Select primary ERMS-bearing fish that are myf5-GFP-positive and mylpfa-mCherry-positive, using an epifluorescence microscope.
6. ERMS Tumor Preparation
1. Sacrifice selected primary ERMS-bearing zebrafish in 1.6 mg/ml tricaine methanesulfonate (MS222) for 10 min or until no operculum
movement is evident.
2. Process each tumor-bearing zebrafish separately. Place fish in a clean Petri dish and dissect around the tumor using a razor blade and fine
forceps (as shown in Figure 1B). Transfer the dissected tumor tissue to a clean Petri dish.
3. Add 100 μl of pre-chilled 0.9x Phosphate Buffer Saline (PBS) supplemented with 5% Fetal Bovine Serum (FBS). Mince tissue with a clean
razor blade >20 times until cells are in a uniform suspension.
4. Add 900 μl of the same buffer (0.9x PBS + 5% FBS), pipette up and down several times to dissociate cells using a 1000 μl filtered pipette tip.
Filter through a 40 μm mesh strainer into the corresponding 50 ml conical tube. Store on ice.
5. Wash the Petri dish with an additional 2-4 ml of buffer, and pass through the same mesh strainer and into the corresponding conical tube.
6. Centrifuge at 1,000 x g, for 10 min, at 4 °C.
7. Discard supernatant and resuspend in 100 μl of buffer.
8. Count the total number of viable cells using trypan blue dye and a hemocytometer.
9. Dilute cells to desired concentration in the same buffer (0.9x PBS + 5% FBS). Cells should be diluted to 5 x 103 cells/μl for transplanting 5 μl
per recipient zebrafish in a total of 2.5 x 104 cells per recipient.
10. Flow Cytometry analysis can also be performed with a small amount of the suspension from step 6.5 to quantize the relative ratios of
fluorescent cells within the sample.
 
NOTE: Set aside 100 μl of cell suspension (following filtering in step 3.5) and dilute with 400 μl of 0.9x PBS + 5% FBS suspension buffer for
Flow Cytometry analysis. To ensure proper gating, perform additional analysis using single transgenic tumor tissue or muscle isolated from
adult wild type, myf5-GFP and mylpfa-mCherry fish. Perform Flow Cytometry essentially as described in step 2 of Section 1.
7. Transplantation of ERMS into Adult rag2 Homozygous Mutant Zebrafish
1. Clean a 10 μl 26S G micro-syringe by drawing in and expelling 10% bleach solution (5 times), followed by 70% ethanol (5 times), and then
followed by suspension buffer (0.9x PBS + 5% FBS, 10 times).
2. Anesthetize recipient homozygous rag2 mutant fish by adding single drops of tricaine methanesulfonate (MS222 4 mg/ml stock solution) into
a Petri dish containing the fish in system water until operculum movements are slow and fish are still.
3. Place anesthetized recipient zebrafish on a wet paper towel or sponge, with the ventral side facing up.
4. Inject 5 μl of the cell suspension into the peritoneal cavity (2.5 x 104 cells per recipient).
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NOTE: The injection needle should be cleaned between injections of different tumors as described in step 4.1. 5 to 10 μl can be efficiently
transplanted intraperitoneally, depending on recipient fish size. Tumor engraftment can be accomplished by injecting 1 x 104 to 5 x 105
unsorted cells per recipient fish (Table 1).
5. Carefully place recipient zebrafish into a clean tank with a plastic spoon.
6. Assess recipient zebrafish for engraftment rates at 10, 20, 30 days post-transplantation by imaging anesthetized fish under bright field and
epifluorescence microscopy.
7. Utilize engrafted fish for downstream applications including Fluorescence Activated Cell Sorting (FACS) to assess differentiation status
(Figure 3H), standard histological analysis (Figure 3F), imaging therapy responses15, and/or serial transplantation approaches including
limiting dilution analysis11.
Representative Results
A procedure for preparing and transplanting skeletal muscle cells from α-actin-RFP transgenic donors into immune compromised homozygous
rag2 mutant zebrafish has been demonstrated (Protocol Section 1, Figure 1A and Figure 2). Skeletal muscle tissue was prepared from α-actin-
RFP transgenic donors and the resulting single cell suspension contained 84.3% viable cells as assessed by DAPI exclusion following Flow
Cytometry analysis (Figure 2B). RFP-positive cells comprised 35.3% of this single cell suspension (Figure 2C). Transplantation of cells into the
dorsal skeletal muscle of rag2 homozygous mutant recipient fish led to consistent and strong engraftment as assessed by differentiation of single
cells into multinucleated fibers (1 x 106 cells injected per fish, Table 1, Figure 2D-I). Wild type recipient fish failed to engraft muscle fibers over
the 30-day experiment (n = 13). By 10 days post transplantation, 9 out of 14 rag2 homozygous mutant zebrafish contained RFP-positive muscle
fibers near the site of injection (64.3%, Figure 2E,F). Importantly, engrafted RFP-positive muscle persisted to 30 days post-transplantation
(Figure 2G-I), with a subset of animals being followed for 115 days post-engraftment and exhibiting robust and persistent muscle engraftment
(data not shown). These results are similar to those reported previously by our group23 using the same protocol (Table 1).
We have also presented a method for the generation, preparation and transplantation of ERMS tumor cells into the peritoneal cavity of rag2
homozygous mutant recipient fish (Protocol Section 2, Figure 1B and Figure 3). ERMS were generated in double transgenic myf5-GFP; mylpfa-
mCherry fish that have been shown to allow the visualization of intra-tumoral heterogeneity and functional analysis of tumor cell subpopulations
following transplantation11. However, further molecular characterization of each subpopulation is difficult because fish are small when they
develop ERMS between 10 to 30 days of life and the number of tumor cells are limiting for downstream applications. One solution is to expand
tumor cell numbers by engrafting ERMS into adult recipient zebrafish. To date, similar experiments have been completed using CG1-strain
syngeneic fish and required in excess of 4 generations of backcrossing to develop syngeneic lines that were transgenic for myf5-GFP; mylpfa-
mCherry. To circumvent these issues, we demonstrated the utility of immune compromised rag2 homozygous mutant recipient zebrafish to
engraft primary ERMS from a AB-strain zebrafish. All primary ERMS engrafted into rag2 homozygous mutant animals, facilitating expansion
of the tumor (Table 1). Similar results were recently reported where 24 of 27 rag2 homozygous mutant zebrafish engrafted ERMS, while 0 of
7 wild type siblings engrafted disease23. A representative example of an engrafted ERMS is shown at 30 days post-transplantation in Figure
3E. Engrafted ERMS share histological features of embryonal rhabdomyosarcoma, similar to that found in the primary tumor (Figure 3B and
3F). FACS analysis confirmed that ERMS contained functionally distinct tumor propagating cells and differentiated cells that express myf5-GFP
and/or mylpfa-mCherry. Survival rates following the intraperitoneal injection procedure were in excess of 95%. Recipient zebrafish commonly
succumb from tumor burden after the 30 days post-transplantation time point.
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Figure 1. Protocol schematic for (A) normal and (B) malignant skeletal muscle cell transplantation into rag2 homozygous mutant
zebrafish. Optional steps are marked with (*).
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Figure 2. Skeletal muscle engraftment into rag2 homozygous mutant zebrafish. (A) α-actin-RFP transgenic donor zebrafish. (B) Cell
viability of isolated muscle cell suspension as assessed by DAPI dye exclusion and flow cytometry. (C) Proportion of RFP-positive cells found
within the muscle cell suspension from α-actin-RFP donor (red), compared to a wild type control (grey). (D-E) Merged bright field and fluorescent
images of wild type animals (D) or rag2 homozygous mutant fish (E) at 30 days post-transplantation. (F) Engraftment rates over time. Red
denotes number of engrafted animals while grey shows non-engrafted fish. Number of animals analyzed at each time point are indicated. (G-
I) High magnification images of boxed region in panel E shown at 10 (G), 20 (H) and 30 (I) days post-transplantation, showing retention of
differentiated muscle fibers over time (arrowheads). Scale bars equal 2 mm. Please click here to view a larger version of this figure.
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Figure 3. Transplantation of myf5-GFP; mylpfa-mCherry ERMS into rag2 homozygous mutant zebrafish. (A-D) rag2-kRASG12D induced
primary ERMS arising in AB-strain myf5-GFP; mylpfa-mCherry zebrafish at 30 days of life. (E-H) rag2 homozygous mutant zebrafish engrafted
with ERMS and analyzed at 30 days post-transplantation. (A, E) Merged bright field and fluorescent images of primary and transplanted ERMS.
Tumor area is outlined and arrowhead indicates injection site in E. (B, F) Hematoxylin- and eosin-stained paraffin sections of primary (B) and
engrafted ERMS (F) showing areas of increased cellularity associated with cancer. (C, G) Cell viability as assessed by DAPI dye exclusion and
flow cytometry. (D, H) Fluorescent tumor cell sub-populations, as assessed by flow cytometry. Scale bars equal 2 mm (A, E) and 50 μm (B, F).
Please click here to view a larger version of this figure.
 
Table 1. Engraftment results for muscle and ERMS cell transplantation. (*) denotes previously reported data using the same techniques23.
Data is reprinted with permission from Nature Methods. Please click here to view a larger version of this table.
Discussion
Efficient and robust engraftment of adult dorsal skeletal muscle was attained with a very simple cell preparation method followed by injection of
cells into the dorsal musculature of rag2 homozygous mutant fish. In general, intramuscular injection procedures were very robust, with some
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associated death immediately following the implantation procedure, ranging from 10% to 35% depending on experiment. Additional optimization
will likely center on utilization of smaller gauge needles for injection and development of stationary injection apparatus using a microscope and
micromanipulator, which will facilitate ease of implanting cells. Our approach also used unsorted muscle cells from donor animals and only
contained approximately 30% muscle progenitor cells. Use of transgenic reporter lines that label stem cells and FACS isolation will likely provide
enriched cell suspensions that lead to increased engraftment into recipient fish. Skeletal muscle cells could also be enriched and cultured prior
to transplantation, as previously described29. Remarkably, our results also indicate that the steps of niche establishment and differentiation of
donor muscle tissue occur before 10 days post transplantation, establishing this model as a robust and fast experimental platform to assess
muscle engraftment and regeneration. Moreover, these experiments starkly contrast with those completed in mice, where pre-injury of muscle
with cardiotoxin or barium chloride is required two days prior to engraftment30,31. It is likely that needle injury produced during the transplantation
procedure potentiates engraftment by stimulating the production of a regenerative environment within the recipient animal32,33. We also envision
that our method will be easily adapted to the transplantation of skeletal muscle tissue from younger zebrafish, allowing assessment of genetic
mutations that affect early skeletal muscle development but lead to lethality at the larval stages.
We have also provided a detailed protocol for engraftment of zebrafish ERMS by intraperitoneal injection into non-conditioned, rag2 homozygous
mutant fish. This approach was useful for expansion of double transgenic primary tumors without the need for generating tumors within a
syngeneic transgenic line. Our recent work has shown that cell transplantation approaches provide novel experimental models to assess ERMS
drug sensitivity in vivo, where a single tumor can be expanded into thousands of animals and assessed for effects on growth, self-renewal,
and neovascularization15. Moreover, we have successfully engrafted a wide range of tumors into rag2 homozygous mutant fish including T
cell acute lymphoblastic leukemia, melanoma, and ERMS23. Looking toward the future, we envision these lines will be useful for assessing
important functional properties of cancer in vivo including assessing intra-tumoral heterogeneity, invasion, metastasis, angiogenesis, and therapy
resistance. Moreover, the generation of rag2 homozygous mutant fish in the optically clear Casper strain zebrafish34 will likely facilitate direct
imaging of many of these hallmarks of cancer.
In total, we provide detailed protocols for the successful engraftment of fluorescently-labeled normal and malignant skeletal muscle in to adult
rag2 homozygous mutant immune compromised zebrafish.
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3
MYF5 is a Marker of TPCs in a
Zebrafish Model of ERMS
"[...] by the help of Microscopes, there is
nothing so small, as to escape our inquiry;
hence there is a new visable World
discovered to the understanding"
Robert Hooke
Micrographia (1665)
3.1 Chapter 3 - Preamble
A population that enriches for Tumor Propagating Potential was identified pre-
viously in the most undifferentiated, mononuclear compartment of the zebrafish
skeletal muscle. These cells were isolated by Fluorescence Activated Cell Sort-
ing (FACS) of rag2-DsRed-positive; alpha-actin-GFP-negative tumors and sub-
sequently transplanted by limiting dilution transplantation to assess efficient en-
graftment (Langenau et al., 2007).
By devising several multi-colour labelling approaches, this population was now
further narrowed into a myf5-GFP-positive, mylpfa-mCherry -negative population.
Furthermore, through live in vivo imaging, we were able to image for the first
time tumor initiation and intra-tumor heterogeneity in a model of ERMS at single-
cell resolution, based on the expression of muscle differentiation state-specific
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promoters. While proliferating, more undifferentiated myf5-GFP cells are the first
to expand from resident satellite cell-like cells, mid-differentiating, myoblast-like
myogenin-H2B-mRFP cells emerge later, seed new areas of growth and cross
collagenous matrix between myotomes as well as enter the vasculature. We
also describe that a subset of RMS cells undergoes fusion and differentiates into
aberrant long, multinucleated, mylpfa-lyn-cyan-positive muscle fibers.
My involvement in the last stages of this work led to the main focus of my
research work on the role of MYF5 and MYOD1 in RMS self-renewal and growth,
which is featured in Chapter 4.
3.2 Chapter 3 - Contribution
My contribution to this work:
• Maintenance of several transgenic zebrafish lines, including AB/a-actin-RFP,
TuAB/myf5-GFP, AB/myogenin-H2B-mRFP, AB/mylpfa-lyn-cyan, AB/mylpfa-
mCherry and myf5-GFP;
• Preparation, sectioning and IF against Myosin Heavy Chain in frozen sec-
tions followed by confocal microscopy imaging of double colour myf5-GFP;
mylpfa-mCherry zebrafish ERMS tumors;
• Zebrafish ERMS tumor preparation, FACS and transplantation into syn-
geneic recipients
3.3 Chapter 3 - Publications
This collaboration resulted in:
• Co-authorship for the following publication (reprinted in full below):
Ignatius, M. S. et al. (2012). “In vivo imaging of tumor-propagating cells, re-
gional tumor heterogeneity, and dynamic cell movements in embryonal rhab-
domyosarcoma.” In: Cancer Cell 21.5, pp. 680–93. ISSN: 1878-3686. DOI: 10.
1016/j.ccr.2012.03.043
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SUMMARY
Embryonal rhabdomyosarcoma (ERMS) is an aggressive pediatric sarcoma of muscle. Here, we show that
ERMS-propagating potential is confined to myf5+ cells and can be visualized in live, fluorescent transgenic
zebrafish. During early tumor growth,myf5+ ERMS cells reside adjacent normal muscle fibers. By late-stage
ERMS, myf5+ cells are reorganized into distinct regions separated from differentiated tumor cells. Time-
lapse imaging of late-stage ERMS revealed thatmyf5+ cells populate newly formed tumor only after seeding
by highly migratory myogenin+ ERMS cells. Moreover, myogenin+ ERMS cells can enter the vasculature,
whereas myf5+ ERMS-propagating cells do not. Our data suggest that non-tumor-propagating cells likely
have important supportive roles in cancer progression and facilitate metastasis.
INTRODUCTION
Rhabdomyosarcoma (RMS) is a pediatric malignancy that
shares common features with skeletal muscle arrested in embry-
onic development (Xia et al., 2002). The two main subtypes of
pediatric rhabdomyosarcoma, embryonal RMS (ERMS) and
alveolar RMS (ARMS), differ in their clinical, biological, and
molecular characteristics. For example, ERMS and ARMS can
be distinguished based on histology and have different long-
term prognoses, with ERMS patients having better overall
outcome than ARMS patients. These divergent clinical features
likely reflect the use of different molecular programs that lead
to transformation. For example, we have identified that the
RAS pathway is active in a majority of human ERMS (Hettmer
et al., 2011; Langenau et al., 2007). By contrast, 85% of ARMS
cells have recurrent chromosomal translocations that juxtapose
PAX3 or PAX7 with the forkhead transcription factor (FKHR) (Xia
et al., 2002). Finally, it is likely that ERMS and translocation-posi-
tive ARMS arise in different cell types that eventually undergo
transformation. Keller et al. (2004) found that PAX3-FKHR+
ARMS can arise from Myf6-expressing myoblast cells but not
dermamyotome or satellite cells that express Pax7. By contrast,
ERMS can arise from either satellite cells or myoblasts that even-
tually reinitiate molecular programs found in satellite cells (Rubin
et al., 2011). Despite elegant studies defining possible cells of
origin in RMS, identification of an ERMS-propagating cell that
is required for continued tumor growth in vivo has not been
described in mice or humans.
Significance
Tumor-propagating potential is not found in all malignant cells, and, in most cancers, cells with more differentiated features
are largely incapable of remaking tumor and yet constitute a majority of the tumor mass. A role for differentiated malignant
cells in tumor growth, including dissemination and metastasis, has not been fully explored. We find that mid-differentiated
myogenin-positive ERMS cells lack tumor-propagating potential yet are responsible for local invasion and can enter the
vasculature. Slow-movingmyf5+ ERMS-propagating cells are recruited to new sites of tumor growth after seeding by differ-
entiated ERMS cells. This finding may explain the clinical observation that Myogenin positivity correlates with poor clinical
outcome in human ERMS and suggests that differentiated tumor cells play critical roles in metastasis.
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Tumor-propagating cells have been characterized in many
malignances, and in some tumors, this potential is confined to
a molecularly definable cell population that can be enriched by
cell surface markers. For example, in acute myeloid leukemia,
a rare CD34+CD38 cell enriches for leukemia-propagating
potential while in breast cancer CD44+CD24low/expression is
associated with tumor-propagating potential (reviewed in Da-
lerba et al., 2007). Molecularly defined, rare CD133+ tumor-prop-
agating cells have also been identified in a subset of gliomas and
exhibit striking differences in response to nitric oxide and
hypoxia inducible factor signaling when compared to more
differentiated tumor cells (Eyler et al., 2011; Li et al., 2009).
Thus, it is likely that many tumors contain hierarchically orga-
nized cell subpopulations that retain the capacity to remake
tumor and yet give rise to differentiated tumor cell progeny.
One might expect that selection would favor the evolution of
tumors with high numbers of tumor-propagating cells at a cost
of differentiated cell types. Paradoxically, however, in most
malignancies, tumor-propagating cells are far less abundant
than differentiated tumor cells that are incapable of remaking
tumor. These data suggest that differentiated tumor cells may
provide important supportive roles in overall growth and mainte-
nance. To date, a role for differentiated, non-tumor-propagating
ERMS cells has yet to be fully explored.
Stem cells often reside in distinct niches in normal tissue, and
their functions are exquisitely controlled by local factors
secreted by supporting cells. For example, hematopoietic stem
cells (HSCs) have been shown to home to niches within the
calvarium that are tightly associated with osteoblasts (Lo Celso
et al., 2009). These and other niche-associated cells presumably
provide paracrine-signaling factors to recruit and maintain these
cells in a specific niche. Unlike other tissues, the muscle stem
cell niche is defined by juxtaposition of satellite cells next to
differentiated muscle fibers, and their numbers and differentia-
tion capacity are controlled by complex signaling pathways
regulated by mature muscle cells (reviewed in Bentzinger et al.,
2012). Despite a large body of data defining stem cell niches in
normal tissue, few studies have identified tumor-specific niches
and/or regions of compartmentalized tumor cell function and
fewer still have used microscopic imaging to directly visualize
tumor-propagating cells within live animals. In one example,
Sipkins et al. (2005) used a combination of multiphoton and
confocal microscopy to image the HSC niche in the calvarium
of mice and demonstrated that these sites can attract multiple
tumor cell types; however, it is unknown if these malignant
cells are capable of reinitiating tumors. In ERMS, as with most
solid tumors, it is unknown whether tumor-propagating cells
reside in distinct regions within the tumor mass and whether
the more differentiated cells play a role in promoting tumor
progression.
Here, we utilize a transgenic zebrafishmodel of ERMS to iden-
tify the tumor-propagating cell in this disease and to define the
functional consequences of tumor cell heterogeneity within live
animals. Because ERMS cell subpopulations can be fluorescent
labeled based on myogenic factor expression, ERMS cell
subtypes can be visualized in live animals and the processes
of cell growth, division, and local dissemination can be visualized
as dynamic processes in live animals. Our data provide an expla-
nation for the large number of non-tumor-propagating cells in
established cancers and reveal an important supportive role
for differentiated tumor cell types in local dissemination and
metastasis.
RESULTS
Imaging Distinct Stages of ERMS Growth
Externally visible ERMS can develop as early as 10 days of life in
zebrafish injected with rag2-KRASG12D (Langenau et al., 2007),
and >80% of ERMS develop in the tail musculature (n > 50). To
assess how tumors initiate and evolve in zebrafish ERMS, we
injected a-actin-GFP transgenic zebrafish at the one-cell stage
of development with rag2-dsREDexpress and rag2-KRASG12D
(Figures 1A–1F), facilitating imaging of ERMS cells in relation to
normal muscle. Microinjection of multiple transgenes into one-
cell-stage animals leads to cointegration and coexpression in
animals that develop ERMS (Langenau et al., 2008). This
approach provides a robust method to create mosaic transgenic
animals with fluorescently labeled ERMS cell subpopulations
(Langenau et al., 2007).
Sequential confocal imaging over several days showed that
ERMS forms in a choreographed and stereotypical manner
(Figures 1A–1F and 1J–1M). Specifically, dsRed+ ERMS mono-
nuclear cells arise at the extreme outer borders of the myotome
segments and move toward the midline where they are initially
unable to bypass the horizontal myosepta—a single cell layer
that separates myotome segments (Figure 1A; stage 1, n = 7).
After several days, a subset of cells cross the horizontal myo-
septa and take up residence between normal muscle fibers
within the newly colonized myotome segment (stage 2; Figures
1B and 1C; n = 5). Differentiated ERMS cells that express both
rag2-dsREDexpress and a-actin-GFP can move laterally into
neighboring muscle segments by transiting through the collagen
matrix of the myoseptum (n = 6; Figures 1D–1F; Movie S1 avail-
able online) or stream into new myotome segments by growing
past the edge of myoseptum (n = 3, early stage 3). The collagen
matrix of the muscle myoseptum is a cell-impermeable barrier
that is the site of muscle attachment in teleost fish and is similar
in function to tendons in mouse and humans. Late-stage ERMS
cells undergo rapid loss of fibers, breakdown of normal muscle
architecture including collagen remodeling, and development
of mononuclear tumor cells, reminiscent of the spindle variant
of human ERMS.
Neovascularization is a hallmark of cancer and an ideal surro-
gate for assessing tumorigenicity. To assess when KRASG12D-
expressing cells are transformed, we monitored neovasculariza-
tion in fli1-GFP transgenic animals that were injected at
the one-cell stage of life with rag2-KRASG12D and rag2-
dsREDexpress. Animals were monitored for tumor growth by
confocal microscopy beginning at 10 days of life (n = 22; Figures
1G–1I). ERMS at stage 1 failed to recruit new vasculature (n = 0
of 3), but stage 2 and early stage 3 ERMS had begun to recruit
new vasculature (n = 8 of 8; Figure 1H) with new branches arising
from both the intersegmental vessels and vertebral artery. By
late stage 3, ERMS developed intricate networks of new vessels
(n = 11 of 11; Figure 1I). Our imaging studies define distinct
stages of ERMS growth and suggest that RAS-expressing cells
become fully transformed by stage 2 of tumor development
(Figures 1J–1M).
Cancer Cell
Dynamic In Vivo Imaging of ERMS
Cancer Cell 21, 680–693, May 15, 2012 ª2012 Elsevier Inc. 681
Identification of Molecularly Distinct Fluorescent-
Labeled ERMS Cell Subpopulations
Previous experiments in zebrafish have identified an ERMS cell
subpopulation that had superior tumor-propagating potential
when compared to other tumor-derived cells. This ERMS-prop-
agating cell was rag2-dsREDexpress+/a-actin-negative and ex-
pressed high levels ofmyf5, c-met, andm-cadherin—markers of
satellite and early muscle progenitor cells (Langenau et al.,
2007). MYF5 is highly upregulated in human ERMS compared
to both translocation positive ARMS and normal muscle (Zibat
et al., 2010) and in comparing zebrafish ERMS to normal muscle
(Langenau et al., 2007). To directly assess whether myf5 labels
distinct ERMS cell subpopulations,myf5-GFP/myosin light chain
2-mCherry (mylz2) syngeneic animals were created by four
rounds of outcrossing to CG1 syngeneic animals (Smith et al.,
2010) and injected at the one-cell stage with rag2-KRASG12D.
myf5-GFP transgenic animals exhibit green fluorescent protein
(GFP) expression in early somitogenesis and later in satellite cells
and early muscle progenitor cells (Chen et al., 2007; Seger et al.,
2011) while the mylz2 promoter drives expression in differenti-
ated muscle cells (Ju et al., 2003; Smith et al., 2010). Fluores-
cent-labeled ERMS cell subpopulations were isolated from
double transgenic animals by fluorescence-activated cell sorting
(FACS). Reanalysis of sorted cells by FACS confirmed that
ERMS contained four distinct populations of cells (purity >
87% and viability > 97%).
To verify that discrete fluorescent-labeled ERMS cell subpop-
ulations were molecularly distinct, sorted cell populations were
Figure 1. Visualizing Distinct Stages of
Embryonal RMS Growth
(A–F) rag2-dsRED-labeled ERMS arising in
a-actin-GFP transgenic zebrafish. The same
animal imaged at 6, 9, and 12 days postfertilization
(dpf) is shown in (A), (B), and (C), respectively. A
representative zebrafish where dsRED+ ERMS
cells have already bypassed the horizontal my-
oseptum and migrated into new segments that
were previously free of tumor (F, stage 3) at 13, 18,
and 24 dpf is shown in (D), (E), and (F), respec-
tively. The horizontal myoseptum is denoted by
white arrows.
(G–I) fli1-GFP transgenic control animal (G)
compared with a rag2-dsRED-labeled ERMS
arising in fli1-GFP transgenic zebrafish at early
stage 2 (H) or a late stage 3 (I).
(J–M) Schematic of stages of ERMS growth.
Scale bars in the upper panels of (A) through (C),
500 mm. Scale bars in the lower panels of (A)
through (C) and in (D) through (I), 100 mm.
See also Movie S1.
assessed for gene expression differences
based on microarray (Figure 2A; Table
S1) and real-time PCR (Figures 2B
and S1). Gene expression analysis was
completed on FACS-sorted ERMS cells
derived from serially passaged tumors,
ensuring that fluorescent-labeled cells
were tumor derived. Microarray analysis
confirmed that each cell subpopulation
exhibited wide differences in gene
expression. Subsequent real-time PCR analysis established
that the myf5-GFP+/mylz2-mCherry-negative cells expressed
high levels of myf5, c-met, and m-cadherin but not pax7a,
pax7b, or differentiated markers (Figures 2B and S1). By
contrast, mylz2-mCherry+ ERMS cells expressed high levels of
mature muscle markers including myod, myogenin, troponin I
fast-twitch isoform 2 (tnni2a), a-actin 1b (acta1b), ventricular
myosin heavy chain-like (vmhcl), actin-related protein 2/3
complex subunit 5B (arpc5b), carboxypeptidase vitellogenic-
like (cpvl), and chemokine (C-X-C motif) receptor 4b (cxcr4b).
Finally, the double-negative cell population comprised predom-
inantly blood cells that express myeloid-specific peroxidase
(mpx) and lymphocyte-specific protein tyrosine kinase (lck). Our
data confirm that fluorescent-labeled ERMS cell subpopulations
can be prospectively isolated to relative purity following FACS
and are molecularly distinct.
Given that FACS could identify unique ERMS cell subpopula-
tions that exhibited wide differences in gene expression, we
questioned whether these cells also differ in rates of proliferation
and cellular turnover. Proliferation was assessed at 6 hr following
intraperitoneal injection of EDU into ERMS-affected animals
(Figures 2C–2E and S1). myf5-GFP+/mylz2-mCherry-negative
cells (24.1% ± 4.8%) incorporated EDU over a 6 hr pulse,
whereas differentiated ERMS cells that express mylz2-mCherry
were far less proliferative (8.9% ± 5.0%; p < 0.00001). By
contrast, following 3-day administration of EDU, all fluorescent-
labeled ERMS cell subfractions exhibited equal proliferative
capacity, suggesting that myf5-GFP+/mylz2-mCherry-negative
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cells divided and differentiated over this time (data not shown). In
addition to striking differences in cell proliferation betweenERMS
cell subpopulations, myf5-GFP+/mylz2-mCherry+ cells had
higher levels of apoptotic cellular turnover when compared with
myf5-GFP+/mylz2-mCherry-negative and myf5-GFP-negative/
mylz2-mCherry+ cells (p < 0.01, Fisher’s exact test; Figures 2F–
2J). Taken together, our fluorescent transgenic approach iden-
tifies unique ERMS cell subpopulations that have different fluo-
rescent reporter expression, divergent gene expression profiles,
and varied capacities for proliferation and apoptosis.
myf5-GFP+ Cells Are the ERMS-Propagating Cell
Population
To assess if myf5-GFP transgene expression enriches for
ERMS-propagating potential, cells were isolated from transplant
animals that developed myf5-GFP+/mylz2-mCherry+ ERMS
(Figures 3A–3G) and subjected to two rounds of FACS in the
presence of propidium iodide or DAPI to isolate highly purified
and viable cells (Figures 3H–3K; 87.7%–99.7% purity and
>98% viability). ERMS cell subpopulations were introduced into
CG1 syngeneic recipient animals at limiting dilution (Figure 3L–
3R), and animals were assessed for engraftment from 10 to
120 days posttransplantation (Table 1). All animals developed
ERMSbefore45daysposttransplantation, confirming that slower
cycling ERMS-propagating cell types would not bemissed in our
analysis. In three ERMS tumors tested, the tumor-propagating
activitywas confined to themyf5-GFP+/mylz2-mCherry-negative
cell subpopulation (Table 1),with an average frequencyof 1 in 146
cells capable of reinitiating tumors in recipient animals (range 1 in
87–245, 95% confidence interval). By contrast, only 1 in 4,206
myf5-GFP+/mylz2-mcherry+ cells were capable of inducing
tumors (range 1 in 1,550 to 11,409, 95% confidence interval,
p = 3.38e-15 when compared to ERMS-propagating activity in
myf5-GFP+/mylz2-mcherry-negative cells). Of 61 animals, none
Figure 2. Fluorescent Transgenic Approaches Identify Discrete and Molecularly Definable ERMS Cell Subpopulations in myf5-GFP/mylz2-
mCherry Transgenic Fish
(A) Heat map showing differential gene expression between FACS-sorted ERMS cell subpopulations isolated from serially passagedmyf5-GFP/ mylz2-mCherry
ERMS (microarray log fold-change > 1.5).myf5-GFP+/mylz2-mCherry-negative (G+),myf5-GFP+/mylz2-mCherry+ (G+R+),myf5-GFP-negative/mylz2-mCherry+
(R+), and double negative (DN).
(B) Quantitative real-time PCR of sorted ERMS cell subpopulations. Expression values, ±1 SD.
(C and D) Confocal images of EDU-stained sections from serially passaged myf5-GFP+/mylz2-mCherry+ ERMS. Tumor regions with large numbers of either
myf5-GFP+ (C) ormylz2-mCherry+ ERMS cells (D). Blue denotes DAPI+ nuclei, and white denotes EDU+ nuclei. Yellow arrows indicate EDU-labeled cells. Scale
bar, 25 mm.
(E) Quantification of EDU incorporation over a 6 hr EDU pulse. Data for myf5-GFP+/mylz2-mCherry-negative ERMS cells are denoted by green bars, data for
myf5-GFP+/mylz2-mCherry+ cells are indicated by yellow bars, and data formyf5-GFP-negative/mylz2-mCherry+ cells are indicated by red bars. Three individual
tumors shown as well as cumulative data across all tumors (Total). *p < 0.00001. Error bars, ±1 SD.
(F) FACS plot of serially passaged myf5-GFP/mylz2-mCherry ERMS.
(G–J) Gated ERMS cells assessed for DAPI and AnnexinV-APC staining (double negative, DN) (G); myf5-GFP+/mylz2-mCherry-negative (G+) (H); myf5-GFP+/
mylz2-mCherry+ (G+R+) (I); and myf5-GFP-negative/mylz2-mCherry+ (R+) (J). Live cells are shown within the DAPI-negative/AnnexinV-negative gates.
See also Figure S1 and Table S1.
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Figure 3. ERMS-Propagating Cells Express myf5-GFP but Not the mylz2-mCherry Differentiated Muscle Marker
(A) Schematic of experimental design.
(B–D) A primary ERMS arising in syngeneic myf5-GFP/mylz2-mCherry transgenic zebrafish (35 dpf). Broken black line denotes tumor area.
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engrafted disease from terminally differentiated myf5-GFP-
negative/mylz2-Cherry+ cells (lower bound for ERMS-propa-
gating potential was 1 in >5,969 cells). In total, we observed
a remarkable 28- to >40-fold enrichment of tumor-propagating
potential within our myf5-GFP+/mylz2-mCherry-negative cell
type when compared with other sorted ERMS cell subpopula-
tions. Similar results were also observed in primary ERMS.
Specifically, three primary ERMS tumors were isolated from
20- to 30-day-old larval zebrafish, pooled, and fluorescent-
labeled ERMS cell subpopulations were isolated by FACS. Of
eight animals, three engrafted disease from 102 myf5-GFP+/
mylz2-mCherry-negative cells, whereas the remaining ERMS
cell subpopulations could not transfer disease at this cell dose
(0 of 23, purity 83%–98% and viability > 98.6%, p = 0.012,
Fisher’s exact test). These results further support our finding
that themyf5-GFP+/mylz2-mCherry-negativepopulation ishighly
enriched for ERMS-propagating activity.
To assess the long-term tumor-propagating potential of the
myf5-GFP+/mylz2-mCherry-negative ERMS cells, cells were re-
isolated from transplant recipient animals (Figure 3N) and intro-
duced into CG1, syngeneic recipient animals (>78.9% purity
and 96% viable; Figures 3O–3R). Again, the myf5-GFP+/mylz2-
mCherry-negative cell subpopulation was capable of remaking
ERMS (Figure 3S–3U; Table 1). Histological analysis showed
that primary and serially transplanted ERMS arising from myf5-
GFP+/mylz2-mCherry-negative cell populations have similar
morphology and overall proportions of fluorescent-labeled
ERMS cell subpopulations (Figures 3C, 3D, 3F, 3G, 3M, 3N,
3T, and 3U).
Visualizing myf5-GFP+ ERMS-Propagating Cells In Vivo
To assess whether myf5-GFP+ ERMS cells could be directly
visualized in live animals, rag2-dsREDexpress and rag2-
KRASG12D were coinjected into one-cell-stage myf5-GFP
transgenic animals and assessed by confocal microscopy.
Discrete myf5-GFP+ tumor cells could be readily identified by
confocal imaging with a majority of myf5-GFP+ ERMS cells
coexpressing both GFP and dsREDexpress (97.5 ± 2.9%; n =
568 cells counted in three animals). Moreover, myf5-GFP+ early
muscle progenitor cells from control animals were relatively rare
(n = 3 [animals]; 2.3 ± 2.3 cells per imaging field), whereasmyf5-
GFP+ cells were abundant in ERMS (n = 3; 194.2 ± 23.7 cells per
field, t test, p = 0.0002). Taken together, our data suggest that
a vast majority of myf5-GFP+ cells contained within the bound-
aries of the ERMS mass are tumor derived.
To further refine the ERMS cell subpopulations for imaging
studies, triple fluorescent transgenic ERMS animals were
created by microinjecting myogenin-H2B-RFP, mylz2-lyn-cyan,
and rag2-KRASG12D into one-cell-stage myf5-GFP transgenic
animals (Figures 4A–4C). Histone fusion proteins are long lived
and confined to the nucleus, whereas lyn-cyan encodes for
membrane localized blue fluorescent protein. Because trans-
genes cointegrate as concatamers (Langenau et al., 2008),
ERMS cells coexpress all three transgenes and label distinct
tumor cell compartmentsassociatedwith stagesofmuscledevel-
opment (Figure S2). In normal development,myf5 is expressed in
satellite cells and early muscle progenitor cells, myogenin is ex-
pressed in committed, mid-differentiated muscle myoblasts,
and mylz2 is expressed in differentiated myoblasts. Transgenic
reporters have been described for all three of these promoters,
and each drives expression within the correct cellular compart-
ments during normal muscle development (Chen et al., 2007;
Duet al., 2003; Juet al., 2003).Moreover, geneexpressionstudies
confirm that these promoters drive correct tissue-specific gene
expression in ERMS (Figure S2), and additional cell transplanta-
tion experiments establish that myf5-GFP+/myogenin-negative
cell types exclusively retain ERMS-propagating potential (Fig-
ure S2). For example, 4 of 18 animals engrafted ERMS from 102
myf5-GFP+/myogenin-H2B-RFP-negative sorted ERMS cells
(E–G) Fluorescent-labeled ERMS engraft into syngeneic secondary recipient animals when transplanted with unsorted primary ERMS cells.
(H–K) FACS plots of fluorescent-labeled ERMS cells isolated from secondary recipient fish following two rounds of FACS.
(L–R) Transplantation of myf5-GFP+/mylz2-mCherry-negative FACs sorted cells induced ERMS in tertiary transplant animals (L–R) and quaternary recipients
(S–U).
Hematoxylin- and eosin-stained sections (C, F, M, and T) and FACS (D, G, N, and U) of primary and serially passaged ERMS. Scale bars, 2 mm (for B, E, L, and S)
and 100 mm (for C, F, M, and T).
Table 1. Limiting Dilution Cell Transplantation Identifies that
myf5-GFP+/mylz2-mCherry-negative Cells Are the ERMS-
Propagating Cells
ERMS #1 2
Transplants 3 Transplants
Cell # G+ G+R+ R+ Neg G+
1,000 6 of 6 2 of 7 0 of 6 0 of 7 6 of 6
10 5 of 9 0 of 9 0 of 8 0 of 10 7 of 8
10 0 of 8 0 of 8 0 of 9 0 of 7 0 of 10
TPC # 1 in 140** 1 in 3,461 NA NA 1 in 67
95% CI 59–329 872–13,740 NA NA 31–143
ERMS #2 2
Transplants
Cell # G+ G+R+ R+ Neg
1,000 6 of 6 0 of 6 0 of 6 0 of 6
10 4 of 7 2 of 10 0 of 10 0 of 10
10 1 of 8 0 of 9 0 of 10 0 of 8
TPC # 1 in 109** 1 in 3,495 NA NA
95% CI 44–270 808–15,120 NA NA
ERMS #3 2
Transplants
Cell # G+ G+R+ R+ Neg
1,000 2 of 3 0 of 2 0 of 3 0 of 4
10 8 of 9 0 of 8 0 of 8 1 of 8
10 1 of 8 0 of 9 0 of 9 0 of 9
TPC # 1 in 159** NA NA 1 in 4,840
95% CI 63–401 NA NA 632–37,094
Asterisks denote significant differences in tumor-propagating cell
number (TPC #) between myf5-GFP+/mylz2-mCherry-negative and
double-positive ERMS cells (**p < 0.00001). Neg, negative; NA, not appli-
cable; 95% CI, 95% confidence interval.
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Figure 4. myf5-GFP+ ERMS-Propagating Cells Are Dynamically Reorganized during Tumor Growth
(A) Schematic of the experimental design.
(B) A myf5-GFP transgenic animal injected at the one-cell stage of life with rag2-KRASG12D, myogenin-H2B-RFP, and mylz2-lyn-cyan with triple fluorescent-
labeled ERMS at 16 days of life.
(C) A merged confocal image of the boxed region shown in (B).
(D) Control myf5-GFP transgenic animal injected with myogenin-H2B-RFP and mylz2-lyn-cyan. myf5-GFP+ muscle precursor cells are denoted by green
arrowheads.
(E–G) Representative image of an ERMS-affected zebrafish labeled withmyf5-GFP,myogenin-H2B-RFP, andmylz2-lyn-cyan at stages 1, 2, and 3, respectively.
Green arrowheads denote myf5-GFP+ cells, whereas red arrowheads denote mononuclear myogenin-H2B-RFP+ ERMS cells.
(H) Late stage 3 ERMS from a triple fluorescent-labeled animal.
(I and J) Boxed regions in (H) imaged at higher magnification show regional partitioning of differentiated cells (I) compared with myf5-GFP+ ERMS-propagating
cells (J).
(K) Quantification of myf5-GFP+ cells during stages of ERMS growth when compared to control animals.
(L) Quantification of mononuclear myogenin-H2B-RFP+ cells during stages of ERMS growth when compared to control animals.
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(68.5% purity, 99.8% viable), whereasmyogenin-H2B-RFP+ cell
types could not induce tumors, regardless of whether they ex-
pressedmyf5-GFP (n = 0 of 32, p = 0.013, Fisher’s exact test).
Confocal imaging of fluorescent-transgenic ERMS fish that
express myf5-GFP/myogenin-H2B-RFP/mylz2-lyn-cyan easily
identified myf5-GFP+ cells, of which a small subset coexpress
myogenin-H2B-RFP (Figure 4C). Some myogenin-H2B-RFP+
cells with nuclear fluorescent protein expression fail to express
either myf5-GFP or mylz2-lyn-cyan, indicating that these cells
aremost similar tomidmyoblast stages.Gene expression studies
confirm thatmyogenin-promoter expression drives H2B-fluores-
cent protein expression in a subset of myosin-heavy-chain-ex-
pressing muscle cell populations, implying that these represent
differentiated cell types (Figure S2). Nearly all mylz2-lyn-cyan+
cells coexpress myogenin-H2B-RFP (99.5% ± 1%; n = 8
ERMS, n > 1,700 cells counted), reflecting that H2B-fluorescent
protein expression persists in more differentiated ERMS cells.
myf5-GFP+ cells Are Reorganized into Discrete
Compartments during Late-Stage Tumor Growth
We next wanted to define the location of ERMS cell subpopula-
tions during various stages of tumor growth. myf5-GFP trans-
genic animals were injected with rag2-KRASG12D, myogenin-
H2B-RFP, and mylz2-lyn-cyan and imaged by confocal
microscopy starting at 10 days of life. Stage 1 ERMS exhibited
greatly expanded numbers ofmyf5-GFP+ cells when compared
to control animals and were confined to regions immediately
adjacent to muscle fibers (Figures 4D–4G and 4K). Mononuclear
myogenin-H2B-RFP+ and double-positive myogenin-H2B-
RFP+/ mylz2-lyn-cyan+ ERMS cells were not observed in stage
1 ERMS; however, they were detected by stage 2 and increased
in number as tumors progressed to stage 3 (Figures 4F–4I and
4L). By late stage 3 ERMS, myf5-GFP+ cells lost fiber contacts
and began to populate discrete portions of the tumor that were
physically separated from more differentiated myogenin-H2B-
RFP- and mylz2-lyn-cyan-expressing ERMS cells (Figures 4H–
4J and 4M). The myf5-GFP+ cells were often located within
different myotome segments compared to differentiated ERMS
cell subpopulations; however, regional partitioning of cells based
on differentiation status was also observed within a single
myotome segment and in transplanted animals (Figure S2), con-
firming that compartmentalization did not result from physiolog-
ical constraints imposed during development but rather was an
intrinsic property of ERMS growth.
Human ERMS Cells Are Also Compartmentalized Based
on Myogenic Factor Expression
To assess whether human RMS cells also contain distinct
regions of tumor cells based on myogenic factor expression,
primary human ERMS and xenografted human ERMS derived
from RD and SMS-CTR cell lines (Linardic et al., 2005) were as-
sessed for myogenic marker expression, including Myogenin,
PAX7, and MYOD. Distinct regions of high and low Myogenin-
expressing cells were seen in a vast majority of primary tumor
samples (n = 12 of 14, p < 0.03, Student’s t test) and were
present in all xenograft tumors (n = 7, six regions per tumor,
p < 0.02, Students’s t test; Figure 5 and Figure S3; Table S2).
By contrast, most ARMS cells expressed Myogenin, and its
expression was not confined to specific areas within the tumor
mass (n = 10; range = 79%–99%), suggesting that regional par-
titioning of tumor cells based onMyogenin expression is specific
to ERMS. We also stained four primary human ERMS tumors for
PAX7 and identified regions of high and low expression in two of
the four tumors. In one ERMS sample, expression was diffuse
while the other tumor was PAX7 negative, indicating that not all
primary ERMS cells express PAX7. Unfortunately, MYF5 anti-
bodies have not been developed to detect human protein within
paraffin-embedded sections, precluding analysis of less differ-
entiated regions contained within the tumors.
myogenin+ ERMS Cells Are Highly Migratory and
Precede the Recruitment ofmyf5+ ERMS-Propagating
Cells into Newly Colonized Areas of Growth
Having established that the myf5-GFP-expressing ERMS cell
population contains tumor-propagating activity, we wanted to
assess if these cells also promote invasive tumor growth. Multi-
photon intravital microscopy recordings frommyf5-GFP/myoge-
nin-H2B-RFP or myf5-GFP/myogenin-H2B-Amcyan transgenic
tumor zebrafish revealed that myf5-GFP+ single-positive
ERMS cells were largely stationary and displayed only confined
crawling movements (Figures 6A–6F and S4; Movies S2, S3, S4,
and S5). In contrast, myogenin+ ERMS cells were robustly
migratory and had the ability to invade across myotome
segments through a normally impenetrable collagen matrix.
Cells that expressed lower amounts of the H2B-fluorescent
fusion protein were orderly arranged along the direction of
muscle fibers, had uniform nuclear shape, and did not show
any motility (Movies S2 and S3), suggesting that these were
differentiated tumor cells of which a subset had undergone
fusion (Figure 6F, right).
ERMS cell subpopulations also differ in their proliferative
capacity. Primary ERMS cells from myf5-GFP+/myogenin-H2B-
RFP+ animals were pulsed with EDU for 6 hr and then sectioned
and assessed for EDU incorporation (Figures 6G–6I).myf5-GFP+
ERMS cells were highly proliferative (39.4% ± 9.4%; n = 3),
whereas myf5-GFP-negative/myogenin-H2B-RFP+ cells rarely
proliferated (2.6% ± 3.8%; n = 3, p = 0.0001). In vivo multiphoton
imaging of transplant and primary ERMS confirmed that
myf5-GFP+/mylz2-negative ERMS-propagating cells are highly
proliferative, with 27 of 90 GFP+ cells dividing into two daughter
cells (n = 3 tumors). Multiphoton imaging revealed that resting
myf5-GFP+ ERMS cells are elongated (Figure 6J) and then round
up in shape just prior to cell division (Figure 6K). Following this
dynamic shape change, myf5-GFP+ ERMS cells quickly divide
(M) Quantification of regional compartmentalization of ERMS cells based on differentiation status in late stage 3 tumors (n = 3). Green bars denote regions that
contain higher percentages of myf5-GFP+ ERMS-propagating cells compared to white bars where myf5-GFP+ cells are less abundant and conversely more
differentiated.
Error bars in (K–M), ±1 SD. Scale bar, 500 mm for (B) and 50 mm for (C–J).
See also Figure S2.
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into two GFP-labeled daughter cells (Figures 6L–6M). Subse-
quently, these daughter cells begin to reacquire parental
morphology (Movie S6), reminiscent of normal myf5-GFP+
muscle precursors. By contrast, 0 of 90mylz2+ cells proliferated
over this time, regardless of whether they expressedmyf5-GFP.
To further visualize the dynamic movements of ERMS cells
in vivo, late stage 3 triple transgenic ERMS affected animals
were serially imaged over 16 hr to capture cell movements
(Figures 7A–7H; Movie S7). As was seen in our multiphoton
imaging, myf5-GFP+ cells that lack differentiated marker
Figure 5. Human Embryonal RMS Exhibit Regional Portioning of Cells Based on Myogenic Factor Expression
(A–D) Primary human ERMS.
(E–L) RD human cell lines (E–H) or human RAS-transformed myoblasts (I–L) introduced into SCID/beige mice.
(M–O) Primary human ARMS. Hematoxylin/Eosin-stained sections (A, E, I, and M) and anti-Myogenin immunohistochemistry performed on adjacent sections
(B, F, J, and N). Regions containing high numbers of Myogenin+ cells are denoted by red outline, while regions with low numbers of Myogenin+ cells are denoted
by black outline (B, F, and J). ARMS did not show regional portioning based on Myogenin staining (N). Magnified views of areas with high concentrations of
Myogenin+ cells (C, G, K, and O) or areas with low or absent expression (D, H, and L).
(P–Q) Quantification of regional compartments in primary andmetastatic human RMS (P) and in mice xenografted with human RD and SMS-CTR ERMS cells and
humanRAS-transformedmyoblasts (myoblasts, in Q). Numbers in (Q) denote tumors arising in separate animals. Blue bars denote areas with high percentages of
Myogenin+ cells compared to areas with low numbers of cells (red bars). Green bars denote diffuse and ubiquitous expression of Myogenin within ARMS. Error
bars, ±1 SD. Scale bars, 50 mm (for A, C–E, G–I, K–M, and O) and 200 mm (for B, F, J, and N).
See also Figure S3 and Table S2.
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expression move only locally within the tumor and exhibit
regional crawling movements, whereas myogenin-H2B-RFP+/
mylz2-lyn-cyan-negative cells are highly motile and could be
easily visualized migrating into adjacent nonaffected normal
tissue (Figures 7A–7D; Movie S7). By contrast, differentiated
ERMS cells that express myogenin-H2B-RFP and mylz2-lyn-
cyan are largely stationary.
To investigate which ERMS cells were the first to migrate into
unaffected tissue, we conducted serial imaging experiments
over longer observation intervals, focusing on regions that
were adjacent to expanding tumor. Serial confocal imaging of
fluorescent ERMS fish over several days revealed that myoge-
nin-H2B+ ERMS cells precede the recruitment of myf5-GFP+
cells into newly colonized areas of tumor growth (n = 7; Figures
7I, 7J, and S4). Not only do fluorescent-labeled myogenin-
H2B+ ERMS cells move locally within the tumor, but they also
enter the vasculature (Movie S8). A small portion of myogenin-
H2B-RFP+/myf5-GFP-negative cells were associated with
vasculature and could invade neovascular beds in fli1-GFP
transgenic animals (Figures 7K and 7L). To verify the fidelity of
H2B-fluorescent labeling of ERMS cell subfractions and to
directly visualize if myf5-GFP+ ERMS cells can enter the vascu-
lature, we induced ERMS in stable transgenic animals that
express myf5-GFP/flk1-mCherry by coinjecting both rag2-
KRASG12D and myogenin-H2B-Amcyan. As was seen using
the H2B-RFP transgenic reporter, we found that myogenin-
H2B-Amcyan+ cells are highly migratory (Movies S4 and S5),
were the first cell type to colonize new areas of tumor growth,
and could be observed transiting the vasculature (Figures 7M
and 7N; Movies S5 and S9). By contrast,myf5-GFP+ ERMS cells
exhibited reduced motility when compared with myogenin+
ERMS cells and were never observed entering the vasculature
Figure 6. myf5-GFP+ ERMS-Propagating Cells Are Slow Moving but Highly Proliferative whilemyogenin-H2B-RFP+ Cells Do Not Divide but
Are Highly Migratory
(A–E) Multiphoton recording of a stage 3 ERMS arising inmyf5-GFP/myogenin-H2B-RFP transgenic zebrafish (B and C) Magnified view of the boxed region in (A)
showing myf5-GFP+ (B) or myogenin-H2B-RFP+ ERMS cells (C).
(D and E) Tracks of cell movement over the 6.7-hr observation period. The same areas are shown as in (B) and (C), respectively.
(F) Mean track velocities of representative cell types contained within the tumor mass. *p < 0.001.
(G and H) EDU staining of double transgenic myf5-GFP+/myogenin-H2B-RFP+ primary zebrafish ERMS (35 dpf). Confocal image of a tumor section with high
numbers ofmyf5-GFP+ ERMS cells (G) compared to a section with high numbers ofmyogenin-H2B-RFP+ cells (H). White denotes nuclei that have incorporated
EDU. EDU incorporation into myf5-GFP+ or myogenin-H2B-RFP+ ERMS cells denoted by green or red arrows, respectively.
(I) Quantification of proliferation over the 6 hr EDU pulse. myf5-GFP+/myogenin-H2B-RFP-negative (green bars), double positive (yellow bars), and myf5-GFP-
negative/ myogenin-H2B-RFP+ (red bars). Error bars, ±1 SD. Asterisk denotes significant differences, *p = 0.0001.
(J–M) Static images of a myf5-GFP+ ERMS cells dividing. Scale bars, 50 mm (for A, G, and H), 25 mm (for B–E), and 15 mm (for J–M).
See also Figure S4 and Movies S2, S3, S4, S5, and S6.
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(n = 10 animals). Again, slow-moving myf5-GFP+ cells were
found in newly colonized regions only after initial invasion by
myogenin+ ERMS cells.
DISCUSSION
Myf5 as a Marker of ERMS-Propagating Cells
The limiting dilution cell transplantation studies outlined here
confirm the existence of a highly purified and molecularly defin-
able ERMS-propagating cell that expresses myf5, m-cadherin,
and c-met but not differentiated muscle markers. The myf5-
GFP+ ERMS-propagating cell gives rise to all the other differen-
tiated ERMS cells contained within the tumor mass and exhibits
enhanced proliferative capacity as assessed by EDU incorpora-
tion and direct in vivo cell imaging. These results are in keeping
with our previous work showing that ERMS-propagating activity
was largely confined to the rag2-dsRED+/a-actin-negative
ERMS cell population that preferentially expressed myf5 and
other activated satellite cell markers (Langenau et al., 2007).
However, rag2-dsRED+/a-actin-negative ERMS cells exhibited
only amodest 3-fold enrichment for tumor-propagating potential
when compared to rag2-dsRED+/alpha-actin+ ERMS cells
(Langenau et al., 2007). By contrast, experiments outlined here
using new fluorescent transgenic reporter lines and syngeneic
zebrafish show that the myf5-GFP+/mylz2-negative ERMS cells
exhibit a remarkable 28- to >40-fold enrichment of tumor-prop-
agating potential when compared to other ERMS-derived cell
populations.
Myf5 is a myogenic regulatory factor related to MyoD and
has important roles in muscle development. For example,
Figure 7. myf5-GFP+ ERMS-Propagating Cells Are Recruited to New Areas of Tumor Growth Only after Seeding bymyogenin+ ERMS Cells
(A–H) Time-lapse images of myf5-GFP transgenic animal injected with rag2-KRASG12D, myogenin-H2B-RFP and mylz2-lyn-cyan. Panels are merged image
planes taken every hour. myogenin-H2B-RFP+ cells migrate into normal tissues over time (white boxed region). Magnified views of time-lapse images doc-
umenting thatmyf5-GFP+ cells are largely stationary whilemyogenin-H2B-RFP+ cells are highly migratory andmigrate away fromGFP+ cells (denoted by arrows
in E–H).
(I and J) Serial imaging of a myf5-GFP transgenic animal injected with rag2-KRASG12D and myogenin-H2B-RFP shown at 14 and 17 dpf, respectively. White
boxes denote a region that initially contained only myogenin-H2B-RFP+ cells (I) but was later colonized by myf5-GFP+ cells (J).
(K and L) ERMS developing in a fli1-GFP transgenic animal injected with rag2-KRASG12D, myogenin-H2B-RFP, and mylz2-lyn-cyan. (K) Merged z-stacks
showing three myogenin-H2B-RFP+ cells associated with and inside fli1-GFP+ vessels, which was confirmed by imaging a single image plane at higher
magnification (L, white arrowhead).
(M and N) ERMS developing in a flk1-mCherry transgenic animal injected with rag2-KRASG12D and myogenin-H2B-cyan showing four cells entering the
vasculature (white arrowheads in M) and a single plane image showing two cells transiting into the vasculature at higher magnification (white arrowheads in N).
Scale bar, 50 mm (for A–H, K, L, and N) and 100 mm (for I, J, M).
See also Figure S4 and Movies S7, S8, and S9.
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MyoD/Myf5-deficient mice lack muscle, while deficiencies in
only one of these genes does not affect muscle specification
(Rudnicki et al., 1993), suggesting important and yet redundant
functions of these genes in development. It has also been shown
that Myf5 is highly expressed in activated satellite cells and has
important roles in postnatal muscle regeneration in response to
injury (Cooper et al., 1999; Gayraud-Morel et al., 2009; Ustanina
et al., 2007), suggesting that Myf5 may regulate self-renewal in
normal muscle satellite cells. Microarray analysis and cross-
species comparisons have shown that MYF5 is upregulated in
both zebrafish and human ERMS but not translocation-positive
ARMS (Langenau et al., 2007; Zibat et al., 2010), and recent
work fromRubin et al. (2011) has shown thatMyf5 is differentially
expressed in murine ERMS regardless of which muscle cell
subpopulation is initially targeted for transformation. These
results suggest that Myf5 gene programs are likely reinitiated
in transformed cells and may have important roles in driving
ERMS growth. By contrast, translocation-positive ARMS fail to
expressMYF5, precludingMYF5 marker expression as an iden-
tifying characteristic of ARMS-propagating cells and raising the
interesting possibility that the molecular mechanisms regulating
tumor-propagating potential differ between molecular subtypes
of RMS. Given the critical roles of the Myf5 transcription factor in
muscle development and regeneration in mice, it will be impor-
tant to assess if myf5 is a marker of ERMS-propagating cells
or if it plays a regulatory role in ERMS self-renewal and growth.
Regional Partitioning of ERMS Cells Based
on Differentiation Status
Evidence in solid tumors to support a discrete, specialized
microenvironment that augments tumor growth and proliferation
is now just beginning to emerge. For example, tumor-propa-
gating cells, including those of glioblastomas, have been shown
to reside in a vascular niche that promotes both their mainte-
nance and their ability to divide and produce daughter cells
capable of inducing tumors (reviewed by Gilbertson and Rich,
2007). In other solid tumors arising in skin, prostate, and breast,
tumor stromal fibroblasts also serve an essential role inmaintain-
ing a favorable microenvironment for tumor growth and expan-
sion. For example, work by Orimo et al. (2005) has shown that
stromal fibroblasts associated with invasive breast carcinoma
cells can promote tumor growth and angiogenesis through
secretion of SDF-1. In normal muscle, stem cell numbers are
exquisitely regulated by paracrine factors like Wnt5a (Pole-
sskaya et al., 2003), Myostatin (McCroskery et al., 2003), and
Notch ligands (Conboy et al., 2003). Many of these factors are
secreted by normal fibers that can sense injury and elicit recruit-
ment and expansion of muscle progenitors that are required for
regeneration. Thus, mature muscle provides a supportive micro-
environment that facilitates homeostatic regulation of muscle
stem cells. In our zebrafish ERMS model, we document that
myf5-GFP+ ERMS-propagating cells are initially juxtaposed to
muscle fibers in an expanded muscle satellite/progenitor cell
niche, suggesting that early stage ERMS cells cannot escape
the constraints of muscle architecture or are held in check by
local secreted factors emanating from normal muscle. By the
late stages of ERMS growth, ERMS-propagating cells are reor-
ganized and take up residence in defined regions within the
tumor mass. Following this regional partitioning of ERMS cells,
mid-differentiated myogenin+ ERMS cells show enhanced
migratory capability and move away from the ERMS-propa-
gating cells fromwhich they had arisen. Thesemid-differentiated
myogenin+ ERMS cells are highly migratory, seed new areas of
tumor growth, and cease to move once they turn on differenti-
ated muscle markers including muscle myosin light chain.
Such biologically constrained characteristics of ERMS cells
would ensure that tumor-propagating cells remain confined to
regionally defined areas and do not compete with differentiated
ERMS cells for local resources including growth factors and
oxygen. The extent to which regional partitioning of tumor cells
occurs in other solid tumors is unknown; however, assuming
this phenomenon is found in diverse cancer types, it will be
important to determine if regional partitioning of tumor cells
provides protective advantages to tumor-propagating cells,
facilitating the retention of a small number of cancer cells that
evade treatment and eventually give rise to disease relapse.
A Role for Differentiated, Non-Tumor-Propagating Cells
in Facilitating Tumor Growth and Metastasis
Myogenin immunohistochemical reactivity found in >80% of
RMS cells distinguishes patients with poor clinical outcome
(Heerema-McKenney et al., 2008), suggesting that Myogenin+
cells have a unique role in RMS progression and metastasis. In
our model, myogenin-H2B+ cells arise from myf5-GFP+
ERMS-propagating cells, lack tumor-propagating potential,
and are the first cell type to migrate into new areas of tumor
growth. A subset of myogenin+ ERMS cells infiltrate blood
vessels—a first step toward metastasis—and are also the first
to colonize new areas of tumor growth, only to be infiltrated later
by slow-migratingmyf5+ ERMS-propagating cells. Our work rai-
ses the interesting possibility that differentiated, non-ERMS-
propagating cells may create a supportive environment that
augments growth and is responsible for local tumor invasion.
For example, it is possible that once mid-differentiated
myogenin+ cells infiltrate new areas of growth, that they secrete
factors that recruit slow-movingmyf5+ ERMS-propagating cells,
facilitating tumor spread. Alternatively, it is possible that
myogenin+ cells break down collagen and cell-cell contacts,
acting as trailblazers to establish migratory tracks that allow
slow-moving myf5+ ERMS-propagating cells to transit into
newly forming tumor. Our work also highlights that metastatic
capacity and tumor-propagating potential need not be confined
to the same tumor cell subpopulations, but rather that local infil-
tration and metastasis may be facilitated by differentiated, non-
tumor-propagating cells. We expect that these same principles
may be more broadly applicable to a diversity of cancers,
accounting for why tumors retain large numbers of differentiated
cell types that themselves are incapable of reconstituting tumor.
Our findings of a myf5+ ERMS-propagating cell population
and a myogenin+ migratory population both contributing to
tumorigenesis may have profound therapeutic implications.
Instead of targeting only tumor-propagating cells for destruction,
drug design should also take into account themechanisms regu-
lating the homeostasis of more differentiated tumor cells and
their nonproliferative roles in regulating growth. Moreover, ther-
apies that focus on modulating the differentiation status of
ERMS cells should attempt to force the conversion of tumor-
propagating cells into cells with terminally differentiated
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myoblast characteristics that are incapable of recreating tumor,
cannot migrate, and fail to enter into the vasculature.
EXPERIMENTAL PROCEDURES
Study Approval
These studies were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care under protocol #2011N000127
(zebrafish), the Duke University Institutional Animal Care & Use Committee
under protocol A 036-03-02 (mouse), and the Partners Human Research
Committee under protocol #2009-P-002756 (human). Samples were obtained
from the Pathology Department ofMassachusetts General Hospital. Use of de-
coded, paraffin-embedded human tissue samples does not require informed
consent.
Animals
CG1-strain (Smith et al., 2010), a-actin-GFP (Higashijima et al., 1997), myf5-
GFP (Chen et al., 2007), fli1-GFP (Lawson and Weinstein, 2002), flk1-mCherry
(Wang et al., 2010), and mylz2-mCherry transgenic zebrafish (Smith et al.,
2010) have been reported previously.
The rag2-KRASG12D, rag2-dsREDexpress, myogenin-H2B-RFP, myoge-
nin-H2B-Amcyan, and mylz2-lyn-cyan constructs were microinjected into
one-cell-stage zebrafish singly (rag2-KRASG12D injected into myf5-GFP/
mylz2-mCherry syngenic zebrafish, 60 ng/ml) or as combinations with linear-
ized DNA at a final combined concentration of 120 ng/ml essentially as
described (Langenau et al., 2008).
FACS and ERMS Cell Transplantation
FACS analysis and ERMS cell transplantation were completed essentially as
described elsewhere (Smith et al., 2010; Langenau et al., 2007). Sort gates
were placed based on wild-type control fish and myf5-GFP+, mylz2-
mCherry+, or mylz2-lyn-cyan+ ERMS. DAPI, propidium iodide, or TOPRO3
was used to isolate viable cells. ERMS tumors were double sorted to obtain
pure, viable cell populations. Sort purity was assessed after two rounds of
sortingwhen possible. Following limiting dilution cell transplantation into nonir-
radiated syngeneic CG1-recipient animals, fish were analyzed for fluorescent
tumor engraftment from 10 to 120 days posttransplantation. Tumor-propa-
gating potential was quantified using the Extreme Limiting Dilution Analysis
software (http://bioinf.wehi.edu.au/software/elda/). A subset of transplanted
fishwas sectioned and stainedwith hematoxylin and eosin to confirm the pres-
ence or absence of ERMS.
Immunohistochemistry, EDU Staining, and Annexin V Staining
Paraffin embedding and sectioning, cryostat sectioning, and immunohisto-
chemical analysis were performed essentially as described elsewhere
(Langenau et al., 2007; see also Supplemental Experimental Procedures).
EDU staining was performed using the Click-iT Alexa Fluor 647 imaging kit
(Invitrogen). Annexin analysis for apoptotic cells was performed via FACS
using annexin V conjugated to Alexa Fluor 647 (Invitrogen).
Gene Expression Analysis
Total RNA was isolated from AB-strain embryos 6 and 24 hr postfertilization
and FAC-sorted ERMS cell subpopulations (TRIzol, GIBCO/BRL) in the pres-
ence of glycol blue. Quantitative real-time PCR utilized gene-specific PCR
primers (Supplemental Experimental Procedures), and expression was
normalized to 18 s and b-actin controls to obtain relative transcript levels using
the 2-DDCT method. Relative gene expression was normalized within individual
samples, and cumulative transcript expression across the four ERMS cell
subpopulations was set to 25. Samples were assessed in relation to embryos
6 and 24 hr postfertilization to ensure that results for 2-DDCT results for any
given gene were not lower than 10-fold expression found in normal develop-
ment. Microarray experiments were completed essentially as described (fold
change cutoff > 1.5-fold log scale; Langenau et al., 2007). Microarray data
have been deposited into the GEO database (GSE32425).
Laser Scanning Confocal Microscopy and Dual Photon Imaging
Larval zebrafish were anesthetized in Tricaine and embedded in a single drop
of low melt 1% agarose on a glass bottom petri dish (No 1.5, Mat Tek Corpo-
ration). Each petri dish was supplemented with fish water and imaged using an
inverted Pascal or LSM510 Zeiss laser scanning confocal microscope or an
upright Ultima IV multiphoton microscope (Prairie Technologies). Quantifica-
tion was completed by counting the total numbers of fluorescent-labeled
ERMS cell subpopulations contained in two 250 3 150 mm areas per animal
(Figures 4K and 4L; control, n = 7; stage 1, n = 3; stage 2, n = 4; stage 3,
n = 7). Because regional niches can be compartmentalized within a single
myotome segment, a smaller area was assessed for total numbers of myf5-
GFP+ and myogenin-H2B-RFP+ ERMS cells (50 3 50 mm2 area, six areas
per tumor; Figure 4M).
For cell tracking, sequences of image stacks were transformed into
maximum intensity-projected movies using Imaris 7.1 software (Bitplane)
and exported asQuicktimemovies. Manual two- or three-dimensional tracking
was performed using the manual tracking plugin in ImageJ or using Imaris 7.1.
Annotation and further processing ofmovies was completed using ImageJ and
Quicktime 7.
SUPPLEMENTAL INFORMATION
Supplemental Information includes nine movies, two tables, four figures, and
Supplemental Experimental Procedures and can be found with this article
online at doi:10.1016/j.ccr.2012.03.043.
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Supplemental Data 
 
Movie S1, related to Figure 1. Provided as a Quicktime movie file. Z-stack images of 
an alpha-actin-GFP transgenic fish injected at the one-cell stage of life with rag2-
KRASG12D and rag2-dsREDexpress that developed ERMS by 17 days of life. Movie 
shows a differentiated rag2-dsRED+/alpha-actin-GFP+ cell that transits through the 
collagen-rich, cell-impermeable myoseptum that separate myotome segments (see cells 
denoted by arrow heads).  
 
Table S1, related to Figure 2. Provided as an Excel file.  Affymetrix probes and gene 
list for microarray analysis shown in Figure 2A. The microarray data can be accessed 
with Geo accession number GSE32425. 
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Figure S1, related to Figure 2. ERMS cell subpopulations from myf5-GFP/mylz2-
mCherry transgenic zebrafish exhibit differences in gene expression and cell 
proliferation.  
(A-R) Quantitative real-time PCR analysis of myogenic factors (A-O), a myeloid cell 
marker (mpx, P), the KRASG12D transgene (Q), or a MAP-kinase regulated gene (dusp6, 
R). myf5-GFP+/mylz2-mCherry-negative (G+), myf5-GFP+/mylz2-mCherry+ (G+R+), 
myf5-GFP-negative/mylz2-mCherry+ (R+), and double negative (DN).  Myogenin 
(myog), myosin light-chain 2 (mylz2), myogenic factor 6 (myf6), troponin I fast-twitch 
isoform 2 (tnni2a), alpha-actin 1b (acta1b), chemokine (C-X-C motif) receptor 4b 
(cxcr4b), ventricular myosin heavy chain-like (vmhcl), actin related protein 2/3 complex 
subunit 5B (arpc5b), carboxypeptidase vitellogenic-like (cpvl), myeloid-specific 
peroxidase (mpx), and dual specificity phosphatase 6 (dusp6). Expression is depicted as 
relative fold change where the total expression value of all transcripts was normalized to 
25 within a given sample.  RT-PCR of 6- and 24-hour embryos ensured that relative 
expression was in the correct range. The blue, green and red bars represent analysis of 
three independent tumors. Expression values +/- one standard deviation. 
(S-Z) Transplanted myf5-GFP+/mylz2-mCherry+ ERMS pulsed with EDU for 6 hours 
and stained to analyze EDU incorporation. Single fluorescent planes for images shown in 
Figure 2C-D.   Sections show areas with higher numbers of myf5-GFP+ (S-V) or mylz2-
mCherry+ cells (W-Z). (S, W) GFP alone, (T, X) mCherry alone,  (U, Y) EDU alone, (V, 
Z) DAPI alone. Yellow arrows indicate EDU-labeled cells. Scale bar equals 25 µm.  
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Figure S2, related to Figure 4.  The myogenin promoter labels differentiated ERMS 
cells subfractions. (A-C) FACS plots of muscle cells from non-transgenic (A), myf5-
GFP+ ERMS (B), and myogenin-H2B-Amcyan+ ERMS (C) that were used to place the 
sort gates. (D) FACS analysis of ERMS arising in myf5-GFP transgenic fish coinjected 
with rag2-KRASG12D + myogenin-H2B-Amcyan. Four primary myf5-GFP/ myogenin-
H2B-Amcyan+ ERMS tumors were pooled in this analysis and subsequently, cell 
subfractions isolated by FACS.  
(E-H) Purity of the isolated cell subfractions following two-rounds of FACS, myf5-
GFP+/myogenin-H2B-Amcyan-negative (E), myf5-GFP+/myogenin-H2B-Amcyan+ (F), 
and double negative cells (H).  Assessment of post-sort purity of the myf5-GFP-
negative/myogenin-H2B-Amcyan+ cell type was not possible due to limiting numbers of 
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cells obtained from the first sort.  We show the high enrichment of cells following the 
first round sort (G).   
(I) Quantitative real-time PCR of fluorescent-labeled ERMS cell subpopulations.  myf5-
GFP+/myogenin-negative (GFP+), myf5-GFP+/myogenin-H2B-Amcyan+ 
(GFP+/Amcyan+), myf5-GFP-negative/myogenin-H2B-Amcyan+ (Amcyan+), double 
negative cells (Negative). m-cadherin (mcad), myogenin (myog), myosin light chain 2 
(mylz2), troponin I fast-twitch isoform 2, (tnni2a), alpha-actin 1b (acta1b), myeloid-
specific peroxidase (mpx), and lymphocyte-specific protein tyrosine kinase (lck). 
Expression values are +/- one standard deviation. 
(J-Y) The myogenin promoter drives fluorescent protein expression in a subset of 
differentiated ERMS cells that stain with a myosin heavy chain antibody, MF20.  ERMS 
arising from myf5-GFP transgenic animals that were injected with rag2-KRASG12D and 
myogenin-H2B-RFP (J-Q). Sections were stained with the MF20 antibody and imaged at 
low (J, K) and high magnification (L-Q).  Single image planes are shown for MF20 (N), 
GFP (O), H2B-RFP (P), or DAPI (Q). Merged images of MF20, GFP, and H2B-RFP (J, 
L) or MF20, GFP, H2B-RFP, and DAPI (K, M).  Myogenin-H2B-RFP+ cells that co-
localized with MF20 (Red arrows) or myf5-GFP are denoted (White arrow).  Not all 
myf5-GFP+ cells expressed myogenin-H2B-RFP (Green arrows).  In total, 94.8%+/-2.4% 
of myogenin-H2B-RFP+ cells expressed either GFP or MF20 within the tumor mass 
(n=653 cell counted across 3 tumors, tumor mass denoted by broken white lines).  
Moreover, a large subset of infiltrating myogenin-H2B-RFP/myf5-GFP-negative cells 
found in newly colonized areas also coexpress MF20 (see red arrows to in panels J, K). 
Scale bars are 50 µm (J, K) and 20 µm (L-Q). 
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(R-Y) ERMS from myf5-GFP animals co-injected with rag2-KRASG12D and myogenin-
H2B-Amcyan.  Sections were stained with MF20 and imaged at low (R, S) and high 
magnification (T-Y). Single image planes are shown for MF20 (V), GFP (W), H2B-
Amcyan (X), or DAPI (Y). Dapi was pseudocolored red to enhance contrast in images 
and easily identify co-expressing cells.  Merged images of MF20, GFP, and H2B-
Amcyan (R, T) or MF20, GFP, H2B-Amcyan, and DAPI (S, U). 90.5% myogenin-H2B-
Amcyan+ cells expressed either myf5-GFP or MF20, confirming that these cells share 
muscle characteristics and are not labeling large numbers of off-target cell types.  myf5-
GFP+/myogenin-H2B-Amcyan-negative/MF20-negative cell (green arrow) and myf5-
GFP-negative/myogenin-H2B-Amcyan+/MF20+ cells (blue arrows) are denoted in S-X. 
Scale bars equal 50 µm (R, S) and 20 µm (T-Y). 
(Z-AK) Tumor-propagating potential is confined to the myf5-GFP+/myogenin-H2B-
RFP-negative ERMS cell population. FACS analysis of muscle from non-transgenic 
control animals (Z), a single-positive myf5-GFP+ ERMS (AA) and a single-positive 
myogenin-H2B-RFP+ ERMS (AB) used to place the sort gates.  
(AC) Unsorted primary cells from a myf5-GFP/myogenin-H2B-RFP ERMS engraft 
robustly into syngeneic recipient animals when transplanted with 2.5x104 cells. Animal 
shown at 30 days post-transplantation. Scale bar is 2 mm (AC). 
(AD-AH) Fluorescent-labeled ERMS cell sub-populations were isolated from primary 
transplant animals and sort purity assessed following two rounds of FACS (AE, AF, AG, 
AH). Post-sort purity for myf5-GFP-negative/myogenin-H2B-RFP-negative (AE), myf5-
GFP+/myogenin-H2B-RFP-negative (AF), and myf5-GFP-negative/myogenin-H2B-
RFP+ (AH) cells. Cell numbers were limiting for the myf5-GFP+/myogenin-H2B-RFP+ 
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ERMS cells sub-fraction, precluding post-sort analysis following two rounds of FACS.  
Data is presented here for the first round sorting, which shows high enrichment for this 
cell sub-fraction (AG).  
(AI) Only the myf5-GFP+/ myogenin-H2B-RFP-negative cells induce ERMS in recipient 
animals (1x102 sorted cells, n=4 of 18). Scale bar is 2 mm (AI). 
(AJ, AK) Sections of ERMS arising in animals engrafted with myf5-GFP+/ myogenin-
H2B-RFP-negative cells.   Engrafted ERMS contained single positive myf5-GFP+ (green 
arrow heads), myf5-GFP+/ myogenin-H2B-RFP+ double positive (yellow arrow heads), 
and myogenin-H2B-RFP+ ERMS cells (red arrow head) validating that myf5-
GFP+/myogenin-H2B-RFP-negative tumor-propagating cell gives rise to all other 
fluorescent-labeled ERMS cell sub-fractions.  Scale bars are 50 µm (AJ, AK). 
(AL-AT) Zebrafish primary and transplanted ERMS have distinct tumor compartments 
comprised of myf5+ ERMS cells and differentiated cells that can be found within 
adjacent or the same myotome segment.   
(AL-AO) Regional partitioning of cells based on differentiation status in primary ERMS 
arising in a myf5-GFP transgenic animal that had been injected at the one-cell stage of 
life with rag2-KRASG12D, myogenin-H2B-RFP, and mylz2-lyn-cyan.  myf5-GFP+ cells 
and myogenin-H2B-RFP+/mylz2-lyn-cyan+ ERMS cells confined to different myotome 
segments (AL, AM) or within the same myotome segment (AN, AO).  Regions enriched 
for myf5-GFP+ cells are denoted by white dashed lines. Scale bar equals 50 µm (AL-
AO). 
(AP-AT) ERMS arising in transplanted fish also exhibit regional compartmentalization of 
tumor cells based on differentiation status.  Serially passaged myf5-GFP+/mylz2-
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mCherry+ ERMS cells from CG1-strain fish were injected into the musculature of non-
transgenic, 5-day-old syngeneic recipient embryos (1x103 unsorted ERMS 
cells/transplant recipient). A representative animal with prominent ERMS was 
photographed at 15 days of life using standard epiflourescence stereomicroscopy (AP-
AS) or multiphoton microscopy (AT). Bright field (AP), GFP (AQ), mCherry (AR), or 
merged fluorescent images (AS). Broken white and blue lines demarcate regions with 
higher numbers of myf5-GFP+ or mylz2-mCherry+ ERMS cells, respectively. (AT) 
Merged Z-static image showing clear demarcation of ERMS cell subfractions based on 
differentiation status.  Scale bar equals 1mm (AP-AS), 100 µm (AT). 
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Figure S3, related to Figure 5. Immunohistochemistry for MYOD and PAX7 in 
human RMS.  Quantification carried out over 6 areas.  Percentages are shown as the 
total number of IHC+ cells divided by tumor cells in each area.  (A-B) MYOD 
expression in human primary ERMS (A) and xenograft tumors derived from human 
ERMS cell lines and transformed myoblasts (B).  (C-D) PAX7 expression in human 
primary ERMS (C) and xenograft tumors derived from human ERMS cell lines and 
transformed myoblasts (D).  Human ERMS cell lines are denoted by RD and SMS-CTR.  
Transformed myoblasts are denoted Myoblast.  Numbers following each designation (i.e. 
RD #1) describe individual tumors that arose in independent xenograft animals. Blue 
columns indicate regions of high-staining and red columns indicate regions of low 
staining.  Samples with only blue columns indicate diffuse ubiquitous staining.  Error 
bars +/- one standard deviation. 
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Table S2, related to Figure 5.  Quantification of regional expression of myogenic 
factors in human RMS. 
 
MYOGENIN       
Human Primary ERMS       
SAMPLE ID 
LOW 
(%) SD 
HIGH 
(%) SD T-TEST 
TOTAL CELLS 
COUNTED 
h7028 37 4 59 3 0.0018 1282 
h36190 15 12 66 1 0.0021 1939 
h4447 3 3 31 14 0.029 3331 
h13837 0 0 92 1 N/A 361 
h28279 11 6 40 14 0.03 365 
       
Human TMA       
1720 11 6 33 8 0.015 318 
1755 4 1 21 5 0.0041 310 
1785 4 3 14 1 0.001 443 
1788 12 2 34 1 0.00011 211 
1718 10 5 43 4 0.00097 765 
1765 17 2 38 12 0.04 304 
1784 18 7 37 5 0.017 393 
1790 19 5 42 9 0.018 512 
1745 N/A  99 1  150 
1711 1 1 N/A   250 
       
Human Xenografts       
HTR-IRF 7 4 30 5 0.0031 2075 
THR-2LF 7 3 30 2 0.00046 1929 
RD2 4 2 38 5 0.00033 3569 
RDV1 5 2 35 7 0.0023 1667 
RDV2 6 3 28 4 0.0015 2782 
Mouse       
SMP0311 2 0.2 12 1 0.00027 1577 
SMP3011 3 2 24 12 0.034 987 
SMP0318 1 0.3 55 30 0.038 756 
SMP04-Tu3 1 0.8 20 3 0.00056 769 
SMP0303 2 0.9 10 3 0.014 937 
SMP04-Tu1 2.6 0.7 26 9 0.0094 1065 
SMP04-Tu2 0.9 0.2 13 3 0.0028 711 
       
Pax7       
Human Primary ERMS       
SAMPLE ID 
LOW 
(%) SD 
HIGH 
(%) SD T-TEST 
TOTAL CELLS 
COUNTED 
h7028 N/A  64 7  1916 
h36190 0.2 0.2 44 4 0.00003 753 
h4447 0 0 N/A   453 
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h13837 28 13 51 12 0.08 1587 
h28279 2 2 33 11 0.01 505 
       
Human Xenografts       
HTR-IRF N/A  94 4  358 
THR-2LF N/A  98 1  324 
RD2 N/A  78 6  432 
RDV1 N/A  80 8  384 
RDV2 N/A  81 4  357 
       
MyoD       
Human Primary ERMS       
SAMPLE ID 
LOW 
(%) SD 
HIGH 
(%) SD T-TEST 
TOTAL CELLS 
COUNTED 
7028 51 2 87 5 0.0002 1866 
36190 N/A  86 4  248 
4447 12 6 73 12 0.0012 546 
13837 N/A  95 2  314 
60654 0     250 
28270 N/A  81 2  252 
       
Human Xenografts LOW SD 
HIGH 
(%) SD  
TOTAL CELLS 
COUNTED 
HTR-IRF N/A  94 2  268 
THR-2LF N/A  97 3  252 
RD2 N/A  64 7  348 
RDV1 N/A  77 5  390 
RDV2 N/A  81 2  386 
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Figure S4, related to Figure 6. myf5-GFP+ ERMS-propagating cells are highly 
migratory and are recruited to new areas of tumor growth only after seeding by 
myogenin-H2B-Amcyan+ ERMS cells. 
(A-D) Migratory characteristics of myf5-GFP+ and myogenin-H2B-Amcyan+ ERMS 
cells. ERMS arising in an 18-day-old myf5-GFP/flk1-mCherry stable transgenic animal 
injected at the one-cell-stage with rag2-KRASG12D + myogenin-H2B-Amcyan.  Animal 
was imaged using a multiphoton microscope every 2.5 minutes for >6 hours.  Amcyan is 
not retained in phagocytic cells and 100% of cells show correct nuclear morphology (n=5 
tumors, >2,500 cells analyzed, see Supplemental Movies S5 and S6). (B-C) Magnified 
view of boxed regions shown in panel A.  Representative cell tracking of myf5-GFP+ (B) 
or myogenin-H2B-Amcyan+ ERMS cells (C). (D) Mean track velocities for 
representative cell types contained within the tumor mass. Asterisk denotes p < 0.0001. 
Mean track velocities error bars are expressed as +/- one standard deviation. 
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 (E-G) Serial imaging of an ERMS arising in a myf5-GFP transgenic animal injected with 
rag2-KRASG12D and myogenin-H2B-Amcyan imaged using a multiphoton microscope at 
14, 17 and 20 dpf. Blue arrows indicate myogenin-H2B-Amcyan+ cells and green arrows 
point to single positive myf5-GFP+ cells.  The anterior is oriented to the left with the 
tumor developing the in extreme posterior portion of the tail.  The ERMS is growing 
from right to left. Dotted white outline highlights myotome boundaries. The large white 
areas are pigment cells that auto-fluoresce during multiphoton imaging. Scale bar is 50 
µm (A), 30 µm (B-C), 100 µm (E-G). 
 
Movie S2, related to Figure 6. Provided as a Quicktime movie file. A 16-day-old 
myf5-GFP transgenic fish injected with rag2-KRASG12D and myogenin-H2B-RFP that 
developed prominent ERMS was imaged for 6.7 hours by multi-photon intravital 
microscopy.  A 409 x 409 x 30 µm volume was recorded every 2.5 minutes. Note that in 
addition to the stationary, RFPdim cells that likely represent differentiated ERMS cells, 
two highly motile intratumoral populations of RFPhigh cells can be identified: One with 
nuclear RFP pattern, and one with a punctate pattern, which likely represents the 
lysosomes of a rare phagocytic cells that have infiltrated the tumor and engulfed RFP 
labeled tumor cells. This latter cell type is rare and largely confined to a specific region to 
the right in this movie. While nuclear RFP+ tumor cells migrate larger distances, myf5-
GFP+ cells show mostly confined motility. Movie is accelerated 9000 over real time. 
Scale bar is 50 µm. 
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Movie S3, related to Figure 6. Provided as a Quicktime movie file. Left panel shows a 
frame from movie S2 with magnified views of intatumoral regions. 1: Peripheral tumor 
mass with myf5-GFP+ and myogenin-H2B-RFP single+ as well as some double-positive 
tumor cells. 2: myogenin-H2B-RFP low expressing cells likely representing differentiated 
ERMS cells, some of which have fused into fibers. 3: Central tumor mass with the 
highest concentration of cells with punctate RFP pattern, likely representing rare, 
phagocytic immunocytes that have engulfed tumor cells.  Phagocytic cell types are easily 
discerned in our movies based on morphology (they do not have nuclear labeling of the 
RFP protein) and are relatively rare.  In this image, 577 of 599 RFP+ cells express 
nuclear RFP and do not have phagocytic cell morphology (cells within boxed region #3 
were excluded in this analysis). Movie is accelerated 9000 over real time. Scale bar on 
left is 50 µm. Scale bar on right is 25 µm. 
 
Movie S4, related to Figure 6. Provided as a Quicktime movie file. An 18-day-old 
myf5-GFP/flk1-mCherry transgenic fish injected with rag2-KRASG12D and myogenin-
H2B-Amcyan that developed prominent ERMS was imaged for 6.7 hours by multi-photon 
intravital microscopy.  A 409 x 409 x 39 µm volume was recorded every 2.5 minutes. 
myogenin-H2B-Amcyan+ ERMS cells have prominent nuclear labeling and are highly 
migratory, whereas myf5-GFP+ ERMS cell subpopulations are largely stationary. Note 
that phagocytic cells are not present in these movies, allowing easy tracking of ERMS 
cells sub-fractions. Movie is accelerated 9000x over real time. Scale bar is 50 µm full 
frame, and 30 µm cropped fields. 
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Movie S5, related to Figure 6. Provided as a Quicktime movie file. A 14-day-old flk1-
mCherry transgenic fish injected with rag2-KRASG12D and myogenin-H2B-Amcyan that 
developed prominent ERMS was imaged for approximately 6 hours by multi-photon 
intravital microscopy.  A 409 x 409 x 20 µm volume was recorded every 2.5 minutes. 
Highly motile intratumoral populations of Amcyan+ cells can be identified and tracks for 
5 highly motile cells are represented. Also highlighted is a single myogenin-H2B-
Amyan+ ERMS cell that is entering the flk1-mCherry-labeled vasculature. Movie is 
accelerated 9000x over real time. Scale bar is 50 µm full frame, and 30 µm cropped 
fields. 
 
Movie S6, related to Figure 6. Provided as a Quicktime movie file.  Cell division 
within myf5-GFP+/mylz2-mCherry-negative ERMS cell subpopulation in a 15-day-old 
fish. Serially passaged ERMS cells from myf5-GFP/mylz2-mCherry CG1-strain fish were 
injected into the musculature of non-transgenic, 5-day-old syngeneic recipient embryos 
(1x103 unsorted ERMS cells/transplant recipient). A 222 minute movie captured every 
2.5 minutes of a dividing myf5-GFP+/mylz2-mCherry-negative cell. The movie is 
accelerated 2000x real time. Scale bar is 15 µm.  
 
Movie S7, related to Figure 7. Provided as a Quicktime movie file. 16 hour time-lapse 
movie of a late stage 3 myf5-GFP/myogenin-H2B-RFP/mylz2-lyn-cyan expressing ERMS 
arising in a 22-day-old animal.  Images were captured using a standard point-scanning 
laser confocal in four Z-planes and merged to create a 20 µm slice viewed every hour.  
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Movie S8, related to Figure 7. Provided as a Quicktime movie file. A 180 minute 
time-lapse movie of a stage 3 myf5-GFP/myogenin-H2B-RFP expressing ERMS at 14 
dpf. Image capture rate was 24 frames/hour and each frame represents a merged Z-stack 
image.  Note a single RED+ cell that slowly migrates into the image plane and then 
rapidly transits away from the tumor, indicative of entering the circulatory system and 
being shuttled away from the tumor.  
 
Movie S9, related to figure 7. Provided as a Quicktime movie file. A 3-D rendering of 
a z-stack made in Quicktime showing two myogenin-H2B-Amcyan+/myf5-GFP-negative 
cells entering the flk1-mCherry-labeled vasculature (same fish and region as shown in 
Figure 7M, N within the main text). Z-stacks were captured every1.5 µm apart.  
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Supplemental Experimental Procedures 
 
 
Vectors 
The rag2-KRASG12D and rag2-dsREDexpress constructs have been described 
previously (Langenau et al., 2007).  myogenin and mylz2-transgenic promoter expression 
has been reported (Du et al., 2003; Ju et al., 2003; Smith et al., 2010); however, our 
promoter constructs were modified to be three-way gateway compatible. Specifically, the 
myogenin and mylz2 promoters were cloned into a pENTR5’TOPO cloning (Invitrogen) 
gateway vector to create 5’ entry clones.  Middle gateway clones were created by PCR 
amplification of H2B-RFP, H2B-Amcyan and lyn-cyan and cloning into the pENTR-D-
TOPO vectors (Invitrogen). The 3’ entry clone and pDestTol2pA2 destination vectors 
were obtained form the Tol2kit (Kwan et al., 2007).  All reactions were completed as 
described (Kwan et al., 2007), ultimately producing the myogenin-H2B-RFP, myogenin-
H2B-Amcyan and mylz2-lyn-cyan constructs.  Each was linearized using restriction 
enzyme digest, purified, and injected as combinations with other transgenes into one-cell 
stage animals as previously described (Langenau et al., 2008). 
 
Fluorescence-activated cell sorting (FACS) and ERMS cell transplantation  
Single cell suspensions were made from primary ERMS arising in 20 to 52-day-
old myf5-GFP/mylz2-mCherry syngeneic zebrafish and 5X103 unsorted cells were 
injected into the peritoneum of CG1-strain syngeneic zebrafish as described (Smith et al., 
2010). ERMS cells were isolated from engrafted animals between 18-45 days post-
transplantation and FACS was completed in the presence of DAPI or propidium iodide to 
identify live cells. During the second round of FACS sorting, 2.5x104 cells were sorted 
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directly into 800 microliters of Trizol, while 1x101, 1x102, 1x103 fluorescent-labeled 
ERMS cells were sorted into wells of a 96-well plate which also contained 2x104 whole-
blood carrier cells from CG1 animals (2x104).  Samples were resuspended in 5 
microliters of 0.9X PBS+5% FBS and injected into the peritoneal cavity of CG1-strain 
adult fish.  Sort-purity was assessed following two rounds of FACS. 
 
 
Microarray 
Serially passaged myf5-GFP+/mylz2-mCherry+ ERMS were harvested from two 
individual tumors and cell subpopulations isolated following two rounds of FACS.  Cells 
were resuspended in RNAlater solution.  RNA was isolated and purified using a Qiagen 
RNA purification kit. Samples were amplified, labeled, and hybridized to Affymetrix 
zebrafish microarrays as described previously (Langenau et al, 2007).  CEL files were 
imported into D-Chip and normalized in batch to an invariant set using log2 fold-change.  
Samples were compared in D-Chip to identify probe sets with >20% presence calls and 
fold-change of >1.5.  A GCT file was created in D-Chip and then used for visualization 
of the data in Genepattern.  The microarray data can be accessed with Geo accession 
number GSE32425. 
 
Primers used for quantitative real time PCR (qRT-PCR) 
 
Gene Primer 5'-3' sequence 
hKRAS-QRT-F-137 TTGATGGAGAAACCTGTCTCTTGG 
hKRAS-QRT-R-247 CAAATACACAAAGAAAGCCCTCCC 
myf5-QRT-F-707 CCAGACAGTCCAAACAACAGACC 
myf5-QRT-R-795 TGAGCAAGCAGTGTGAGTAAGCG 
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myoD-QRT-F-638 CAGTGGAGACTCTGATGCTTCCAG 
myoD-QRT-R-744 AGCTGTCATAGCTGTTCCGTCTTC 
pax7a-331F ACACCCGACGTTGAAAAGAG 
pax7a-431R TCACACACTCCGTCCTTCAG 
pax7a-1281F GCACCACTCTCTCACAAGACGGC 
pax7a-1375R GCTGTCAGCCGAGAGTCCGC 
pax7b-16F GGAACAGTACCGCGAATGAT 
pax7b135R GAATACACCGCCAAGCTGAT 
myog-QRT-F-775 GTGGACAGCATAACGGGAACAG 
myog-QRT-R-868 TCTGAAGGTAACGGTGAGTCGG 
myf6-QRT-F-580 TCCCAGATGGCAGGTCATAGAG 
myf6-QRT-R-683 GGCTCTTCAGTGGAAATGCTGTC 
cdh15-QRT-F-1875 TGACATCCGAGACAACGTCTTTC 
cdh15-QRT-R-1969 CACTGGGGCTCCTCAGAAAATC 
mylz2-452F ACCGCAGAGGAGATGAAGAA 
mylz2-547R TCCGTGTGTGATGACGTAGC 
desmin-QRT-F-771 CGAGATTGACTCTCTCAAGGGCAC 
desm-QRT-R-877 GGGCGATAGTGTCCTGATAACCAC 
myh1/vmhcl-276F GCTGACCTTTCTCCATGAGC 
myh1/vmhcl-370R TGACACAAAACAGCCCTGAG 
c-MET-1369F GTCATCCAGGTGGTGGTTTC 
c-MET-1483R CGTTGTGATGCTGTGGAGAC 
mpo-1096F GCCACTCGTCAGAAAATCCT 
mpo-1180R GATTCTCATCGACACGAGCA 
dusp6-339F ATTGCGGGAAAATCAGTTTG 
dusp6-437R CTGGAGCCAGAACCTCTCAC 
tnni2a-445F TCAGGCTCTGCTGGGCTCCA 
tnni2a-559R TACGCCAGTCGCCGACCTGT 
acta1b-645F CTGAGCGCGGTTATTCTTTC 
acta1b-729R TCCAGAGCCACATAGCACAG 
cpvl-184F TTGGAGCTGACCCGGGCAAA 
cpvl-266R CACCAGGAAGGGGACCCACC 
cxcr4b-2044F GAGGGGTCCGAGCCAACTCC 
cxcr4b-2130R AGAGCATGATGGCTGATAGCAGGT 
arpc5b-286F TCATGGGTGCTCTACAGGCAGTATT
arpc5b-392R AGCACCTTCAGCACCAGACCTTC 
b-actin-QRT-F GCTGTTTTCCCCTCCATTGTT 
b-actin-QRT-R TCCCATGCCAACCATCACT 
ef1a-QRT-F-188 CATCGAGAAGTTCGAGAAGGAAGC 
ef1a-QRT-R-296 GTCAATGGTGATACCACGCTCAC 
18s-QRT-1-F TCGCTAGTTGGCATCGTTTATG 
18s-QRT-1-R CGGAGGTTCGAAGACGATCA 
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Xenograft cell transplantation into mice 
Human ERMS cell lines and human skeletal muscle myoblasts transformed to 
mimic ERMS were evaluated as xenografts by subcutaneous injection into 
immunodeficient SCID/beige mice as described (Linardic et al., 2005). Resulting tumors 
were harvested at necropsy, with portions fixed in formalin for paraffin embedding. 
Mouse experiments were approved by the Duke University Institutional Animal Care & 
Use Committee under protocol A 036-03-02. 
 
Immunohistochemistry,  EDU and Annexin V staining 
Paraffin embedding and sectioning, cryostat sectioning, and 
immunohistochemical analysis were performed essentially as described (Guyon et al., 
2003; Langenau et al., 2005). Human samples were stained with PAX7 (Developmental 
Studies Hybridoma Bank Hybridoma bank), MyoD1 (Richard Allen Scientific), and 
Myogenin (DAKO Corporation), secondary antibodies used were biotinylated horse anti-
mouse/Vector, BA-2000 and UltraView HRP-conjugated multimer antibody reagents 
(Vectorlabs, Ventana Medical Systems) and subsequently slides were stained with DAB. 
Three areas of high- and low- staining were photographed per tumor sample at 100X and 
400X magnification. Cell counts represent the number of antibody stained cells divided 
by the total number of tumor cells within a given area.  Human RMS samples were 
obtained from the MGH pathology tissue bank or from the Stanford collection where 
myogenin-staining was previously completed on a larger cohort of patient samples 
(Heerema-McKenney et al., 2008).  
EDU was injected into the peritoneum of ERMS fish (10mM EDU, 5 microliters, 
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Click-iT Alexa Fluor 647 imaging kit, Invitrogen). After 6 h or 72h post-injection, 
animals were anesthetized, fixed in 4% paraformaldehyde at 4 ˚C over night, and 
subsequently imbedded in OCT.  Frozen blocks were sectioned at 10 micron-thickness 
and stained for EDU. Sections were mounted using Vectashield with or without Dapi, 
coverslipped, and imaged by confocal microscopy.  
For analysis of apoptosis, ERMS tumor cells were first transplanted 
intraperitoneally into 6-7 week-old zebrafish.  Approximately 10 days post-engraftment, 
the tumor was dissected from each fish.  Tumor cells were dissociated using a razor blade 
and filtered through a 40-micron cell strainer.   Cells resuspended in 5%FBS/0.9X PBS 
were stained with annexin V conjugated to Alexa Fluor 647 (Invitrogen) following the 
manufacturer’s protocol. Stained cells were analyzed by flow cytometry.  For gating, 
DAPI was used to identify dead cells.  Cells isolated from mylz2-mCherry transgenic 
fish, mylz2-GFP transgenic fish and TuAB wild-type fish were used as controls to place 
the fluorescent gates, respectively. 
 
Multiphoton Intravital Microscopy 
 
Fluorescent transgenic animals that developed ERMS were imaged at 14 - 21 dpf.  
Animals were embedded in 1% low melting temperature agarose and immersed in fish 
water containing tricaine in 6 cm tissue culture dishes, which were placed on a custom-
built heating plate to maintain the buffer temperature at 25 ˚C. The heating plate was 
transferred to the stage of an Ultima IV upright multiphoton microscope (Prairie 
Technologies) equipped with an infrared-optimized Olympus 20x/0.95 NA water 
immersion objective and controlled by Prairieview software. For multiphoton excitation a 
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Ti:sapphire laser with a 10-W MilleniaXs pump laser (Mai Tai DeepSee, Spectra-
Physics) was tuned to 990 nm for optimal excitation of both EGFP and mRFP.  For 
imaging Amcyan, EGFP and mCherry a combination of Deepsee at 930 nm to detect 
Amcyan and EGFP and Mai Tai pulsed at 1030 nm to detect mCherry was used. To 
detect a combination of Amcyan and EGFP we used Deep See at 830 nm and Mai Tai at 
930 nm. For four-dimensional recordings of cell movement, stacks of 13 - 36 optical 
sections spaced 1.5-2.5 µm apart were acquired every 150 seconds for up to 7 hours in 
order provide image volumes of 30 - 40 μm in depth and 409 μm in width. Emitted light 
was detected through 525/50 and 595/50 nm bandpass filters with non-descanned 
detectors to generate two-color images. Sequences of image stacks were transformed into 
maximum intensity-projected movies using Imaris 7.1 software (Bitplane) and exported 
as Quicktime movies. Motion-artifacts in recordings were corrected using the auto-
alignment plugin (stackreg) of ImageJ (http://rsb.info.nih.gov/ij/). Manual 2-D tracking 
was performed using the manual tracking plugin in ImageJ and Spots tool in Imaris 7.1 
software (Bitplane). Annotation and further processing of movies were done in ImageJ 
and Quicktime 7.
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4
Myogenic Regulatory Factors
Induce Self-renewal and Growth in
ERMS
"In the attempt to make scientific
discoveries, every problem is an
opportunity, and the more difficult the
problem, the greater will be the importance
of its solution."
Edward O. Wilson
at TEDtalks, Advice to Young Scientists
(2012)
4.1 Chapter 4 - Preamble
As discussed in the General Introduction (Chapter 1), consensus in the Rhab-
domyosarcoma field has been that expression of MRFs likely reflects the target
cell of transformation rather than myogenic transcriptional programs being re-
quired for continued tumor growth.
Despite the well-known roles for MYOD1 and MYF5 in muscle development,
their importance in regulating self-renewal during regeneration, and their ability
to reprogram fibroblasts into a muscle cell fate, a functional role for these factors
in regulating RMS tumor growth has yet to be reported.
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4. Myogenic Regulatory Factors Induce Self-renewal and Growth in ERMS
We have previously reported that MYF5 is a marker of Tumor Propagating
Cells in a fluorescent transgenic zebrafish RMS model (see Chapter 3 and Ig-
natius et al., 2012).
Here, we have used this model to show that MYF5 is sufficient to confer self-
renewal to ERMS cells. Transgenic tumors that aberrantly express MYF5 in differ-
entiated RMS cells initiate earlier, have higher penetrance and tend to be larger
than control tumors. These tumors also have increased numbers of self-renewing
TPCs. Consistent with redundant roles for MYF5 and MYOD1 in normal mus-
cle regeneration and stem cell self-renewal, we identified two classes of human
ERMS that largely express only one of these factors. Loss-of-function studies
revealed that MYF5 and MYOD1 are required for sustained human RMS growth
both in vitro and in mouse xenograft experiments. ChIP-seq experiments went on
to reveal that MYF5 and MYOD1 bind common DNA regulatory elements likely to
arrest human ERMS in early stages of muscle development while simultaneously
promoting cell cycle progression.
We propose a model where MYF5 and MYOD1 converge on common molec-
ular pathways to regulate human RMS growth and self-renewal, similar to their
overlapping roles in muscle development and regeneration. Taken together, we
show that cancer self-renewal pathways are likely shared with their non-malignant
counterparts and that these processes are aberrantly activated during malignant
transformation, an emerging concept in cancer biology with few better examples
than that reported here.
4.2 Chapter 4 - Contribution
I contributed to the main body of work here presented. I was responsible for
driving this project from its very beginning, including experimental design, exper-
imental work, analysis, writing and the establishment of collaborations.
4.3 Chapter 4 - Publications
This work, of which I am the first author, was submitted to a scientific journal
at this date. The unpublished manuscript is reproduced below in this Chapter.
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Abstract  
 
Rhabdomyosarcoma (RMS) is a common pediatric sarcoma of muscle. Myogenic 
regulatory transcription factors, including Myogenic factor 5 (MYF5) and Myoblast 
determination protein D (MYOD), are highly expressed in RMS. These factors are 
required for normal muscle development and self-renewal of stem cells during 
regeneration. Moreover, myf5 is a marker of self-renewing, tumor-propagating cells in 
zebrafish kRASG12D-induced embryonal rhabdomyosarcoma (ERMS) and is highly 
expressed in 60% of human ERMS. Yet, roles for MYF5 or MYOD in regulating ERMS 
growth, self-renewal, and tumor maintenance have not been defined.  Here, we show that 
Myf5 is sufficient to confer self-renewal to differentiated zebrafish ERMS cells. These 
tumors initiate earlier, have higher penetrance and are larger than control tumors. 
Consistent with redundant roles for Myf5 and MyoD in normal muscle regeneration and 
stem cell self-renewal, we identified two classes of human ERMS that express either high 
levels of MYF5 or MYOD.  Human ERMS largely express only one of these genes, with 
either MYF5 or MYOD being required for sustained tumor growth in vitro and in vivo. 
We propose a model where MYF5 and MYOD bind common promoter/enhancer 
elements and act redundantly to regulate ERMS proliferation and self-renewal, similar to 
their overlapping roles in muscle development and regeneration. 
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Introduction 
Rhabdomyosarcoma (RMS) is the most common pediatric sarcoma and is 
characterized by impaired myogenic differentiation. RMS commonly express myogenic 
regulatory transcription factors (MRFs) including Myogenic factor 5 (Myf5) and 
Myoblast determination protein D (MyoD) (Clark et al. 1991; Parham 2001; Kumar et al. 
2000; Sebire and Malone 2003). RMS is comprised of two molecular subtypes. Alveolar 
RMS (ARMS) harbor Pax7-FOXO and Pax3-FOXO genomic fusions (Sorensen et al. 
2002) and have few recurrent genomic changes (Chen et al. 2013b; Shern et al. 2014). By 
contrast, 90% of human embryonal rhabdomyosarcoma (ERMS) have RAS pathway 
activation and a higher mutation burden when compared with ARMS (Langenau et al. 
2007; Chen et al. 2013b; Shern et al. 2014). Common mutations found in ERMS include 
inactivation of Tp53 and activating mutations of FGFR4, PDGFA, and NOTCH1 (Chen 
et al. 2013b; Shern et al. 2014). Despite a favorable prognosis for a majority of RMS 
patients, the outcome for relapsed disease remains poor irrespective of subtype, with 50% 
of patients succumbing to disease (Hettmer et al. 2014). Importantly, continued tumor 
growth and relapse are driven by molecularly defined tumor propagating cells (TPCs). 
These self-renewing TPCs are often retained following treatment and ultimately drive 
refractory, metastatic, and relapse disease (Reya et al. 2001). TPCs have been identified 
in animal models and human RMS (Ignatius et al. 2012; Chen et al. 2014; Walter et al. 
2011). However, to date, the molecular mechanisms driving TPC frequency and self-
renewal in ERMS have not been fully defined.  
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Despite the similarity of RMS cells with embryonic and regenerating muscle, the 
cell-of-origin for these tumors is still controversial.  For example, RMS can arise from 
muscle stem cells and myogenic precursor cells (Blum et al. 2013; Hettmer et al. 2011, 
2015; Abraham et al. 2014; Rubin et al. 2011; Tremblay et al. 2014; Langenau et al. 
2007; Storer et al. 2013), mesenchymal stem cells (Shinkoda et al. 2009; Lisboa et al. 
2008), or adipocyte precursors (Hatley et al. 2012). Given the heterogeneity of cell types 
found in RMS and the suggested multiple cells-of-origin, several groups have posited that 
sarcomas comprise a continuum of myogenic differentiation, reflecting the target cell of 
transformation rather than myogenic programs being required for continued tumor 
growth (Keller and Guttridge 2013; Rubin et al. 2011; MacQuarrie et al. 2013; Kikuchi et 
al. 2011). MYF5 and MYOD have important roles in muscle development and 
regeneration (reviewed in Buckingham and Rigby 2014), are highly expressed in  human 
and animal models of RMS (Langenau et al. 2007; Rubin et al. 2011), and can reprogram 
fibroblasts into proliferating myoblasts (Tapscott et al. 1988; Braun et al. 1989); yet, a 
functional requirement for these MRFs in regulating RMS growth and self-renewal has 
not yet been described.  
Cellular and animal models of RMS have facilitated a detailed understanding of the 
molecular pathogenesis of this disease and have provided new insights into the self-
renewal mechanisms required for RMS growth (Hinson et al. 2013; reviewed in Kashi et 
al. 2015).  For example, a zebrafish transgenic model of kRASG12D-induced ERMS has 
been developed that accurately recapitulates the molecular underpinnings of human 
disease (Langenau et al. 2007; Le et al. 2007, 2013; Chen et al. 2013a; Storer et al. 2013; 
Chen et al. 2014). Using this model, we have previously identified a molecularly-defined 
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population of tumor cells that drives continued tumor growth (Langenau et al. 2007; 
Ignatius et al. 2012). These tumor-propagating cells (TPCs) have self-renewal properties 
akin to normal stem cells and express high transcript levels for muscle stem cell markers, 
including c-met, cdh15 (m-cadherin), and myf5 (Langenau et al. 2007; Ignatius et al. 
2012). Remarkably, MYF5 is also reactivated in a large subset of human ERMS and is 
commonly re-expressed in animal models of ERMS, irrespective of the cell of origin 
(Abraham et al. 2014; Rubin et al. 2011; Storer et al. 2013; Tremblay et al. 2014). Based 
on these findings, we reasoned that MYF5 might have a major role in regulating growth 
and self-renewal in a subset of ERMS. 
 Here, we show that Myf5 is not only a marker of zebrafish TPCs, but is sufficient 
to impart self-renewal to differentiated ERMS cells in vivo. Myf5 re-expression also lead 
to tumors that initiate earlier, had higher penetrance of disease, and were larger than 
when compared with kRASG12D-alone expressing ERMS. Experiments in human ERMS 
uncovered significant inter-tumor heterogeneity of MRF expression with MYF5 or 
MYOD defining largely mutually exclusive groups of tumors. Functional studies 
uncovered that both MYF5 and MYOD are required for continued ERMS proliferation, 
likely acting redundantly with one another to regulate the same self-renewal programs 
found in normal muscle development and regeneration. Consistent with this 
interpretation, ChIP-seq analysis identified common binding sites of MYF5 and MYOD 
in promoter and enhancer regions of genes that regulate cell cycle and muscle 
differentiation. Finally, we show that MYF5 is also required for continued human ERMS 
tumor growth in vivo. Our data supports a previously unappreciated role for MYF5 and 
MYOD in regulating growth, proliferation, and self-renewal in rhabdomyosarcoma.  
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Results 
Re-expression of myf5 in zebrafish ERMS cells leads to highly differentiated tumors, 
increased penetrance, and early tumor onset  
myf5 is highly expressed in undifferentiated, self-renewing ERMS cells in the 
zebrafish kRASG12D-induced ERMS model (Langenau et al. 2007; Ignatius et al. 2012). 
For example, cell transplantation and direct live cell imaging has revealed that myf5-
GFP+ cells drive tumor growth and label TPCs in the zebrafish model (Chen et al. 2014; 
Ignatius et al. 2012). To assess roles for myf5 in regulating ERMS growth, we forced its 
expression in differentiated ERMS cells that lack self-renewal and tumor-propagating 
potential.  Specifically, rag2-kRASG12D was coinjected with a transgene that 
overexpressed myf5 within the differentiated, myosin expressing cells (mylpfa-myf5) (Xu 
et al. 1999). Importantly, myf5-GFP+; mylpfa-mCherry+ ERMS cells do not normally 
express high levels of myf5, have low proliferative capacity, and do not sustain ERMS 
growth in vivo (Ignatius et al. 2012). Histological analysis revealed that ERMS arising in 
rag2-kRASG12D;mylpfa-myf5 AB-strain transgenic fish were histologically more 
differentiated than when compared to those that express only kRASG12D (Fig. 1A-F), 
consistent with imparting self-renewal to more differentiated ERMS cells.  Tumors were 
histologically staged based on differentiation as described previously (Storer et al. 2013).  
Briefly, undifferentiated RMS were scored as stage 1 and were comprised mostly of 
small round blue cells, while the most differentiated tumors were classified as stage 3 and 
were comprised of large numbers of rhabdomyoblasts and cells with fiberous and spindle 
cell morphology (Fig. S1A).  Primary kRASG12D-induced ERMS were comprised of 50% 
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undifferentiated stage 1 ERMS (n=5 of 10, Fig. 1B,C and Fig. S1).  By contrast, mylpfa-
myf5 expressing primary ERMS contained only 7.7% stage 1 ERMS (n=2 of 26, p=0.015, 
Chi-square, Fig. 1E-F).  These latter ERMS samples had highly differentiated tumor cells 
and were scored histologically as stage 2 and 3 ERMS (Fig. 1F and Fig. S1A).  
Transcriptional profiling of bulk tumor cells by qRT-PCR confirmed that mylpfa-myf5 
expressing ERMS cells had high myf5 transgene expression, were more differentiated, 
and had elevated expression of TPC-associated markers including c-met and cdh15 (Fig. 
1G).  These data show that re-expression of myf5 in more differentiated myosin-
expressing ERMS cells leads to tumors with differentiated morphology and was 
consistent with the re-activation of muscle stem cell self-renewal programs in 
differentiated cell types. 
Tumors arising in double transgenic rag2-kRASG12D; mylpfa-myf5 expressing ERMS 
were also larger by 30 days of life than those that express only kRASG12D (Fig. 1H, 
p=0.0108, Student’s t-test).  However, apoptosis and proliferation rates were not altered 
following re-expression of myf5 (Fig. S2), supporting our findings that mylpfa-myf5 
expressing ERMS initiate earlier and with higher penetrance than those that express only 
rag2-kRASG12D (Fig. 1I, p<0.001, log-rank Mantel-Cox test).  Together, these data show 
that re-expression of myf5 in more differentiated myosin+ ERMS cells not only leads to 
more differentiated tumors, but also accelerated tumorigenesis by enhancing initiation 
and penetrance of kRASG12D-induced ERMS. 
To confirm that differentiation changes seen on histological review were confined 
to fully transformed ERMS cells, we next assessed the histology of ERMS following 
transplantation into immune-deficient rag2E450fs recipient fish (Fig. 2A-F) (Tang et al. 
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2014). As expected, kRASG12D-expressing ERMS were comprised exclusively of 
undifferentiated stage 1 tumors (Fig. 2B,C and Fig. S1, n=10 transplanted fish arising 
from 4 independent tumors).  By contrast, ERMS that re-expressed myf5 had 
differentiated histology and were comprised of only stage 2 and 3 tumors (Fig. 2E,F and 
Fig. S1, n=15 transplanted fish from 4 independent tumors, p<,0.001, Chi-square test). 
Consistent with our histological evaluation, flow cytometric analysis revealed that 
differentiated, mylpfa-mCherry-positive (R+) tumor cells were greatly expanded in 
ERMS that aberrantly express myf5 (Fig. 2G-I, p=0.006, Student’s t-test). These same 
tumors had reduced numbers of myf5-GFP (G+) and double-positive (G+R+) cells. As 
was seen in primary ERMS, mylpfa-myf5 expressing ERMS also initiated earlier with 
higher penetrance when engrafted into rag2e450fs recipient animals (Fig. 2J, 2.5x105 
cells/fish, p=0.046, Mantel-Cox log-rank statistic) and had a trend toward being larger 
when assessed at 30 days post-transplantation (Fig. 2K). Effects on ERMS differentiation 
were confirmed in CG1 strain syngeneic animals, showing that mylpfa-myf5 expressing 
ERMS were more differentiated based on morphology (Fig. S3, p<0.01, Chi-square test) 
and contained larger numbers of differentiated, mylpfa-mCherry-positive (R+) ERMS 
cells following engraftment into syngeneic recipient fish (Fig. 2L, p<0.001, Student’s t-
test).  These transplanted tumors also had significant reductions in myf5-GFP (G+) and 
double-positive (G+R+) ERMS cells.  Together, these data confirm that mylpfa-myf5 
expressing ERMS were fully transformed and yet more differentiated than ERMS that 
express only kRASG12D.  
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myf5 confers self-renewal and tumor-propagating ability to differentiated ERMS cells 
 Because endogenous myf5 expression labels self-renewing TPCs in zebrafish 
kRASG12D-induced ERMS (Ignatius et al. 2012; Chen et al. 2014), we next questioned if 
self-renewal and TPC frequency might be altered in mylpfa-myf5 expressing ERMS.  
Specifically, rag2-kRASG12D was coinjected with or without mylpfa-myf5 into one-cell 
stage, CG1 syngeneic myf5-GFP/mylpfa-mCherry transgenic animals. Following tumor 
growth, cell subpopulations were isolated by FACS and transplanted into syngeneic 
recipient fish at limiting dilution (1x103-10 cells/fish, purity >85%, and >95% viability).  
As previously reported (Ignatius et al. 2012), only the myf5-GFP+ single-positive ERMS 
cells from kRASG12D-alone expressing ERMS could efficiently engraft tumors into CG1-
strain syngeneic recipient animals (Fig. S3, Table 1; n=3 ERMS).  By contrast, both the 
myf5-GFP+ single-positive (G+) and differentiated myf5-GFP+; mylpfa-mCherry+ 
double positive (G+R+) ERMS cells could engraft disease when isolated from mylpfa-
myf5 expressing ERMS  (n=3 tumors analyzed, Table 1 and Fig. 3A-K). Double positive 
cells isolated from mylpfa-myf5 expressing ERMS had a >6 fold increase in engraftment 
potential when compared with kRASG12D -alone expressing ERMS (p=0.0002, ELDA 
analysis).  Importantly, engrafted tumors displayed similar histology following 
engraftment with sorted cells (Fig. 3B,E,H and Fig. S3). Quantitative real-time PCR of 
sorted cell fractions showed similar gene expression in either kRASG12D-expressing or 
kRAS+myf5 expressing ERMS, with the exception of myf5, which was highly expressed 
in the G+R+ population (Fig. 3L,M). Taken together, these data show that re-expression 
of myf5 can lead to acquisition of self-renewal potential in differentiated mylpfa-
expressing ERMS cells.  
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MYF5 and MYOD expression define unique subsets of human RMS 
 To explore the role of MRFs in human RMS, we next assessed MYF5 and MYOD 
transcript expression in human primary tumor samples.  Analysis of microarray gene 
expression (n=133 samples; Davicioni et al. 2009) and RNA sequencing data sets (n=98 
samples; Shern et al. 2014) uncovered that MYOD and MYF5 were co-expressed along 
with specific muscle genes and defined two distinct gene regulatory modules in human 
RMS.  One gene module included the co-expression of MYF5, MYF6 and PAX7 while the 
other expressed MYOD, CDH15, and MYOG (Fig. 4A,B). This correlation in gene 
expression was seen in comparison of all human RMS or within tumors arising 
specifically in the ERMS subtype (Fig. S4), suggesting that MYF5 and MYOD likely sit 
atop a transcriptional hierarchy to regulate muscle-specific gene programs in RMS.  
 We next assessed a panel of human RMS cell lines for expression of MYF5 and 
MYOD following Western blot analysis. Remarkably, we found that the expression of 
these proteins was largely mutually exclusive in human RMS (Fig. 4C), suggesting that 
these proteins may act redundantly to regulate human RMS self-renewal. This analysis 
also uncovered that only the Rh18 cell line expressed MYF5 in our panel of commonly 
used human RMS cell lines. MYF5 and MYOD expression were also assessed at the 
single cell level through immunofluorescence and verified that MYF5 and MYOD were 
mutually exclusively expressed within single ERMS cells from in Rh18 and RD cells 
(Fig. S5). ChIP-seq was performed for MYF5 in Rh18 cells and compared with 
previously published ChIP-seq data for MYOD performed in RD cells (see Materials and 
Methods section).  This analysis uncovered a common set of promoter and enhancer 
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regions bound by both MYOD and MYF5 (Fig. S6A). 86% of commonly bound genomic 
DNA regions were confined to enhancers as defined by H3K27 acetylation occupancy.  
Unbiased analysis of commonly bound target genes using GREAT revealed an 
enrichment of genes that regulate myogenic cell fate and cell cycle (Fig. S6). Enrichment 
of GO terms included “embryonic skeletal system development”, “skeletal muscle tissue 
development” and “cyclin-dependent protein kinase holoenzyme complex” (binomial 
p<1x10-9). Signal tracks of ChIP-seq and RNA-seq independently confirmed common 
binding of MYF5 and MYOD to genes that regulate myogenic cell fate and cell cycle 
(Fig. S6C). Collectively, our data show significant inter-tumoral heterogeneity in the 
expression of myogenic factors within both ERMS and ARMS and suggests convergence 
of these transcription factors on regulating a common set of genes that modulate 
myogenic cell fate and cell cycle.  
MYF5 and MYOD are required for continued tumor growth in human ERMS 
Human Rh18 ERMS cells express high levels of MYF5 and were utilized in loss-
of-function studies to assess roles in regulating proliferation, growth, and apoptosis. 
MYF5 protein expression was effectively reduced following siRNA-MYF5 knockdown 
(Fig. 4D) and resulted in significant impairment of cell proliferation as assessed by EdU-
incorporation and flow cytometry (Fig.4E, p<0.001, Student’s t-test, N=3, triplicate).  For 
example, si-MYF5 treated cells showed a remarkable 70% reduction in S-phase cycling 
cells following 48 hours of treatment (p<0.001, Student’s t-test, Fig. 4D).  siRNA-MYF5 
treated cells also had impaired growth when assessed by manual nuclei counts following 
knockdown (Fig. 4F, p <0.01, Student’s t-test, N=3, triplicate).  Apoptosis was not 
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increased in siRNA-MYF5 treated cells (Fig. S7C). These results were independently 
confirmed using stable knock-down with three independent lentiviral shRNAs specific to 
MYF5 (Fig. 4G-I, protein knockdown ranged from 50%-95%). All shRNA-MYF5 
knockdown cells showed a remarkable cell cycle arrest with a virtual abrogation of S-
phase cycling cells (Fig. 4H and Fig. S7A,B; p<0.001, Student’s t-test).  This phenotype 
was accompanied by a significant 60% decrease in cell number as assessed by manual 
nuclei counts and compared with shRNA control treated cells (Fig. 4I, N>3, triplicate). 
As was seen in siRNA-treated cells, apoptosis was not elevated following shRNA-MYF5 
knockdown (Fig. S7D), suggesting that the major mechanism regulated by MYF5 was 
regulation of cell cycle and proliferation. 
Given the prominent role MYF5 had in regulating cell growth in human ERMS 
and imparting self-renewal potential to zebrafish ERMS cells, we next wanted to assess if 
MYF5 was required for ERMS maintenance and growth in vivo.  Rh18 cells were 
infected with shRNAs and harvested at 72 hours post-infection. MYF5 knock-down was 
confirmed by Western blot analysis (Fig. 5A). Luciferase-mKate expressing Rh18 cells 
were transplanted into the flanks of NOD/SCID/IL2rg null mice (1x106 viable cells in 
matrigel per site). Control shRNA cells were implanted subcutaneously into the left flank 
and MYF5 knock-down cells into the right (n=6 animals, 2 independent shRNAs). 5 
hours after injection, mice were injected with luciferin and bioluminescence was 
measured.  This analysis confirmed that the same amount of control and knockdown cells 
had been injected into recipient mice (Fig. 5B, top panels).  Serial bioluminescence 
imaging showed that as early as 7 days post-implantation, tumor volume was reduced in 
MYF5 knockdown cells while control cells continued to grow (Fig. S8).  MYF5 
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knockdown cells continued to be further reduced at 14, 28, and 42 days post-
transplantation, with MYF5 knockdown cells being largely undetected at late time points 
(p=0.01, Student’s t-Test; Fig. 5B,C and Fig. S8). Taken together, these data show that 
MYF5 is required for continued tumor cell growth in vivo and confirm roles for MYF5 in 
tumor maintenance and cellular growth in human RMS. 
To assess if other MRFs can drive continued tumor growth and proliferation, we 
next performed MYOD knockdown in human RD ERMS cells. siRNA or shRNA knock-
down resulted in reduced proliferation and a striking reduction in S-phase cycling cells 
(Fig. 4J,K,M,N and Fig. S7E,F, p<0.001, Student’s t-test). RD cell number was reduced 
>30% following stable shRNA-MYOD knockdown (Fig. 4O), yet cells did not exhibit 
increased apoptosis (Fig. S7G).  These phenotypes were similar to those obtained 
following MYF5 knock-down in Rh18 cells, albeit with different kinetics and penetrance. 
Similar results were obtained following si-MYOD treatment of additional RMS cell lines 
including ERMS cell lines 381T and RMS559 and the ARMS cell line Rh3.  These cells 
lines all had >30% reduction in S-phase cells following siRNA treatment. Along with our 
ChIP-seq analysis, our data suggest that both MYF5 and MYOD likely regulate common 
gene programs that control cell self-renewal, cell cycle and myogenic differentiation 
arrest in a wide range of human RMS. 
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Discussion 
 
Rhabdomyosarcomas express bHLH myogenic regulatory transcription factors 
(MRFs), including MYF5 and MYOD (Clark et al. 1991; Kumar et al. 2000; Sebire and 
Malone 2003) but fail to activate terminal muscle differentiation programs. Several 
mechanisms have been shown to play a role in this differentiation arrest. These include 
disruption of the balance of MRF-E12 heterodimers and inhibitor complexes (Yang et al. 
2009; MacQuarrie et al. 2013), presence of inhibitory miRNAs (MacQuarrie et al. 2012), 
and deregulation of cell cycle (Fiddler et al. 1996). These data have therefore led to the 
suggestion that MRFs do not have a role in RMS transformation or in sustained tumor 
growth, but are rather retained from the target cell of transformation (Keller and 
Guttridge 2013).  Indeed, MYOD overexpression fails to differentiate ERMS cells (Yang 
et al. 2009), yet both MYF5 and MYOD potently reprogram fibroblasts into proliferating 
muscle cells (Tapscott et al. 1988; Braun et al. 1989). Our work using the zebrafish 
kRASG12D transgenic model has uncovered that endogenous Myf5 expression marks 
tumor-propagating ERMS cells (Chen et al. 2013a, 2014; Ignatius et al. 2012), leading us 
to experimentally assess roles for MYF5 in regulating ERMS growth and self-renewal in 
the studies outlined here.  Our experiments have shown that Myf5 can impart tumor-
propagating potential to differentiated cells in the kRASG12D–induced zebrafish ERMS 
model, suggesting important roles for myogenic regulatory transcription factors in 
regulating self-renewal and growth.  These data were confirmed by loss-of-function 
studies in human ERMS where MYF5 or MYOD loss suppressed RMS proliferation and 
reduced viability in vitro.  Similar effects were also observed in xenograft studies, where 
MYF5-deficient ERMS cells failed to grow in vivo.  Taken together, our results support 
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powerful and unappreciated roles of myogenic transcription factors in driving sustained 
ERMS growth, likely by deregulating both myogenic gene programs and cell cycle genes.  
These data strongly contrast with current thinking in the field that myogenic transcription 
factors are commonly expressed in tumors, indicative of cell-of-origin rather than having 
true functional effects on tumorigenesis. 
It is becoming increasingly appreciated that developmental transcription factors and 
pathways are commonly co-opted by cancer to regulate growth and self-renewal. For 
example, the TAL1/SCL bHLH transcription factor is required for hematopoietic stem 
cell specification and self-renewal during development. TAL1/SCL is overexpressed in 
60% of T-cell acute lymphoblastic leukemia (T-ALL) (Ferrando et al. 2002) and can 
reprogram thymocytes into self-renewing, pre-leukemic cells (Gerby et al. 2014). This 
same paradigm has also been seen in brain tumors.  For example, the bHLH transcription 
factor OLIG2 is required for self-renewal of normal neural progenitor cells (Imayoshi and 
Kageyama 2014) and yet, is also a marker of glioblastoma TPCs and regulates self-
renewal in both mouse and human disease (Ligon et al. 2007; Trépant et al. 2014; Suva et 
al. 2014; Beyeler et al. 2014). Our results in ERMS parallel those outlined for T-ALL and 
glioblastoma, showing that MYF5 is capable of reprogramming differentiated ERMS 
cells into self-renewing cells and is required for sustained proliferation, growth, viability, 
and self-renewal of human RMS. Our work has also uncovered redundancy in MRF 
function in RMS growth, with MYOD being expressed in a substantial fraction of human 
RMS and required for proliferation.  Taken together, these results demonstrate that cancer 
pathways are likely shared with their non-malignant counterparts and suggest a dominant 
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way cancers drive elevated self-renewal is through aberrant activation of well-established 
developmental pathways that drive tissue specification, growth, and regeneration. 
 Our molecular analysis also uncovered that MYF5 and MYOD are largely 
mutually-exclusively expressed in human ERMS and each drives sustained growth in 
tumors that express these factors. For example, loss-of-function studies confirmed 
important roles for both MYF5 and MYOD in regulating proliferation both in vitro and in 
vivo. During skeletal muscle development, Myf5 and MyoD act redundantly to regulate 
muscle specification and differentiation (Buckingham and Rigby 2014). Myf5 and MyoD 
are also required for self-renewal of adult muscle satellite cells. For example, Haldar and 
colleagues have concluded that a subset of muscle progenitors are specified by MyoD 
without the contribution of Myf5 (Haldar et al. 2008, 2014). Tajbaksh and colleagues 
have shown that a subset of adult muscle progenitors express Myf5 and then MyoD 
sequentially during their specification with both being required for muscle regeneration 
following injury (Comai et al. 2014). This same redundancy of Myf5 and MyoD in 
development and muscle injury has been reported in zebrafish (Hinits et al. 2009; Siegel 
et al. 2013), Drosophila (Abmayr and Keller 1998) and Xenopus (Chanoine and Hardy 
2003), showing a high conservation of these developmental pathways throughout 
evolution.  Indeed, Myf5 and MyoD can act redundantly in reprogramming fibroblasts 
into muscle cell fates (Braun et al. 1989; Tapscott et al. 1988) and overlap in binding of 
common enhancer and promoter targets (Conerly et al. 2016). Our data in ERMS 
suggests a model where either MYF5 or MYOD are re-activated in RMS cells and act 
redundantly to sustain self-renewal and proliferation.  We also posit that these factors 
regulate a common core self-renewal program in RMS downstream of either MYF5 or 
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MYOD, providing new and exciting avenues of study and potential new therapeutic 
strategies for the treatment of this disease. 
 
 
Materials and Methods  
 
 
Animals and protocol approvals 
Studies were approved by the Massachusetts General Hospital Subcommittee on 
Research Animal Care under the protocol #2011N000127 (zebrafish) and #2013N000038 
(mouse). Biosafety lentiviral work was approved by the Partners IBC under protocol 
#2013B000039. Zebrafish used in this work include: CG1 strain (Mizgirev and Revskoy 
2006), myf5-GFP (Chen et al. 2007) and mylpfa-mCherry (previously mylz2-mCherry) 
(Xu et al. 1999) transgenic zebrafish lines and  ragE450fs homozygous fish (Tang et al. 
2014; Tenente et al. 2014). myf5-GFP/mylpfa-mCherry double transgenic fish (AB strain) 
were outcrossed 10 times into CG1-strain zebrafish to generate compound syngeneic 
transgenic zebrafish (Ignatius et al. 2012). 6-week-old NOD/SCID/Il2rg null female mice 
were used in this work (N=12). 
 
Micro-injection and ERMS generation in transgenic zebrafish 
rag2-kRASG12D and mylpfa-mCherry constructs were described previously 
(Langenau et al. 2007; Smith et al. 2010).  The mylpfa-myf5 construct was obtained by 
gateway cloning using a zebrafish myf5 ORF from 24hpf zebrafish embryo cDNA 
(http://tol2kit.genetics.utah.edu). rag2-kRASG12D and mylpfa-myf5 constructs were 
linearized with XhoI, phenol:chloroform-extracted, ethanol-precipitated, resuspended in 
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0.5× Tris-EDTA + 0.1 M KCl, and injected into one-cell stage embryos of the respective 
backgrounds, as previously described (Tenente et al. 2014; Langenau et al. 2007). 
 
Quantification of zebrafish RMS size, tumor onset, and penetrance. 
Zebrafish were monitored every 3-4 days for time-to-tumor onset using an epi-
fluorescent stereomicroscope.  Animals were imaged at 10 days of life until 55 days of 
life. Primary tumor size was quantified from photomicrographs taken at 30 days of life 
and calculated by multiplying fluorescence intensity by D2 pixel area using the ImageJ 
software package as previously described (Chen et al. 2014). Kaplan-Meier tumor onset 
analysis was performed using Graphpad Prism® Software and statistically analyzed using 
the Log-rank statistic.  
 
Zebrafish histology and immunohistochemistry 
Paraffin embedding, sectioning and immunohistochemical analysis of zebrafish 
sections were performed as described (Chen et al. 2013a, 2014; Ignatius et al. 2012). 
Antibodies used for immunohistochemistry included: phospho-H3 (1:6000, Santa Cruz) 
and cleaved-caspase3 (1:250, Cell Signaling). All histopathology procedures were 
performed at the MGH and BWH DF/HCC Research Pathology Cores. Slides were 
imaged using a transmitted light Olympus BX41 microscope. Pathology review and 
staging were completed by G.P.N.  Tumor histology classification was assigned as 
described in Supplemental Figure S1 with stage 1 being the least differentiated with 
tumors being comprised of only small round blue cells.  Stage 2 and 3 ERMS were 
assigned based on the preponderance of rhabdomyoblast cells, fiberous and spindle cell 
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morphology, with a low proportion of interspersed smaller round blue cells. Staging was 
completed essentially as described (Storer et al., 2013). 
 
Zebrafish ERMS cell transplantation 
FACS analysis and RMS cell transplantation by intraperitoneal injection were 
completed essentially as described (Chen et al. 2014; Ignatius et al. 2012; Smith et al. 
2010; Langenau et al. 2007). RMS tumor cells were stained with DAPI to exclude dead 
cells and sorted twice using a Laser BD FACSAria II Cell Sorter. Sort purity and viability 
were assessed after two rounds of sorting when possible, exceeding 85% and 95% 
respectively. Fish were monitored for tumor engraftment from 10 to 120 days post 
transplantation. Tumor-propagating cell frequency was quantified following 
transplantation into CG1 syngeneic recipient fish using the Extreme Limiting Dilution 
Analysis software (http://bioinf.wehi.edu.au/software/elda/). A subset of transplanted fish 
were fixed in 4% PFA, sectioned, stained with Hematoxylin and Eosin, and staged for 
differentiation score.   
 
Gene expression analysis 
 Quantitative real-time PCR was completed using a Roche Lightcycler 480 
machine. PCR primers and specific conditions are available in Supplemental Table 1. 
Relative quantification was performed using the -ΔΔCt method relative to 18S. 
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Human RMS cell lines 
The human RD cell line was obtained from ATCC’s cell biology collection 
(Manassas, Virginia). SMS-CTR, 381T, Rh3, Rh5 and Rh30 cell lines were kindly 
provided by Dr. Corrine Linardic (Duke University, North Carolina), the Rh18 cell line 
(fusion-negative) by Dr. Peter Houghton (Ohio State University, Ohio) and RMS559 by 
Dr. Jonathan Fletcher (Brigham and Women’s Hospital, Massachusetts). The human 
MB1208-1 human skeletal muscle cell line was kindly provided by Dr. Louis Kunkel 
(Boston Children’s Hospital, Massachusetts). Characteristics of these human RMS 
(Hinson et al. 2013; Sokolowski et al. 2014) and skeletal muscle (Alexander et al. 2011) 
cell lines  have been reported previously.  
 
Western blot analysis 
Total cell lysates from human RMS cell lines were obtained following lysis in 
2%SDS lysis buffer supplemented with protease inhibitors (Santa Cruz Biotechnology).  
Samples were boiled, vortexed and homogenized through a 28G syringe. 20-40 μg of 
protein was loaded in 4-20% Mini-Protean TGX gels (Biorad) and transferred onto PVDF 
membranes.  Western blot analysis used primary antibodies: rabbit a-MYF5 (1:5000, 
Abcam ab125078), mouse a-MYOD1 (1:1000, Abcam ab16148), rabbit a-MYOD1 
(1:1000, Abcam ab133627), rabbit a-GAPDH (1:2000, Cell Signaling 2118), mouse a-
TUBULIN (1:2500, Abcam ab4074) and secondary antibodies: HRP anti-rabbit (1:2000, 
Cell Signaling 7074) or HRP anti-mouse (1:3000, GE Healthcare NA93IV). Blocking 
was completed using 5% skim milk/TBST. Membranes were developed using a ECL 
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reagent (Western Lightening Plus-ECL, Perkin Elmer or sensitive SuperSignal West 
femto Maximum Sensitivity Substrate, Thermo Scientific).  
 
MYF5 and MYOD siRNA and immunofluorescence  
 Gene-specific smart-pool or control siRNAs (Dharmacon, GE Life Sciences) 
(0.01μM) were reverse-transfected into cells using RNAiMax lipofectamine transfection 
reagent (Life Technologies) in flat clear bottom 96 well plates. Cells were then fixed at 
96 hours post transfection in 4% PFA/PBS, washed in x1 PBS and permeabilized in 0.5% 
TritonX-100/PBS. Antibodies used were rabbit a-Myf5 (1:400, Abcam ab125078) and 
mouse a-MyoD (1:200, Abcam ab16148) in 2% goat serum/PBS, Alexa 488 goat anti-
mouse (1:1000, Invitrogen A11029) and Alexa 594 goat anti-rabbit (1:1000 Invitrogen 
A11037).  Cells were incubated with DAPI (1 μg/ml), and imaged at 200x using a 
LSM710 Zeiss Laser scanning confocal microscope.  Images were processed in ImageJ 
and Adobe Photoshop.  
 For EdU and AnnexinV assays, gene-specific smart-pool or control siRNAs 
(Dharmacon, GE Life Sciences) (5μM) were added to Rh18, RD, 381T, RMS559 and 
Rh3 cells in a 6-well plate and incubated for 24-72 hours prior to analysis. 
 
MYF5 and MYOD lentiviral shRNA knock-down 
Scrambled (SCR) control shRNA and hMYF5 or hMYOD1 specific shRNAs were 
delivered on the pLKO.1-background vector (from MGH Molecular Profiling 
Laboratory) and packaged using 293T cells (see Supplemental Material for sequences). 
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RMS cells were infected with viral particles for 24h at 37oC with 8μg/ml of polybrene 
(EMD Millipore). 
 
 Cell viability, EdU proliferation analysis, and apoptosis assays  
 Nuclei counts were performed following incubation with NucBlue Live 
ReadyProbes® Reagent (Life Technologies).  Cells were imaged at 100X and 400X 
magnification using an inverted fluorescent microscope. Manual cell counts were 
performed using the ImageJ® software.  Three fields were counted per well and 
completed in triplicate. Cell cycle analysis was performed using the EdU Click-iT® plus 
EdU Flow Cytometry-AlexaFluor® 647 picol azide assay (Life Technologies) following 
2h (RD, 381T, Rh3, RMS559) or 6h incubation (Rh18) with 10 μM EdU.  Apoptosis was 
assessed using the AnnexinV-AlexaFluor® 647/PI assay (Life Technologies). Flow 
cytometric analysis was performed using the SORP4 Laser BD LSRII Flow Cytometer 
and processed with the FlowJo® Software. 
 
Gene expression correlation analysis 
 Previously published microarray gene expression data were processed and 
normalized using Robust Multichip Average (RMA) normalization (Davicioni et al. 
2006).  Previously published RNAseq gene expression data from human RMS were 
processed and normalized using a standard Tuxedo pipeline (Shern et al. 2014, Trapnell 
et al. 2012).  The resulting expression values from the microarray and RNAseq datasets 
were then log2 transformed. Pearson correlation was determined for the following genes: 
CDH15, MYF5, MYF6, MYOD1, MYOG, PAX3, and PAX7. The correlation heatmap was 
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plotted using the R package “fheatmap” (Fantastic Heatmap. R package version 1.0.1. 
http://CRAN.R-project.org/package=fheatmap) and processed using Adobe Photoshop®.   
 
ChIP-seq of human RMS cell lines 
 Chromatin immunoprecipitations were performed on RH18 cells using the Chip-
IT High sensitivity kit (Active Motif) and anti-H3K27ac (Active Motif) or anti-MYF5 
(C-20, Santa Cruz) antibodies.  Resultant purified immunoprecipitated DNA was used for 
library preparation using the TruSeq ChIP sample preparation kit (Illumina) without 
modifications.  11-18 library preps were mixed for multiplexed single read sequencing 
using the NextSeq500 (Illumina).  Previously published MYOD ChIP-seq data from RD 
was downloaded and processed in parallel with the newly generated sequencing data 
(GSE50415).  Reads were aligned to the hg19 reference using BWA.  ChIP-seq peaks 
were identified using MACS 2.1 (Zhang et al. 2008). Gene ontology was performed using 
GREAT (McLean et al. 2010). Differential peak calling between RD and RH18 was 
performed using bedtools v2.25.0 and visualized using NGS plot (Shen et al. 2014). 
Genomic regions were visualized using IGV v2.3.40. 
 
Mouse xenografts and luciferase imaging  
Rh18 ERMS cells were co-infected with pLKO.1-shRNA lentivirus and pLKO.1-
luc-mKate (gift from Drs. Matthijssens and Van Vlierberghe, Ghent University, 
Belgium). At 3 days post-infection, cells were collected and counted. An aliquot of cells 
was analyzed using the SORP4 Laser BD LSRII Flow Cytometer to determine viability 
following DAPI staining. A separated aliquot of cells were harvested and used for 
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Western blot analysis. Equal numbers of viable cells were then embedded into Matrigel 
(Corning) at a final concentration of 1x106 of viable cells per 200 μl. Six-week-old 
NOD/SCID/IL2rg null female mice were anesthetized by isofluorane and transplanted 
with Rh18 scramble-shRNA/mKate-luc cells subcutaneously into the left flank whereas 
Rh18 sh-MYF5/mKate-luc cells injected on the right (200 μl/flank injection). Tumor 
growth was monitored by weekly bioluminescence imaging following subcutaneous 
injection into the loose tissue over the neck of 75mg/kg D-luciferin (Perkin Elmer) in 100 
μl of PBS.  Imaging was completed and analyzed using the IVIS Lumina II (Caliper Life 
Science). Comparison between groups was performed using a Student’s t-test. 
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Table 1. Limiting dilution cell transplantation shows that forced myf5 expression 
confers tumor-propagating ability to myf5-GFP+/mylpfa-mCherry+ cells.	 Engrafted 
animals per cell dose are noted. Experiments for three independent primary-derived 
tumors are shown. G+ (myf5-GFP+/mylpfa-mCherry-), G+R+ (myf5-GFP+/mylpfa-
mCherry+),  R+ (myf5-GFP-/mylpfa-mCherry+),  DN (myf5-GFP-/mylpfa-mCherry-). 
Not applicable (NA); tumor-propagating cell frequency (TPC Freq.); 95% confidence 
interval (95% CI). Lower panel denotes cumulative TPC frequency for all three ERMS 
analyzed per genotype.  Asterisk denotes p=0.0002 by ELDA analysis. 
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Figure Legends 
 
Figure 1. Forced Myf5 expression in myosin-expressing ERMS cells elevates tumor 
cell differentiation, increases tumor size, and accelerates time to primary tumor-
onset. (A-F) Histological analysis of primary ERMS developing in myf5-GFP/mylpfa-
mCherry AB-strain zebrafish. Transgenic kRASG12D-expressing ERMS (A-C) compared 
with those that express both kRASG12 and mylpfa:myf5 (D-F).  Animals imaged at 35 dpf 
(A,D). H&E-stained sections of representative tumors (B,E) and quantification of 
differentiation within individual tumors  (C,F; 1-less differentiated and 3-most 
differentiated).  Asterisk denotes p=0.015 by Chi square test. (G) Quantitative real-time 
PCR gene expression performed on bulk ERMS cells, confirming high myf5 expression, 
increased differentiation, and high expression of self-renewal associated genes in ERMS 
that co-express kRASG12D and mylpfa:myf5 (K+M).   kRASG12D alone expressing 
ERMS (K). Average gene expression with 50% confidence intervals denoted by box, 
respectively (Mean, maximum, and minimum denoted). (H) Relative tumor size of 
primary ERMS at 30 dpf (Mean, maximum, and minimum denoted).  Box shows 50% 
confidence interval. Asterisk denotes p=0.0108, Student’s t-test. (I) Kaplan-Meijer 
analysis denoting time-to-tumor onset (p<0.0001, Log-rank Statistic, n=494 fish analyzed 
for K and n=470 for K+M). Scale bars: 2mm (A,D) and 50 μm (B,E). Asterisks in panels 
G-H denote *, p<0.05 and **, p<0.01 by Student’s t-test. 
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Figure 2. Tumors with forced Myf5 expression are fully transformed and retain a 
differentiated phenotype following engraftment into recipient animals. (A-F) 
Histological analysis of transplanted fish. kRASG12D expressing ERMS arising in 
rag2E450fs transplant recipient fish (A-C) compared with those that express both kRASG12 
and mylpfa-myf5 (D-F). Tumors were created in stable transgenic myf5-GFP/mylpfa-
mCherry transgenic, AB-strain zebrafish and imaged following engraftment into recipient 
fish at 30 days post injection. H&E-stained sections of representative tumors (B,E) and 
quantification of differentiation within individual ERMS  (C,F; 1-less differentiated and 
3-most differentiated). Asterisk denotes p<0.001 by Chi square test. (G,H) Representative 
flow cytometric analysis of fluorescent-labeled ERMS cells isolated from transplanted 
rag2E450fs zebrafish. (I) Graphical summary of ERMS cell subfractions that grow 
following engraftment into immune-deficient rag2E450fs mutant. Individual tumors are 
represented as separate bars with the proportion of G+ (green), G+R+ (yellow) and R+ 
(red) sub-populations denoted. (J) Kaplan-Meijer analysis showing time-to-tumor onset 
in transplanted ERMS arising in rag2E450fs zebrafish (p = 0.046, Log-rank Statistic, 2x105 
cells/fish, n>12 animals per arm, representing ≥3 independently arising primary ERMS). 
(K) Relative tumor size at 30 days post engraftment (same animals analyzed as in J). (L) 
Similar results were obtained following engraftment of myf5-GFP/mylpfa-mCherry 
ERMS cells into syngeneic recipient fish (compare I to L, p<0.0001, Student’s T-test, n> 
≥3 independently arising primary ERMS and assessed in ≥2 animals per transplanted 
tumor).  Scale bars equal 2mm (A,D) and 50 μm (B,E). *, p<0.05; **, p<0.01; ***, 
p<0.001 by Student’s t-test. 
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Figure 3. Limiting dilution cell transplantation shows that forced myf5 expression 
confers tumor-propagating ability to differentiated myf5-GFP+/mylpfa-mCherry+ 
cells. Tumors were generated in myf5/mylpfa-mCherry CG1-stain syngeneic zebrafish. 
Representative tumors arising in primary transplanted fish (A-C) or following 
engraftment with highly purified myf5-GFP+, mylpfa-mCherry-negative (D-F) or myf5-
GFP+, mylpfa-mCherry+ ERMS cells (G-I). Sort purity following FACS was >92% and 
is denoted in panels D and G. Cell viability was >95%.  (J,K) Graphical summary of 
tumor engraftment following limiting dilution cell transplantation using highly purified 
sorted ERMS cells.  Data is combined from all tumors shown in Table 1. ***, p<0.0002 
by ELDA analysis.  (L,M) Gene expression analysis of sorted G+ or G+R+ ERMS cells 
from representative kRASG12D (L) or kRASG12D; mylpfa-myf5 (M) expressing ERMS (SD, 
n=3 technical replicates per tumor).  Asterisks denote **, p<0.01 and ***, p<0.001 by 
Student’s t-test. 
 
Figure 4. MYF5 and MYOD are required for human ERMS proliferation and 
growth.  (A-B) Pearson correlation for gene co-expression in primary human RMS as 
assessed by microarray (A) or RNA-sequencing (B).  (C) Western blot analysis for 
human RMS cell lines.  (D-I) Rh18 ERMS cells following MYF5 knockdown with 
siRNA (D-F) or shRNA (G-I).  (J-O) RD ERMS cells following MYOD knockdown with 
siRNA (J-L) or shRNA (M-O).    Western blot analysis following knockdown at 72h 
(D,J) and 96h (G,M). EDU and Propidium Iodide (PI) cell cycle analysis assessed by 
flow cytometry at 48h (E,K) and 72h (H,N). Viability as assessed by manual nuclei 
counts of NucBlue+ cells at 72 hours (F,L) or 96 hours (I,O).  Standard deviation denoted 
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in FACS plots and viability graphs. *, p<0.05; **, p<0.01; ***, p<0.001 by Student’s t-
test.   
 
Figure 5. MYF5 is required for human ERMS growth and maintenance in xenograft 
transplants.    (A) Western blot analysis following control and MYF5 shRNA 
knockdown in Rh18 cells.  The percentage of MYF5 protein remaining following 48 
hours of knockdown is noted. (B) Luciferase bioluminescent imaging of engrafted tumor 
cells following implantation into the flanks of NOD/SCID/IL2g null mice.  Three 
representative animals are shown at each time point of analysis at day 0 (d0) and day 62 
(d62). Control shRNA cells implanted into left flank and MYF5 knockdown into the right 
(N=6 mice per shRNA). Intensity represents total luminescence units measured per 
region of interest (L.U.) (C) Quantification of tumor volume from 0 and 62 days post 
implantation.  Standard error of the mean. **, p<0.01 by Student’s t-test. 
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Supplemental Figure and Table Legends 
 
Supplemental Figure S1. Histological classification of zebrafish ERMS based on 
differentiation score. This supplemental figure relates to Figures 1 and 2 and 
Supplemental Figure S3. Representative H&E-stained sections of zebrafish ERMS 
assigned to each differentiation category. Primary RMS (A) and transplanted RMS (B). 
Scale bars, 100 μm. 
 
Supplemental Figure S2. Immunohistochemistry analysis of proliferation and 
apoptosis in zebrafish primary ERMS. This supplemental figure relates to Figure 1. 
(A) Representative H&E-stained sections and immunohistochemistry for phospho-H3 
(pH3) and cleaved caspase-3 (CC3). (B) Quantification of the total number of pH3-
positive cells per 400x imaging field (n=average of 3 fields/tumor section). (C) 
Quantification of the total number of CC3-positive cells per 400x imaging field 
(n=average of 3 fields/tumor section). Boxes in B-C denote 50% confidence interval and 
mean, maximum, and minimum shown. kRASG12D [K] (N=5) and kRASG12D; 
mylpfa:myf5 [K+M]  (N=11). Scale bars, 100 μm (A). Not significant by Student’s t-test 
(n.s.). 
 
Supplemental Figure S3. Analysis of transplanted ERMS arising from myf5-
GFP/mylpfa-mCherry transgenic, CG1-strain syngeneic zebrafish with forced Myf5 
expression. This supplemental figure relates to Figures 2 and 3. (A,D) Representative 
images of transplanted fish. ERMS were created in myf5-GFP/mylpfa-mCherry 
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transgenic, CG1-strain syngeneic zebrafish and imaged following 30 days of engraftment. 
(B,E) Representative histology of transplanted tumors. (C,F) Quantification of 
differentiation based on histological review (1-less differentiated and 3-most 
differentiated).  **, p<0.01 by Chi-square test. (G-P) Representative examples of sort 
purity following FACS for cells used in limiting dilution cell transplantation experiments.   
(G-K) kRASG12D-alone expressing ERMS (data shown in main Figure 3J). (L-P) 
kRASG12D + mylpfa:myf5 expressing ERMS (shown in Figure 3A-C).  Sort purity 
following FACS shown in H-K and M-P. Scale bars equal 2mm (A,D) and 100μm (B,E). 
 
Supplemental Figure S4. Pearson correlation of gene expression from RNA 
sequencing data of primary human RMS. This supplemental figure relates to Figure 4. 
(A) Analysis of RNA-sequencing data from primary ERMS (FN-RMS, N=70) and (B) 
fusion-positive ARMS (FP-RMS; N=33 samples).  
 
Supplemental Figure S5. Immunofluorescence for MYF5 and MYOD in Rh18 and 
RD ERMS cell lines.   This supplemental figure relates to Figure 4.  (A) Confocal 
microscopy images of DAPI and antibody immunofluorescence-staining of Rh18 cells 
treated with control siRNA or si-MYF5 for 72 hours. (B) Confocal microscopy images of 
DAPI and antibody immunofluorescence-staining of RD cells treated with control siRNA 
or si-MYOD. Anti-MYOD (green) and anti-MYF5 (red) and counterstained with DAPI 
(blue).  Merged image shown to right. Scale bar equals 100 μm.   Arrows denote 
representative examples of MYF5+/MYOD-negative RH18 cells in A and MYF5-
negative/MYOD+ RD cells in B. 
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Supplemental Figure S6. MYF5 and MYOD bind common promoter and enhancer 
regions and are predicted to regulate genes involved in muscle development and cell 
cycle. This supplemental figure relates to text in Results. (A) ChIP-seq identified 
genomic locations bound by MYOD in RD cells, MYF5 in RH18 cell, and H3K27 
acetylation (H3K27ac).  Common binding sites are denoted by boxed region at the top, 
with 86% of binding sites being found in enhancer regions (right panels).  (B) GREAT 
gene ontology enrichment from regions bound by both MYOD in RD cells and MYF5 in 
RH18 cells. GO Biological Processes, GO Cellular Component predictions, and p-values 
denoted.  (C) Signal tracks of ChIP-seq and RNA-seq surrounding MYOG (top) and 
CCND1 (bottom).  Numbers to the right of each track indicate reads per million mapped 
reads. 
 
Supplemental Figure S7. MYF5 and MYOD are required for human RMS 
proliferation and growth in vitro. This supplemental figure relates to Figure 4 and text 
in Results. (A-D) Rh18 ERMS cells following MYF5 knockdown with shRNA (A,B,D) 
or siRNA (C). (E-G) RD ERMS cells following MYOD knockdown with shRNA (E-F) 
or siRNA (G). (H-S) siRNA knockdown of MYOD completed in additional RMS cell 
lines.  (H-K) 381T ERMS; (L-O) RMS559 ERMS; (P-S) Rh3 ARMS/FP-RMS cells. All 
analysis was completed at 72 hours after infection, with exception to I,J,M,N,Q, and R 
which were completed at 48 hours. Standard deviation is noted in bar graphs. *, p<0.05; 
**, p<0.01; ***, p<0.001, p<0.0001 by Student’s t-test.  Not significant (n.s.) 
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Supplemental Figure S8: MYF5 is required for human ERMS growth and 
maintenance following xenograft transplantation into NOD/SCID/IL2g null mice. 
This supplemental figure relates to Figure 5. (A) Luciferase bioluminescent imaging of 
representative animals shown at 0, 7, 14, 28, 55 and 62 days post-transplantation.  
Control shRNA cells were implanted into left flank and MYF5 knockdown into the right 
(white arrow). Intensity represents total luminescence units measured per region of 
interest (L.U.). (B,C) Quantification of tumor volume changes over time comparing sh-
scramble vs. sh-MYF5 #1 (B) or sh-MYF5 #2 (C). N=6 animals per analysis.  (D,E) 
Quantification of tumor volume at 0 and 62 days post implantation showing paired 
measurements of tumors arising in the same mouse over time. Standard error of the mean 
shown in B-C. **, p<0.01 by Student’s t-test. 
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Supplemental Table 1. Primers and shRNA sequences. 
Primer Name Sequence (5’-3’) 
hKRAS-QRT-F	 TTGATGGAGAAACCTGTCTCTTGG	
hKRAS-QRT-R	 CAAATACACAAAGAAAGCCCTCCC	
zmyf5-QRT-F	 CCAGACAGTCCAAACAACAGACC	
zmyf5-QRT-R	 TGAGCAAGCAGTGTGAGTAAGCG	
zmyog-QRT-F	 GTGGACAGCATAACGGGAACAG	
zmyog-QRT-R	 TCTGAAGGTAACGGTGAGTCGG	
zcdh15-QRT-F	 TGACATCCGAGACAACGTCTTTC	
zcdh15-QRT-R	 CACTGGGGCTCCTCAGAAAATC	
zmylpfa-F	 ACCGCAGAGGAGATGAAGAA	
zmylpfa-R	 TCCGTGTGTGATGACGTAGC	
zdesmin-QRT-F	 CGAGATTGACTCTCTCAAGGGCAC	
zdesmin-QRT-R	 GGGCGATAGTGTCCTGATAACCAC	
zc-met-QRT-F	 GTCATCCAGGTGGTGGTTTC	
zc-met-QRT-R	 CGTTGTGATGCTGTGGAGAC	
z18s-QRT-1-F	 TCGCTAGTTGGCATCGTTTATG	
z18s-QRT-1-R	 CGGAGGTTCGAAGACGATCA	
	 	
sh-RNA Target Sequence 
pLKO.1-sh-hMYF5 #1 GCCACTTTATAAGAAAGTGTA	
pLKO.1-sh-hMYF5 #2 GTCCTGATGTATCAAATGTAT	
pLKO.1-sh-hMYF5 #3 CCCACCTCCAACTGCTCTGAT	
    
pLKO.1-sh-hMYOD1 #1 CCTGTAAATAAGAGTTGCTTT 
pLKO.1-sh-hMYOD1 #2 ACTTCTATGACGACCCGTGTT 
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Discussion, Conclusions and
Future Directions
"Every discovery opens a new field for
investigation of facts, shows us the
imperfection of our theories. It has justly
been said, that the greater the circle of light,
the greater the boundary of darkness by
which it is surrounded."
Sir Humphry Davy
The Collected Works of Sir Humphry Davy
(1840)
Rhabdomyosarcoma is a rare, predominantly pediatric cancer. The slow ad-
vancement in our understanding of this disease and in the development of inno-
vative treatments thus comes from multiple branching factors: the lack of diverse
and widely available in vitro and in vivo models and other specific research tools,
the low number of patients that can be recruited into clinical trials, the scarcity
of biopsied material for research and a generalized unawareness and lack of in-
terest from the scientific, medical, pharmaceutical and general community and
consequent lack of generalized expertise.
By the start of this study (2011-2012), the available mouse models of FN-RMS
had several limitations that rendered its utilization for functionally studying the
role of drivers and modifier genes difficult. These mouse models highlighted the
role of the TP53 pathway in RMS initiation and suggested that RAS-pathway ac-
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tivation could play a role. However, these required multiple genetic perturba-
tions and complex genetic breeding and the tumors developed with long latency
(Fleischmann et al., 2003; Nanni et al., 2003). Well established mouse models of
FP-RMS were being employed (Keller and Capecchi, 2005; Keller et al., 2004a,b)
, but the molecular basis of FN-RMS, being more complex than in FP-RMS PAX3-
and PAX7-FOXO1, was still a matter of intense research and comprehensive
whole-genome approaches had only recently been deployed in primary patient
samples (Davicioni et al., 2006, 2009, 2010).
The prior report of a KRASG12D-driven zebrafish model by Langenau et al.,
2007 undisputedly showed that RAS pathway activation is a potent oncogenic
driver of tumors that morphologically and molecularly resemble ERMS. The
emergence of the zebrafish ERMS model posited clear advantages. High pen-
etrance (up to 40% of animals initiated tumors) and short latency (from 10d to
40d of age) allow for the study of hundreds of independently-generated and po-
tentially genetically-diverse tumors, therefore providing a broad sample of het-
erogeneous tumor locations, aggressiveness or metastatic potential. Importantly,
the zebrafish genome had a properly assembled version allowing for the employ-
ment of unbiased approaches (array or next-generation sequencing based). The
facile mode of generation and the possibility to employ co-injection approaches to
functionally assess oncogenic drivers of modifiers of disease, as well as labelling
sub-populations with fluorescent protein transgenes (Langenau et al., 2008) fur-
ther make it a powerful and attractive model to study the biological basis of this
disease.
Since then, the field has benefited greatly from a concerted effort to further
describe the molecular landscape of RMS (Chen et al., 2013; Shern et al., 2014),
develop novel allograft or xenograft-based and genetic mouse models (reviewed
in Kashi et al., 2015), critically assess and widely distribute cellular models (Hin-
son et al., 2013), and the utilization of these tools to address the main questions
of the field:
• WHAT IS THE CELL OF ORIGIN OF RMS?
• ARE THERE COMMON MECHANISMS TO SARCOMAGENESIS?
• WHAT IS THE MOLECULAR BASIS OF FN-RMS TRANSFORMATION?
• CAN WE FURTHER DEFINE MOLECULAR SUBGROUPS WITHIN RMS WITH A
DIFFERENTIAL BIOLOGICAL BASIS AND PROGNOSTIC VALUE?
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• HOW CAN WE DEVISE A PLETHORA OF MODELS IN BASIC RESEARCH AND
PRE-CLINICAL STUDIES THAT ACCURATELY REPRESENTS THE INTRA- AND
INTER-HETEROGENEITY OF RMS?
• CAN WE UNDERSTAND THE MECHANISMS OF RMS DIFFERENTIATION AR-
REST SO AS TO DEVELOP EFFICIENT DIFFERENTIATION THERAPIES?
• CAN WE UNDERSTAND AND PREVENT RELAPSED DISEASE IN RMS?
The present study has implications in several of these unanswered questions,
which are discussed in this Chapter.
5.1 Insights into intra-tumor heterogeneity, self-re-
newal and relapse
In order to assess self-renewal and differentiation potential of cancer cells,
several functional assays can be deployed.
A combination of these methods has been used to assess RMS intra-tumor
heterogeneity. These methods will be discussed below, in light of the observa-
tions here reported.
5.1.1 In vitro self-renewal assays
Self-renewing cells have been identified as CD133-expressing cells that are
enriched in spheroid (rhabdosphere) cultures in serum-free media and sphere
formation assays are now a standard assay to assess self-renewal effects in vitro
(Walter et al., 2011). Despite being a valuable tool, it is an artificial and indirect
assay and results should be interpreted with caution. In an ideal setting, cells
would be isolated directly from patient material and cultured in serum-free media
with defined growth factors such as the one used by Walter et al., 2011. This me-
dia is supposed to maintain cells in a self-renewing state. Sphere cells can then
be analyzed by sequencing methodologies and its gene expression compared
to both freshly-isolated cells and cells cultured as adherent cultures in regular
serum-media to identify self-renewal signatures of those tumors (similar to what
has been reported for RMS (Walter et al., 2011) and other tumors (Suva et al.,
2009, 2014)).
Additionally, self-renewal capacity of cells can be indirectly assessed by per-
forming sphere-forming assays. It is my view that the most accurate method is
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to use previously-generated spheroid cultures or primary-derived material, dis-
sociate these into single cells and re-plate these cells as single cells or 1-5
fluorescently-labelled cell mixes into multi-well plates. The number of wells with
formed spheres over the total number of cells plated thus acts as a surrogate for
the frequency of these self-renewing cells in the original tumor or culture (Suva
et al., 2014). Another assay that is more routinely used in the field is the assess-
ment of self-renewal of established RMS cell lines growing as adherent cultures
upon genetic or chemical perturbation. Cells are plated at different doses in sep-
arate wells and the media is then switched to the serum-free sphere media. The
number of detaching colonies is counted as a surrogate for TPC-frequency (Be-
lyea et al., 2011; Chen et al., 2014). There are several limitations with this ap-
proach: some established cell lines seem to be able to undergo this transition
more readily than others, limiting the assay to those cell lines; the assay is very
sensitive to external conditions, passage and conditions in which cells are grown
prior the essay; the essay is more effective in scoring all-or-none effects or other
cancer properties, such as the capacity of these cells to grow attached to the
plastic; most importantly, spheres can represent clusters of cells formed by ag-
gregation of cells rather than representing cell clusters originating from one single
self-renewing cell (my observations).
Due to these limitations, I was not able to deploy these assays in the experi-
ments described in Chapter 4. The MYF5-positive Rh18 cell line (Hinson et al.,
2013) utilized in this study does not promptly form spheres through this method.
I am however currently exploring self-renewal effects in vitro upon knock-down of
MYOD1 in MYOD1-positive RD cell cultures, since this is the cell line that more
promptly forms rhabdospheres (data not shown and (Chen et al., 2014)). Un-
fortunately, due to the scarcity of RMS cases, it is not possible for us to obtain
primary-derived xenograft or fresh primary cells of RMS at this time.
5.1.2 In vivo imaging and lineage-tracing
In any case, what better way to understand how cells organize within a tumor,
interact and cooperate in tumor maintenance and growth than to look inside and
observe what is going on?
In the experiments described in Chapter 3, we were able to visualize the
process of tumor initiation and several cellular behaviors of developing zebrafish
RMS tumors. Specifically, RMS mononuclear cells arise at the extreme outer
borders of myotome segments and move toward the midline and remain initially
incapable to bypass the horizontal myosepta, a single cell layer that separates
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myotome segments, until a subset of cells is able to cross this first barrier. Then,
more differentiated, tumor-derived cells are able to further cross a collagenous
barrier analogous to tendons in mammals (see Chapter 3, Figure 1). Other pro-
cesses, such as muscle fiber break-down, neovascularization and intravasation
were also observed at single cell resolution in this study (Ignatius et al., 2012).
Moreover, due to the more recent generation of rag2E450fs immune-compro-
mized zebrafish in an optically clear Casper zebrafish line (Tang et al., 2014,
2016; Tenente et al., 2014; White et al., 2008), these processes can now also be
followed by live-imaging in a transplant setting, without the confounding fluores-
cence coming from non-tumor derived tissue and allowing for the observation of
these events in greater detail, in more advanced stages of tumor development
and in interaction with fully-matured skeletal muscle tissue. Using this line, we
were able to visualize myf5-GFP-labelled TPCs and mylpfa-lyn-Cyan-labelled dif-
ferentiated cells, showing that consistent with what was reported in Ignatius et
al., 2012 in primary tumors, these sub-populations remain in regionally defined
niches and are not anatomically confined by proximity to the vasculature (Tang
et al., 2016) (see Appendix A).
The fact that TPCs are relatively rare in tumors, despite being the main con-
tributers to tumor growth, led to long-standing questions in the Cancer field: How
aren’t TPCs more frequent in tumors? Wouldn’t the process of cancer evolution
and selection promote the expansion of these cell types? Is there a role for non-
self-renewing cell types within tumors?
The regional compartmentalization of MYOG seems to be conserved as seen
in human RMS IHC sections (Ignatius et al., 2012) and MYOG is associated with
increased aggression in RMS (Heerema-McKenney et al., 2008). Our descrip-
tion of a division of labour within RMS cell populations, with more differentiated,
MYOG-positive cells playing a role in invasion and intravasation, provides a corre-
lational explanation for these questions, suggesting that differentiated RMS pop-
ulations play a role in tumor development that is independent of self-renewal ca-
pacity.
Overall, these reports show that Rhabdomyosarcoma recapitulate the hier-
archical organization of the normal muscle tissue counterpart. However, other
aspects of intra-tumor heterogeneity, such as the issue of clonality, are important
to address. Blackburn et al., 2014 have utilized a MYC-induced zebrafish model
of T-cell Acute Lymphoblastic Leukemia (T-ALL) (Langenau et al., 2003) to under-
stand questions of T-ALL clonality and evolution. Taking advantage of the fact that
T cells express unique somatically-rearranged T-cell Receptors (TCRs) and that
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T-ALL recapitulate an arrested early thymocyte stage (Langenau et al., 2003),
polyclonal leukemias could be identified. Monoclonal leukemias from primary
polyclonal tumors were derived by single cell transplantation into syngeneic ani-
mals and self-renewal and aggression was assessed at each step. Furthermore,
aggression/ growth and self-renewal were not necessarily linked. Cell competition
of fluorescently-labelled clones determined that winning clones are generally the
mostly aggressive. Thus, zebrafish have proven to be a useful tool in dissecting
properties of intra-tumor clonality and tumor evolution.
Other more sophisticated multi-colour labelling approaches, through Cre re-
combinase/lox transgenes, have been useful as lineage-tracing tools to assess
questions of intra-tumor heterogeneity, self-renewal and clonality in mouse mod-
els of cancer and stem cell biology (Blanpain and Simons, 2013). Zebrabow ze-
brafish have also been generated and utilized in lineage tracing experiments dur-
ing embryonic development and regeneration (Blackburn and Langenau, 2014;
Pan et al., 2011, 2013).
Besides genomic studies that reported clonal mutations (Chen et al., 2015),
the clonality issue has not been directly assessed in an animal model to date
in Rhabdomyosarcoma. Experiments combining the zebrafish RMS model, the
novel transplantation tools here mentioned and the Zebrabow lines could provide
useful in further exploring these questions.
5.1.3 FACS and Limiting Dilution Transplantation assays
To assess Tumor Propagating Cell potential, different populations of tumor
cells can be isolated by FACS and transplanted into recipient animals (immunod-
eficient or syngeneic). Transplanting cells at limiting dilution allows for estimating
the relative frequency of TPCs by scoring the fraction of tumors generated by the
dose of transplanted cells (Beck and Blanpain, 2013).
Not all tumors were shown to date to contain bona-fide TPCs and this had not
been demonstrated in RMS. Our report in Ignatius et al., 2012 (see Chapter 3)
identifies for the first time a MYF5-GFP-expressing sub-population that enriches
for 1:100 TPC frequency.
5.1.4 Plasticity of intra-tumor cell states and implications for
differentiation therapies
A report by Chen et al., 2014 demonstrated that the proportions of myf5-GFP-
positive (G+), myf5-GFP-positive;mylpfa-mCherry -positive (G+R+), and mylpfa-
140
5.1 Insights into intra-tumor heterogeneity, self-renewal and relapse
mCherry -positive (R+) cells within zebrafish RMS tumors is regulated by beta-
catenin-dependent WNT signaling and impacts self-renewal ability.
In Chapter 4, we also provide evidence that self-renewal ability and pro-
portions of tumor sub-populations can be disrupted. Aberrant MYF5 expres-
sion in G+R+ RMS cells confers self-renewal to this population of cells. These
cells re-express genes associated with classically-described G+ cells (Ignatius
et al., 2012) such as MET and Cadherin 15 (CDH15), while retaining features
of more differentiated RMS cells such as the expression of MYOG and Myosin
(MYLPF). This incomplete reprogramming is however sufficient to confer TPC-
ability to G+R+ cells and does not impact time to tumor onset, penetrance and
tumor growth in primary or secondary tumors.
The idea of differentiation therapy assumes that pushing cells toward a more
differentiated cell state will reduce tumor aggressiveness and eliminate TPCs
completely. Our study shows that aggressive and differentiated tumors can con-
comitantly display comparable self-renewal ability to control tumors. The blur-
ring of the previously compartmentalized lines and roles of these sub-populations
raises several questions, that remain here unaswered:
• ARE THE CELLULAR BEHAVIORS OF THESE TUMORS DIFFERENT FROM THE
ONES DESCRIBED PREVIOUSLY?
This is the obvious impending question from the observations reported in
Chapter 4. Similar experiment to the ones reported in Ignatius et al., 2012, includ-
ing EdU-incorporation in primary and transplanted myf5-GFP; mylpfa-mCherry
RMS zebrafish, transplantation intramuscularly into optically clear rag2E450fs ze-
brafish for live imaging and metastasis assays, should provide useful in the near
future. Additional results here unreported suggest that these tumors may evolve
an ever-increased differentiation concomitant with increased metastasis, with-
out compromising transplantation-ability. We speculate that continuous aberrant
MYF5 expression in these cells leads to tumors that mimic a different, more ag-
gressive, morphologically and molecularly different ERMS subset.
• WHAT ARE THE DOWNSTREAM EFFECTORS OF MYOGENIC FACTOR 5 (MYF5)
THAT ARE RESPONSIBLE FOR CONFERRING TUMOR-PROPAGATING ABILITY
TO THE NEW POPULATION OF TPCS?
In order to address both of these questions, the performance of an unbi-
ased transcriptomic analysis of these tumors would be very useful, for example,
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through RNA-seq. By sequencing the transcripts of sorted populations in MYF5-
aberrantly-expressing tumors as compared to control tumor subsets one could
identify direct targets that elicit self-renewal. The potential of this approach is that
by comparing the genetic signature of previously-defined control-tumor G+ and
G+R+ cells (Ignatius et al., 2012) with G+ and G+R+ in these new tumors, one
could arrive at a core small signature of genes that could be targetable and prior-
itize them for further research studies. Given the low numbers of G+ and G+R+
cells in transplanted MYF5-aberrantly expressing tumors, this option is techni-
cally very challenging. In alternative, primary and secondary unsorted tumors in
control and experimental groups could already provide useful insights.
5.2 Insights into inter-tumor heterogeneity and the
cell-of-origin in RMS
As discussed in Section 1.3 of the General Introduction, the questions of RMS
heterogeneity and the cell-of-origin seem to be intrinsically linked.
In its original report, the cell-of-origin of the zebrafish RMS model was identi-
fied as a DsRed-expressing mononuclear cell located in between skeletal muscle
fibers (Langenau et al., 2007). Subsequently, we showed by in vivo imaging that
the first cells to over-proliferate and emerge are myf5-GFP-positive cells located
in the outer borders of myotome segments (see Chapter 3 and Ignatius et al.,
2012).
Our current understanding of late larval skeletal muscle development is still
lagging behind that of mammals. Zebrafish display a mode of continued growth
which, contrary to mammals, means that their size is subjected to a sense of
external factors such as food availability, and that their body continues to grow
throughout life. While in mammals a muscle resident stem cell, the satellite cell,
has been long described, it seems that different populations of progenitor mus-
cle cells may exist in late larval (>10 dpf) and in the adult stages, the period
when zebrafish RMS tumors initiate (Siegel et al., 2013). Our initial observation
that tumors arise from the outer borders of myotome segments and our obser-
vation of the location (juxtaposed to muscle fibers) and the behavior of normal,
non-malignant muscle myf5-GFP cells (Ignatius et al., 2012 and my unpublished
observations), suggests therefore that the cell-of-origin of zebrafish RMS is a cell
similar to a satellite cell resident in zebrafish skeletal muscle and/or a cell of the
External Cell Layer (ECL). ECL cells reside in the periphery of the myotome, are
actively proliferating and contribute to muscle growth, equivalent to the amniote
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dermomyotome (Siegel et al., 2013). Interestingly, ECL cells express PAX7, while
zebrafish ERMS do not generally express PAX7 to detectable levels (Ignatius et
al., 2012). A possible explanation is that tumors arise from resident PAX7-positive
cells and later loose this expression. An alternative hypothesis is that the ECL
cell pool is heterogeneous, as was described in mouse satellite cells (reviewed in
Chang and Rudnicki, 2014).
Analogous to what was reported in mouse models of RMS by Rubin et al.,
2011, the question of the cell-of-origin was tackled in zebrafish by targeting onco-
genic human KRASG12D torag2- , cdh15- or mylpfa-expressing cell types (Storer
et al., 2013). Tumors that were derived by targeting to satellite cell or early-
myoblast specific promoters, rag2 and cdh15, had a lower differentiation degree
than that of tumors derived from oncogene induction under a late differentiat-
ing myoblast promoter, mylpfa. Importantly, both this and our work showed that
tumor-propagating activity was enriched in the myf5-expressing cell populations.
Additional data that is not here reported supports the notion that different cells
of origin elicit different morphological, histological and pathological features in
RMS. We injected rag2-KRASG12D into a loss-of-function MYF5 mutant zebrafish
line (myf5hu2022) (Hinits et al., 2009; Hinits et al., 2011) that was crossed into the
stable myf5-GFP transgenic line (Chen et al., 2007). This experiment aimed at as-
sessing if MYF5 is required for RMS initiation, given its role in eliciting self-renewal
when targeted to differentiated zebrafish RMS cells. Due to reduced viability of
homozygous zebrafish, I developed a careful rearing and genotyping protocol that
allowed for homozygous zebrafish to reach 10 to 30 dpf in order to observe tumor
initiation. This was consistent with a recent report that loss of viability is due to
aberrant esophageal muscle development (Minchin et al., 2013). To our initial sur-
prise, homozygous mutantmyf5-negative zebrafish initiated tumors, labelled with
myf5-GFP, mylpfa-mCherry or rag2-Dsred to similar incidence that wild-type and
heterozygous animals and with no difference in relative tumor size. Importantly,
these tumors express similar levels of KRAS and other myogenic markers includ-
ing myoD. Our initial hypothesis that this could reflect a mere hyperplastic over-
proliferation of muscle tissue rather than fully transformed cells was rejected after
successful engraftment into optically clear immune-compromised zebrafish (Tang
et al., 2016). However, these tumors display a much different morphology, histol-
ogy and pathological characteristics. We are interested in further characterizing
these tumors, but these preliminary results suggest that, similar to mammals,
a myf5-independent (possibly myod-dependent) muscle progenitor population is
the cell-of-origin of these tumors.
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Overall, our studies support the view that the cell-of-origin influences the char-
acteristics and histological presentation of RMS (my unpublished data). Impor-
tantly, genetic modifiers also influence tumor morphology and histology as in the
reported tumors in Chapter 4. Moreover, our imaging studies reported in Chapter
3 and Ignatius et al., 2012 support a skeletal muscle origin for this RMS model.
5.3 Insights into MRF expression their role in hu-
man RMS
The Myogenic Regulatory Factors MYF5 and MYOD1 were here shown for the
first time to be required for cell cycle progression and tumor growth in vitro and/or
in vivo (Chapter 4). The dependence on lineage-determination bHLH transcrip-
tion factors for cell cycle progression, self-renewal and growth has been reported
in other cancers, such as OLIG1/2 in gliomas (Beyeler et al., 2014; Imayoshi and
Kageyama, 2014; Ligon et al., 2007; Trépant et al., 2014) and TAL1 in T-ALL (Fer-
rando et al., 2002; Gerby et al., 2014). It is surprising to us that this requirement
has not been shown or reported previously and that this has not been explored in
our scientific community. In any case, several questions remain unsolved:
• WHAT ARE THE DIRECT MOLECULAR TARGETS OF MYF5 AND MYOD1 IN
HUMAN RMS CELL LINES?
In Chapter 4, we report that MYF5 and MYOD1 bind promoter and enhancer
sites in the respective ERMS cell lines analyzed. Importantly, transcribed sites
that are common between these two ChIP-seq experiments enrich for GO terms
embryonic skeletal system development, skeletal muscle tissue development and
cyclin-dependent protein kinase holoenzyme complex, suggesting that these fac-
tors commonly regulate genes involved in skeletal muscle differentiation (as pre-
viously reported, Conerly et al., 2016) and cell cycle progression (consistent with
our reported phenotypes) to lock acRMS cells in a self-renewing undifferentiated
state.
However, in order to determine the direct target genes that these proteins are
regulating, we ought to at least perform RNA-seq in control and the respective
knock-down cells, experiments that we are actively performing at this time.
• IS MYOD1 SIMILARLY REQUIRED FOR RMS GROWTH IN VIVO?
In Chapter 4, we reported that Rh18 RMS cells expressing two indepen-
dent sh-RNA hairpins against MYF5 have a dramatic reduction in tumor volume
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(as assessed by bioluminescence) following orthotopic subcutaneous transplan-
tation into immune-compromised mice. The question remains: Does this dramatic
reduction (<7 days) reflect an inability of MYF5-knocked-down cells to prolifer-
ate in vivo and/or their inability to engraft and self-renew in the transplantation
setting? In order to address this question, we aim to perform inducible knock-
down experiments for both MYF5 and MYOD1 by transplanting stably-expressing
Doxycycline-inducible sh-RNA cells, wait for tumors to engraft, and then knock-
down cells. At the present time, the mouse experiment depicted in Chapter
4 is still ongoing. Rh18 cells are routinely used in xenograft-based research
and pre-clinical trials by the NCI-supported Pediatric Preclinical Testing Consor-
tium (PPTC) (Hinson et al., 2013). However, these cells are slowly-growing in
vitro and in vivo (our data in Chapter 4). As soon as these tumors are palpable,
we plan to perform traditional caliper measurements and at the final experiment
end-point to perform a necropsy analysis of these tumors, followed by histology
and IHC for relevant markers.
• WHAT ARE THE SPECIFIC DOWNSTREAM EFFECTS OF CELL CYCLE ARREST
UPON MYF5 AND MYOD1 KNOCKDOWN, IN VIVO?
The cell cycle arrest phenotype here reported in Chapter 4 is very consis-
tent between different knock-down methods (si- or sh-RNA) and is reproducible
among different human cell lines. However, it is still unclear to us how this cell-
cycle arrest phenotype relates to possible downstream cellular effects, namely
apoptosis or senescence as well as the specific effectors of this arrest. We are
seeking to resolve this question through a series of in vitro assays and IHC stain-
ing, upon MRF knock-down.
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As is written in the epilogue above: Every discovery opens a new field for
investigation of facts, shows us the imperfection of our theories. It has justly been
said, that the greater the circle of light, the greater the boundary of darkness by
which it is surrounded.
The work here presented is surely insufficient for a complete understanding
of Rhabdomyosarcoma and general Cancer biology. It is certainly insufficient for
a successful translation of the body of Knowledge toward the betterment of this
underserved patient population. However, it is my hope that these contributions
will be followed up by the field, validated (or not) and that they may inspire more
and more questions to be pursued by others. On a personal note, this work
certainly incited in me a passion for contributing to raising awareness, producing
knowledge and/or contribute to the betterment of treatments in poorly understood
pediatric cancers.
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histone H3 to alter chromatin accessibility and to partially impair 
V(D)J recombination in vivo11. Similar residues are commonly 
mutated in Omenn syndrome, which is an autosomal recessive 
severe combined immunodeficiency. The impaired T- and B-cell 
receptor rearrangement in this disease leads to reduced numbers 
of functionally mature lymphocytes in human patients. We gen-
erated a mutant zebrafish line in the AB strain background that 
contained a frameshift at amino acid E450 resulting in premature 
termination (designated rag2E450fs; Fig. 1b).
We incrossed heterozygous rag2E450fs mutant fish and raised 
them to adulthood. Animals were genotyped at 3 months of age, 
revealing expected Mendelian ratios (146 wild type, 265 het-
erozygous and 129 rag2E450fs mutant fish). rag2E450fs mutants 
were similar in size to heterozygous and wild-type siblings 
(Supplementary Fig. 1), survived fin clip and remained healthy 
for >6 months when raised under standard laboratory conditions. 
Homozygous rag2E450fs mutant zebrafish could reproduce, albeit 
at reduced fecundity when compared with heterozygous sib-
lings (Supplementary Table 1). Histological analysis of 90-d-old 
rag2E450fs mutant zebrafish revealed a notable reduction in thymic 
T cells and an altered thymic architecture including reduced num-
bers of epithelial cells with a preponderance of adipocytes (n = 5 of 
6 mutant animals, Fig. 1c,d). This thymic involution is commonly 
observed in T cell–deficient lines of mice12 and was not detected 
in wild-type siblings (n = 6, P = 0.008, Fisher’s exact test). We also 
noted a similar reduction in thymocyte number in 5-d-old zebrafish 
(Supplementary Fig. 2). Analysis of whole kidney marrow 
revealed that adult homozygous rag2E450fs zebrafish contained all 
blood cell lineages (Fig. 1e,f); however, quantification revealed 
a striking 75% reduction in lymphocytes of rag2E450fs mutant 
zebrafish (Fig. 1g and Supplementary Table 2). Transcript expres-
sion for mature B- and T-cell markers was reduced in rag2E450fs 
mutant marrow, including expression of immunoglobulin heavy 
constant mu (ighm, here referred to as igm), lymphocyte-specific 
protein-tyrosine kinase (lck), T-cell receptor alpha (trac, here referred 
to as tcra) and T-cell receptor beta (trbc2, here referred to as tcrb) 
(Fig. 1h). By contrast, rag1 transcript levels were not reduced in 
marrow of mutant animals. This suggests that early B-cell pre-
cursors were not altered in rag2E450fs mutant zebrafish (Fig. 1h). 
Homozygous rag2E450fs mutants did not exhibit expression dif-
ferences for myeloperoxidase (mpx) and l-plastin (lcp1), a result 
confirming that neutrophil, monocyte, macrophage and other cell 
lineages were not altered in rag2E450fs mutant zebrafish (Fig. 1h 
and Supplementary Table 2).
To directly address the impact of the rag2E450fs mutation on 
mature T and B cells, we assessed whole kidney marrow cells for 
optimized cell 
transplantation using adult 
rag2 mutant zebrafish
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cell transplantation into adult zebrafish has lagged behind 
mouse models owing to the lack of immunocompromised 
strains. here we have created rag2E450fs mutant zebrafish 
that have reduced numbers of functional t and b cells but are 
viable and fecund. mutant fish engraft muscle, blood stem cells 
and various cancers. rag2E450fs mutant zebrafish are the first 
immunocompromised zebrafish model that permits robust, 
long-term engraftment of multiple tissues and cancer.
Cell transplantations of human and mouse cells into immuno-
compromised mice have enhanced our understanding of stem 
cell function, regeneration and cancer. However, transplantation 
experiments in mice are expensive and routinely utilize small 
cohorts of animals, and engraftment is often difficult to visualize 
directly. By contrast, large-scale cell transplantation of fluorescent 
blood and cancer cells into syngeneic and irradiated zebrafish has 
now become routine1–7. However, these approaches require that 
donor cells are from the same strain of syngeneic zebrafish or that 
the recipient immune system is transiently ablated by whole-body 
γ-irradiation 2 d before transplantation. Irradiated recipients even-
tually recover their immune system by 20 d post irradiation and kill 
engrafted cells1,2,6, making long-term engraftment studies difficult. 
To date, immunocompromised zebrafish have not been developed 
as a universal recipient for allograft cell transplantation.
To facilitate transplantation experiments in adult zebrafish, 
we capitalized on recently developed gene inactivation meth-
ods8 and engineered zinc-finger nucleases to target the plant 
homeodomain (PHD) of the zebrafish recombination activating 
gene 2, rag2 (refs. 9,10; Fig. 1a). Mutations in residues of the 
PHD disrupt the RAG2 protein interaction with trimethylated 
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USA. 3Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 4Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. 
5Izaak Walton Killam Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada. 6Department of Surgery, Weill Cornell Medical College, New York, New York, 
USA. 7Department of Medicine, Weill Cornell Medical College, New York, New York, USA. 8These authors contributed equally to this work. Correspondence should be 
addressed to D.M.L. (dlangenau@mgh.harvard.edu).
Received 11 decembeR 2013; accepted 13 June 2014; published online 20 July 2014; doi:10.1038/nmeth.3031
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
  |  ADVANCE ONLINE PUBLICATION  |  nature methods
brief communications
tcrb and igm rearrangements4,13. Homozygous rag2E450fs mutant 
fish lacked tcrb rearranged T cells (n = 7, Fig. 1i), whereas the 
B-cell immune repertoire was reduced in 3 of 7 animals tested. 
Thus, the rag2E450fs mutation results in the production of a hypo-
morphic protein with reduced function in receptor recombina-
tion, leading to a lack of mature T cells and a variable reduction 
of functionally diverse B cells.
Immunocompromised mice, including those deficient in Rag2, 
have been successfully used for adoptive transfer of mouse and 
human cells. Yet, immunocompromised adult zebrafish have not 
been developed that permit stable engraftment of a range of cells 
and tissues. rag1 mutant fish lack all mature T and B cells13 but 
have not been widely used for cell transplantation approaches 
because of reduced viability of adult fish and failure to thrive fol-
lowing fin clip and genotyping. To assess whether hypomorphic, 
rag2-deficient zebrafish were amenable to cell transplantation, we 
first analyzed whether hematopoietic stem cell engraftment was 
enhanced in rag2E450fs mutant lines. Specifically, we sublethally 
irradiated rag2E450fs mutant and wild-type sibling adults with 
10-Gy irradiation to clear the hematopoietic stem cell niche. 
Animals were transplanted 2 d after irradiation treatment by 
intraperitoneal injection with either 5 × 104 or 3 × 105 whole 
kidney marrow cells from unrelated ubiquitin-EGFP donor 
zebrafish14 (ubi-EGFP, Fig. 2a). As expected, none of the wild-type 
figure  | rag2E450fs mutant zebrafish lack 
mature T cells and have a reduced B-cell repertoire. 
(a) Human RAG2 protein with known severe 
combined immunodeficiency mutations denoted. 
Arrowhead, zinc-finger nuclease (ZFN) target 
region. aa, amino acids. (b) Nucleotide (nt) (top)  
and protein sequence (bottom) for the 
rag2E450fs mutation. Yellow, ZFN target sites; 
blue, nucleotide additions; gray, nucleotide 
deletion; arrowhead, amino acid change at 
E450. Underlining shows the amino acid 
sequence following the frameshift, with the 
termination amino acid numbered. (c,d) Thymus 
sections of 90-d-old wild-type (c) and rag2E450fs 
mutant zebrafish (d). Red dashed lines denote 
thymus (left). Right, amplified views of boxed 
regions with adipocytes (A) and vacant thymic 
epithelium (E) shown. (e,f) Whole kidney 
marrow cytospins of wild-type (e) and rag2E450fs 
zebrafish (f) with lymphocytes (black arrows), 
erythrocytes (magenta arrows) and granulocytes 
(blue arrows) denoted. Scale bars: 200 µm (c,d 
left), 50 µm (c,d right) and 20 µm (e,f).  
(g) Cell counts from cytospins performed on 
whole kidney marrow. Error bars, ±1 s.d.,  
*P < 0.05 by Student’s t-test. (h) Gene 
expression analysis of whole kidney marrow 
cells. Error bars, s.e.m.; *P < 0.05 by Student’s 
t-test. (i) PCR analysis for tcrb and igm 
rearrangement of whole kidney marrow cells 
from wild-type (WT) and rag2E450fs zebrafish. 
Neg, negative control. Amplification of tcrb transcripts with primers specific to the variable (V) and constant (C) regions noted (top five rows) and  
igm transcripts spanning the variable H (VH) and constant mu (Cm) regions. ef1α, elongation factor 1 alpha. 
figure  | rag2E450fs mutant fish engraft 
hematopoietic and muscle stem cells.  
(a) ubi-EGFP transgenic donor fish.  
(b,c) Wild-type (WT; b) or homozygous 
rag2E450fs recipient fish (c) transplanted with 
EGFP-labeled marrow and imaged at 45 d post 
transplantation (d.p.t.). Left, fluorescence 
images of whole fish with engraftment rates 
noted. Flow cytometry (center) and cytospin 
analysis (right) of whole kidney marrow from 
donor fish (a) and recipient fish (b,c).  
EGFP+ cells sorted by flow cytometry are 
shown for cytospin analysis in c. Black arrows, 
lymphocytes; magenta arrows, red blood cells; 
blue arrows, granulocytes. (d,e) Fluorescence 
images of WT and rag2E450fs mutant fish 
engrafted with muscle cells from ubi-EGFP transgenic fish imaged at 30 d.p.t. (f) rag2E450fs fish engrafted with muscle cells from α-actin–RFP transgenic 
fish at 30 d.p.t. Engraftment rates for d–f are shown on magnified image panels to the right. Scale bars, 2 mm.
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siblings engrafted blood cells (n = 10), whereas all rag2E450fs 
mutant fish exhibited robust, multilineage blood cell engraftment 
that persisted past 45 days post transplantation (d.p.t., n = 6), 
a full 25 d after immune rejection is normally initiated in irra-
diated wild-type recipient fish2,6 (Fig. 2b,c, P = 0.0002, Fisher’s 
exact test; Supplementary Fig. 3 and Supplementary Table 3). 
Engrafted rag2E450fs homozygous mutant fish also commonly 
exhibited EGFP+ circulating cells by 30 d.p.t. (Supplementary 
Video 1). These data show that hypomorphic rag2E450fs can 
robustly engraft hematopoietic cells from unrelated donors.
To assess the broad utility of the rag2E450fs model for engraft-
ment of regenerative tissues, fluorescently labeled muscle cells 
from adult ubi-EGFP transgenic fish were transplanted by intra-
muscular injection into non-irradiated recipient animals (5 × 104 
cells per fish, 2 µl per animal). Muscle cell viability was >85% fol-
lowing dissociation and single-cell preparation (Supplementary 
Fig. 4). Remarkably, EGFP+ muscle fibers were readily detected 
in all rag2E450fs mutant animals by 30 d.p.t. (n = 3 of 3) but not 
wild-type siblings (n = 4; P = 0.03, Fisher’s exact test; Fig. 2d,e 
and Supplementary Table 3). Fluorescent fibers persisted in 
rag2E450fs mutant fish for up to 60 d.p.t. Histological analysis 
revealed that EGFP+ muscle fibers were viable, contained mus-
cle striations and were indistinguishable from recipient muscle 
tissue (Supplementary Fig. 5). We next wanted to verify the spe-
cificity of our results using a muscle-specific, fluorescent trans-
genic line. Muscle cells were isolated from the dorsal musculature 
of α-actin–RFP transgenic fish15 and injected into the dorsal 
musculature of recipient fish (2.5 × 105 cells per fish). Again, 
robust engraftment of fluorescent muscle was observed in only 
homozygous rag2E450fs mutant fish by 30 d.p.t. (n = 5 of 5, Fig. 2f 
and Supplementary Table 3) and not heterozygous or wild-type 
siblings (n = 5 animals per genotype assessed, P = 0.008, Fisher’s 
exact test). These data show that homozygous rag2E450fs mutant 
fish can engraft cells even in the absence of preconditioning with 
low-dose irradiation.
We next wanted to assess the utility of our model to engraft a 
diversity of transgenic zebrafish cancers including T-cell acute 
lymphoblastic leukemia (T-ALL), embryonal rhabdomyosarcoma 
(ERMS) and melanoma. Specifically, primary Myc-induced 
T-ALL was generated in a mixed Tubingen/AB strain back-
ground16,17 and transplanted into the peritoneal cavity of recipient 
animals (Fig. 3a,e,i). Homozygous rag2E450fs mutant fish robustly 
engrafted T-ALL by 30 d.p.t. (n = 2 of 2, 1 × 105 cells per fish, 
Fig. 3i). By contrast, heterozygous and wild-type siblings failed 
to engraft T-ALL (n ≥ 7 per genotype, P < 0.03, Fisher’s exact test, 
Fig. 3e). Similar results were observed using three additional 
T-ALLs arising in syngeneic CG1 strain zebrafish (1 × 105 cells 
per fish). In total, 39 of 39 rag2E450fs mutants engrafted T-ALL 
arising from CG1 strain fish, whereas 0 of 22 wild-type siblings 
engrafted leukemia (P < 0.0001, Fisher’s exact test, Fig. 3b,f,j 
and Supplementary Table 4), suggesting that engraftment is not 
restricted to particular zebrafish strains or to fish with matched 
major histocompatibility complexes. Homozygous rag2E450fs 
mutant zebrafish also successfully engrafted fluorescently 
labeled KRASG12D-induced ERMS generated in both the CG1 
and AB strain background (n = 4 independent tumors analyzed, 
1 × 104–1 × 106 cells per fish). In total, 24 of 27 homozygous 
rag2E450fs mutant zebrafish engrafted ERMS, whereas 0 of 7 wild-
type siblings engrafted disease18 (P < 0.0001, Fisher’s exact test, 
Fig. 3c,g,k and Supplementary Table 4). Finally, melanomas 
that harbor a TP53 (p53) mutation and overexpress both mitfa 
and BRAFV600E could successfully engraft into rag2E450fs mutant 
zebrafish but not wild-type siblings19,20 (n = 4 tumors analyzed, 
5 × 105–1 × 106 cells per fish). In total, 25 of 25 homozygous 
rag2E450fs mutant fish engrafted melanoma, whereas 0 of 16 wild-
type siblings engrafted disease (P < 0.0001, Fisher’s exact test, 
Fig. 3d,h,l and Supplementary Table 4). No instances of tis-
sue rejection or tumor regression were observed in engrafted 
rag2E450fs mutant fish (n = 104), showing that homozygous 
rag2E450fs mutant zebrafish can robustly engraft cells from a 
diversity of genetic backgrounds and even in the absence of pre-
conditioning of recipient animals with γ-irradiation.
Our experiments highlight the use of hypomorphic rag2E450fs 
mutant fish as a universal recipient for allograft cell transplan-
tation into adult fish, ushering in a new era of large-scale cell 
transplantation studies to directly visualize and assess stem cell 
self-renewal within normal tissues and clonal heterogeneity, 
therapeutic responses and growth in cancer.
methods
Methods and any associated references are available in the online 
version of the paper.
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figure  | Engraftment of zebrafish tumors into  
rag2E450fs mutant fish. (a–d) Donor tumors used  
in cell transplantation studies. (a) dsRed-labeled 
Myc-induced T-cell acute lymphoblastic leukemia 
(T-ALL) arising in TuAB strain fish. (b) zsYellow-
labeled T-ALL from CG1 strain fish. (c) EGFP-
labeled embryonal rhabdomyosarcoma (ERMS) 
from CG1 strain fish. (d) mitfa- and BRAFV600E-
induced melanoma arising in p53-deficient nacre 
strain fish (d). (e–l) Left, merged bright-field 
and fluorescence images of wild-type (e–h) 
or rag2E450fs mutant fish (i–l) at 30 d post 
transplantation. Right, images of whole kidney 
marrow sections (e,i), peripheral blood  
cytospins (f,j) and skeletal muscle (g,k,h,l). 
Magenta arrowhead, red blood cells; white 
arrowhead, renal tubules (e). Scale bars in fish  
images are 2 mm and in histopathology images  
are 25 µm (e,i), 20 µm (f,j) and 50 µm (g,k,h,l).
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Accession codes. ZFIN: rag2E450fs mutant information is available 
under construct number ZDB-GENO-140623-1 and is designated 
rag2fb101.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Animal use and creation of hypomorphic rag2E450fs mutant 
zebrafish. Zebrafish studies were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care, under 
protocol #2011N000127.
rag2E450fs mutant zebrafish were created using the previously 
described zinc-finger nuclease (ZFN) pair that targeted the 
PHD of the zebrafish rag2 gene8. Specifically, RNA was prepared 
for each ZFN arm and microinjected into AB strain zebrafish 
(500 ng/µl). F0 injected animals were raised to adulthood, and sin-
gle male-by-female matings performed. Resultant progeny were 
arrayed into 96-well plates and genomic DNA extracted (n = 12 
individual embryos per cross). PCR was performed using for-
ward primer (5′-ACTGCTCTAGTTGCAATTCCT) and reverse 
primer (5′-AGCTGGGGTCATCTTCAGT) to produce a 585-bp 
PCR amplicon. The PCR cycle parameters were (i) denaturation, 
94 °C for 30 s; (ii) annealing, 54 °C for 30 s; and (iii) elongation, 
68 °C for 45 s; repeated for 35 cycles. PCR samples were purified 
and sent for Sanger sequencing. From this analysis, one line was 
identified with a rag2 frameshift mutation that starts at amino 
acid E450 and results in a premature stop codon mutation (desig-
nated rag2E450fs in this manuscript with an official ZFIN.org allele 
designation of rag2fb101). F1 progeny were subsequently raised to 
adulthood, and heterozygous rag2E450fs fish were identified by 
genotyping (see below).
Genotyping of rag2E450fs mutant zebrafish. The rag2E450fs 
mutant line is best maintained through heterozygous incrossing 
(Supplementary Table 1) and produces progeny at the expected 
Mendelian ratios. The rag2E450fs allele introduces a de novo XcmI 
site, allowing for restriction enzyme–mediated identification 
of the mutant allele (diagrammed with representative results in 
Supplementary Fig. 6). Specifically, adult 2- to 4-month-old fish 
were fin clipped, and genomic DNA was prepared using the modi-
fied HotSHOT method21. Individual genomic DNA was diluted 
tenfold, and 2 µl were used in a standard 25-µl volume PCR using 
Taq DNA polymerase (New England BioLabs, Cat# M0273L) 
with forward primer (5′-ACTGCTCTAGTTGCAATTCCT) 
and reverse primer (5′- AGCTGGGGTCATCTTCAGT) to pro-
duce a 585-bp PCR amplicon. The PCR cycle parameters were 
(i) denaturation, 94 °C for 30 s; (ii) annealing, 54 °C for 30 s; and 
(iii) elongation, 68 °C for 45 s; repeated for 35 cycles. For enzymatic 
digestion, 15 µl of nonpurified PCR reaction were combined with 
0.3 µl XcmI + 2 µl 10× NEB buffer 2.1 + 2.7 µl water. The 20-µl 
reaction was incubated at 37 °C for ≥4 h. Enzymatic digestion 
was visualized by electrophoresis on a 2% Tris-acetate-EDTA 
(TAE) agarose gel containing ethidium bromide. Wild-type fish 
produced a single band at 585 bp. Heterozygous rag2E450fs fish 
produced three bands at 585, 372 and 212 bp due to digestion of 
the mutant allele, with the two higher molecular weight bands 
being most distinctive. Homozygous fish produced two bands at 
372 and 212 bp. A representative image of genotyping analysis is 
shown in Supplementary Figure 6.
Characterization of the rag2E450fs mutant line. RNA in situ 
hybridization of larval fish (Supplementary Fig. 2) and histo-
logical analysis of thymus of adult fish (Fig. 1c,d) were com-
pleted as previously described22. Two-tailed Student’s t-test 
analysis was performed to assess larval thymus size differences 
(Supplementary Fig. 2c). For hematopoietic cell quantification 
(Fig. 1g), cytospins of whole kidney marrow from both rag2E450fs 
mutant fish and wild-type siblings were reviewed by clinical 
hematopathologists (J.N.B. and R.S.L.). At least five 400× mag-
nification fields were analyzed per slide and >200 cells counted 
per animal. Sample identification was blinded during counts and 
genotype revealed only after cell counting was completed. Two-
tailed Student’s t-test analysis was performed to assess changes 
in relative numbers of each blood cell lineage between wild-type 
and rag2E450fs mutant fish. Quantitative real-time PCR (Fig. 1h) 
and nested PCR for tcra and igm rearrangements (Fig. 1i) were 
completed using the primers shown in Supplementary Tables 5 
and 6, essentially as previously described4,23. Two-tailed Student’s 
t-test analysis was performed to assess expression differences in 
hematopoietic marker genes using quantitative PCR (Fig. 1h). 
A threshold of P ≤ 0.05 was considered significant for two-tailed 
Student’s t-test.
Generation of transgenic zebrafish cancers. T-ALL and 
ERMS were created by co-injection of either rag2-Myc or 
rag2-kRASG12D, respectively, along with fluorescent reporters under 
the same promoter into one-cell-stage animals which have 
been previously described16. Tg(mitfa:EGFP);mitfa−/−;p53−/−; 
Tg(mitfa:BRAF(V600E)) melanoma-bearing fish were generated 
as previously described19,20.
Whole kidney marrow transplantation. Donor ubi-EGFP 
fish were euthanized by tricaine overdose (Tricaine-S, Western 
Chemical). Kidney tissue was dissected, placed into a 1.5-ml 
Eppendorf tube containing 100 µl of suspension solution (0.9× 
PBS + 5% FBS) and manually pipetted ≥20 times using a 1-ml 
pipette tip. The kidney tissue suspension was filtered through a 
40-µm strainer (Fisher Scientific, Cat# 352340). Total number 
of viable cells was calculated by Trypan blue (Life Technologies, 
Cat# 15250061) staining and hemocytometer counts. Cells were 
centrifuged at 1,000g for 10 min and then resuspended in desired 
volumes for cell transplantation (Supplementary Table 3). 
Recipient fish were preconditioned with 10-Gy γ-irradiation 
(Cs137 irradiation) 2 d before transplantation. Recipient fish 
were transplanted with the indicated number of viable kid-
ney marrow cells (Supplementary Table 3) injected into the 
peritoneal cavity using a 26s-gauge Hamilton 80366 syringe 
(Sigma-Aldrich, 20779).
Whole kidney cell engraftment was assessed using whole-body 
epifluorescence imaging (Olympus stereomicroscope model 
MVX10, Olympus DP72 microscope digital camera, DP2-BSW 
software version 2.2), direct visualization of circulating cells 
within the tail vasculature beginning at 20 days post transplanta-
tion (d.p.t.) and/or flow cytometry. Flow cytometery of kidney 
marrow was completed in the presence of propidium iodide (PI) 
to exclude dead cells. The EGFP+ cell fraction was isolated from 
the marrow of engrafted rag2E450fs fish and analyzed following 
cytospin preparation.
Muscle cell transplantation. Dorsal musculature of donor 
ubi-EGFP or α-actin–RFP fish was excised from tricaine-overdosed 
animals. Specifically, the dorsal musculature of the tail posterior 
to the anus was harvested for muscle transplantation. The mus-
cle tissue was combined from 10–12 animals and mechanically 
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disassociated by maceration by repeated dicing using a razor blade 
for 5 min on a 10-cm Petri dish containing 500 µl of suspension 
solution (0.9× PBS + 5% FBS). Samples were then supplemented 
with 5 ml of 0.9× PBS + 5% FBS, and a 5-ml serological pipette 
was used to suspend the homogenized tissue by repeated pipetting 
≥30 times. Cells were then filtered through a 40-µm cell strainer 
and washed with 5 ml of 0.9× PBS + 5% FBS. Total number of viable 
cells was calculated by Trypan blue staining and hemocytometer 
counts. Cells were then centrifuged at 1,000g for 10 min and 
resuspended in desired volumes (Supplementary Table 3) before 
transplantations. No irradiation preconditioning was used before 
transplantation of muscle cells into rag2E450fs mutant fish. Muscle 
cell transplantations were completed by injecting 2 µl of donor 
cell preparation into the dorsal musculature on the left side of the 
recipient fish, using a 26s-gauge Hamilton 80366 syringe.
Engraftment was assessed by visualization of fluorescently 
labeled muscle fibers using epifluorescence imaging at 10, 20, 
30, 45 and 60 d.p.t. Engraftment of ubi-EGFP muscle fibers was 
confirmed by immunohistochemistry on section slides using an 
anti-EGFP antibody (JL-8, Living Colors, Cat# 632381). Viability 
of the muscle fibers was confirmed by the absence of cleaved 
caspase-3 expression (Cell Signaling, Cat# 9664) and TUNEL stain-
ing (customized Millipore S7100 kit, Specialized Histopathology & 
TMI Core at Dana-Farber Cancer Institute).
Cancer cell transplantation. Donor fish with T-ALL, ERMS 
and melanoma from different transgenic backgrounds were 
euthanized by tricaine overdose. Animals were imaged using epi-
fluorescence microscopy and tumor cells isolated as previously 
described24. Specifically, tumors were excised from diseased 
animals and placed in 500 µl of 0.9× PBS + 5% FBS on a 10-cm 
Petri dish. Single-cell suspensions were obtained by maceration 
of tissue with a razor blade followed by manual pipetting to dis-
associate cell clumps. Cells were filtered through a 40-µm filter, 
centrifuged at 1,000g for 10 min and resuspended at the correct 
volume (Supplementary Table 4) in a total volume of 5 µl per 
recipient fish for cell transplantation. Cell viability ranged from 
58% to 66% as assessed by PI staining and flow cytometry analysis 
of ERMS tumor cells. 5 µl of tumor cells were transplanted into 
the peritoneal cavity of each recipient fish using a 26s Hamilton 
80366 syringe. No irradiation preconditioning was used for tumor 
cell transplantations outlined in this work.
Tumor engraftment was assessed at 10, 20, 30 and 45 d.p.t. by 
epifluorescence microscopy. Recipient fish were sacrificed when 
moribund or at 45 d.p.t. for animals that failed to engraft dis-
ease (wild type). A subset of transplanted animals was photo-
graphed, and either (i) these were fixed in 4% paraformaldehyde 
for sectioning or (ii) peripheral blood samples were collected for 
cytospins and histological examination.
Statistics. When possible, cell transplantation experiments were 
completed using ≥3 animals per arm to facilitate analysis using 
the Fisher’s exact test. No animals were excluded from our analy-
sis shown in Supplementary Tables 3 and 4, with the exception 
of rag2E450fs mutant fish that engrafted ubi-EGFP+ marrow and 
were scored for circulating EGFP+ cells in the tail at ≥20 d.p.t. We 
did not include these animals in Supplementary Table 3 because 
they were sectioned and marrow analysis by flow cytometry was 
not possible.
Cytospin analysis shown in Figure 1e–g and Supplementary 
Table 2 was reviewed by clinical hematopathologists (J.N.B. 
and R.S.L.). Genotype was revealed only after cell counting was 
completed.
Two-tailed Student’s t-test analysis was performed to assess 
(i) changes in relative numbers of each blood cell lineage between 
wild-type and rag2E450fs mutant fish (Fig. 1g), (ii) expression 
differences in hematopoietic marker genes using quantitative PCR 
(Fig. 1h) and (iii) thymus size differences (Supplementary Fig. 2c). 
Fisher’s exact tests were performed to assess (i) differences in 
adult thymus phenotypes between wild-type and rag2E450fs 
mutant fish (Fig. 1c,d), (ii) engraftment rates of whole kidney 
marrow and muscle transplantations between genotypes (Fig. 2 
and Supplementary Table 3) and (iii) tumor cell transplantations 
(Fig. 3 and Supplementary Table 4). P ≤ 0.05 was considered 
significant for all statistical methods.
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Imaging tumour cell heterogeneity following cell
transplantation into optically clear immune-
deﬁcient zebraﬁsh
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Cancers contain a wide diversity of cell types that are deﬁned by differentiation states,
genetic mutations and altered epigenetic programmes that impart functional diversity to
individual cells. Elevated tumour cell heterogeneity is linked with progression, therapy
resistance and relapse. Yet, imaging of tumour cell heterogeneity and the hallmarks of
cancer has been a technical and biological challenge. Here we develop optically clear
immune-compromised rag2E450fs (casper) zebraﬁsh for optimized cell transplantation and
direct visualization of ﬂuorescently labelled cancer cells at single-cell resolution.
Tumour engraftment permits dynamic imaging of neovascularization, niche partitioning of
tumour-propagating cells in embryonal rhabdomyosarcoma, emergence of clonal dominance
in T-cell acute lymphoblastic leukaemia and tumour evolution resulting in elevated growth
and metastasis in BRAFV600E-driven melanoma. Cell transplantation approaches using
optically clear immune-compromised zebraﬁsh provide unique opportunities to uncover
biology underlying cancer and to dynamically visualize cancer processes at single-cell
resolution in vivo.
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T
he conversion of phenotypically normal cells into
malignant cells is often associated with acquired ‘hallmarks
of cancer’ including elevated growth potential, suppression
of cell death pathways, development of new vascular networks
to feed the growing tumour and acquired cell motility that lead to
invasion and metastasis1,2. Despite our increased understanding
that cancer is driven by molecular changes that convert normal
cells into malignant cells, it has become well recognized that
not all cancer cells are created equal. For example, the process
of clonal evolution that is responsible for initiating cancer is also
a critical driver of intra-tumoral heterogeneity that is
constantly arising throughout the lifespan of a cancer cell3. This
heterogeneity provides a rich diversity of cell types and mutations
on which natural selection can act, ultimately leading to a
subset of cancers that elevate metastatic potential and therapy
resistance4–6. Despite our new found ability to genetically map
individual mutations that are acquired during tumour cell
evolution and progression7–9, it is been difﬁcult to directly
visualize how these mutations affect tumour growth in live
animals. Access to optically clear animal models would permit the
dynamic visualization of the cancer hallmarks and provide
unprecedented access to dissect the molecular underpinnings of
cancer progression at single-cell resolution.
Over the past two decades, the ﬁeld of cancer research has been
empowered by intra-vital imaging (IVM) in mouse models10,11.
Reﬁned imaging tools, including confocal, multi-photon and light
sheet microscopy, have now been applied to a wide range of
cancers to facilitate the discovery of underlying mechanisms that
drive cancer growth in vivo. For example, Kedrin et al. have
utilized photoactivatable ﬂuorescent proteins and cell lineage
tracing to visualize the tumour cell niche in mammary carcinoma.
These studies uncovered that cells adjacent to the vasculature
drive invasion and metastasis12. Using similar approaches,
Calabrese et al. discovered that Nestinþ brain tumour stem
cells reside in a perivascular niche13. Metastasis has also been
observed using IVM. For example, a single extravasated C26
colorectal cancer cell has been shown to proliferate and to
produce highly mobile pre-metastatic lesions in the liver14.
Sophisticated ﬂuorescent labelling techniques, including cell
lineage tracing using Confetti and brainbow constructs15,16,
have now been successfully integrated with high-resolution
microscopy to visually dissect intra-tumoral heterogeneity.
For example, Zomer et al. utilized the Confetti strategy to
label individual mammary tumour cells, and performed proof-
of-concept experiments to show that tumour stem cells can
become alternatively active or quiescent during tumour
development17. Despite these successes, challenges presented by
the opacity of furred rodents, and the requirement for invasive
surgical implantation of imaging windows have limited the
application of IVM. Furthermore, requirements of imaging
through pre-deﬁned windows often prohibit simultaneous
observation of tumour cells from the primary and metastatic
sites within the same animal.
Zebraﬁsh have been developed as a robust model of human
cancer and have now been widely used for visualizing
cancer processes in live animals. For example, our group has
used ﬂuorescent transgenic approaches to label embryonal
rhabdomyosarcoma (ERMS) cells based on differentiation status.
Using these approaches, we have been able to dynamically
visualize tumour cell heterogeneity in vivo, identifying
the existence of a molecularly deﬁned tumour-propagating cell
(TPC) that expresses myf5-GFP and other differentiated cell types
that express myogenin and drive invasion18. Others have utilized
cell transplantation into irradiated, optically clear casper strain
adult zebraﬁsh to visualize melanoma invasion19, and conversion
of T-lymphoblastic lymphoma into leukaemia20. Importantly,
these initial successes utilized cell transplantation into either
syngeneic strains of zebraﬁsh or irradiated recipient animals
that only transiently dampen immune responses. Using
genome-editing approaches21, our group has recently developed
homozygous rag2E450fs zebraﬁsh. These ﬁsh are viable as adults,
have deﬁciencies in T and B cells, and enable robust engraftment
of ﬂuorescently labelled zebraﬁsh tumour cells from a wide range
of cancers and strains of zebraﬁsh22. Despite the utility of the
rag2E450fs model for cell engraftment studies, the rag2E450fs
mutation was created on the pigmented AB-strain and thus it
has been difﬁcult to image tumour cells at single-cell resolution in
engrafted animals.
Here we create transparent casper strain, rag2E450fs mutant
zebraﬁsh and utilize these animals for transplantation studies
to image heterogeneity and various ‘hallmarks of cancer’.
For example, confocal imaging permits the dynamic visualization
of TPCs in ERMS and the emergence of clonal dominance in
T-cell acute lymphoblastic leukaemia (T-ALL). Serial imaging
studies also detail the evolution of metastasis in a subset
of BRAFV600E-driven melanomas and facilitate the direct
visualization of micro-metastatic disease. Our work provides a
universal transplantation model for imaging cancer cell processes,
opening new avenues for visualizing the functional consequences
of cancer cell heterogeneity and clonal evolution at single-cell
resolution in the zebraﬁsh.
Results
Engraftment of allogeneic tumours. We have previously
reported the production of lymphocyte-deﬁcient rag2E450fs
mutant zebraﬁsh that engraft a wide variety of normal and
malignant zebraﬁsh cells22 (ZFIN allele rag2fb101). However, these
initial studies utilized pigmented, AB-strain zebraﬁsh, making it
difﬁcult to directly visualize tumour cells at high resolution
in vivo. To facilitate imaging of cancer in live zebraﬁsh, the
rag2E450fs mutation was bred into the casper background—a
transparent zebraﬁsh that lacks melanocytes and iridophores19.
As expected, rag2E450fs (casper) zebraﬁsh efﬁciently engrafted
ﬂuorescently labelled T-ALL23, neuroblastoma24, ERMS18,25 and
melanoma26,27 (Fig. 1, Supplementary Fig. 1 and Supplementary
Table 1). Tumours derived from CG1, AB and nacre
strain zebraﬁsh engrafted efﬁciently into rag2E450fs (casper)
zebraﬁsh and did not require matching at the major
histocompatibility complex or pre-conditioning with
g-irradiation. Importantly, engrafted tumours exhibited similar
histology as donor tumours (Fig. 1). As has been reported
previously for AB-strain wild-type transplant recipients22,
tumours failed to engraft into unconditioned casper-strain
animals that have an intact rag2 locus (Supplementary Table 1
and Supplementary Fig. 1).
Visualizing the dynamics of tumour neovascularization.
Neovascularization is an important hallmark of cancer and has
been imaged in a variety of cancers18,28,29. To assess the utility
of adult rag2E450fs (casper) ﬁsh for imaging neovascularization
in the transplantation setting, green ﬂuorescent protein (GFP)-
labelled BRAFV600E, tp53 / amelanotic melanoma27 cells were
implanted into the dorsal musculature of 3-month-old rag2E450fs
(casper) ﬁsh (5 105 cells in 2ml per animal). Because
engraftment was initially limited to the dorsal musculature,
melanomas developed adjacent to the skin epidermis.
Neovascularization could be directly visualized by confocal
microscopy following injection of crimson quantum dots30 into
the blood stream at 25 days post transplantation (d.p.t.; Fig. 2a,
n¼ 8 animals). Crimson quantum dots were chosen because they
excite in far-red wavelengths and can be easily differentiated from
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other ﬂuorescent proteins used to label tumour cells in this study,
including AmCyan, GFP, ZsYellow, DsRED and mCherry. To
further reﬁne imaging of neovascularization within solid tumours,
we next created ﬂk1:mCherry; rag2E450fs (casper) ﬁsh with
ﬂuorescently labelled vasculature. Animals were injected intra-
muscularly with GFP-labelled melanoma (5 105 cells in 2 ml per
animal). Following successful engraftment at the site of injection,
vessels were readily visualized by confocal microscopy ( 100
magniﬁcation, 105.71 mm¼ 10 z-stacks, n¼ 4 animals, Fig. 2b).
Finally, we have been able to visualize how neovascularization
changes over time within the same animal, which results in the
creation of dense vascular networks associated with ERMS growth
( 100 magniﬁcation, 223.64 mm¼ 10 z-stacks, Fig. 2c,d).
Together, these experiments demonstrate the ease and utility of
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(CG1)
Melanoma
(nacre)
AB Casper
Donor rag2E450fs recipients
Figure 1 | Zebraﬁsh cancers engraft into homozygous rag2E450fs (casper) animals. Donor animals shown in the left two panels while transplant recipients
are to the right. (a) ZsYellow-labelled Myc-driven T-ALL from the syngeneic CG1 background, (b) EGFP-labelled neuroblastoma from AB background,
(c) mCherry-labelled kRASG12D-driven ERMS from CG1 background, and (d) BRAFV600E-induced melanoma arising in tp53 /nacre background. Tumour
cells were transplanted intra-peritoneally (a,b,d) or intra-muscularly (c) into both rag2E450fs (AB) and rag2E450fs (casper)-recipient ﬁsh. Merged brightﬁeld
and ﬂuorescent images are shown at 30 d.p.t. Cytospins of leukaemia cells are shown in a, whereas haematoxylin and eosin (H&E)-stained sections are
shown in b–d. Scale bars equal 5mm in whole animals images, 20mm for cytospins shown in a, and 50mm for histology sections shown in b–d.
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Figure 2 | Imaging neovascularization in rag2E450fs (casper) zebraﬁsh engrafted with ﬂuorescently labelled melanoma and ERMS. (a) GFP-labelled,
amelanotic melanoma implanted into rag2E450fs (casper) ﬁsh (n¼ 8 animals) and imaged following intravascular injection of crimson quantum dots
(Qtracker 655). Whole animal images to the left and confocal images to the right ( 100 magniﬁcation, 100–200mm z-stack). Quantum dot ﬂuorescence
has been pseudo-coloured white. (b) GFP-labelled, amelanotic melanoma implanted into ﬂk1:mCherry; rag2E450fs (casper) transgenic zebraﬁsh (n¼4
animals). (c–d) GFP-labelled ERMS engrafted into ﬂk1:mCherry; rag2E450fs (casper) transgenic zebraﬁsh (n¼ 5 animals) and serially imaged over time (c, 13
d.p.t. and d, 21 d.p.t.). White arrowheads denote the site of intra-muscular injection of tumour cells. Scale bars equal 5mm in whole animal images and
200mm in confocal images.
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imaging neovascularization in solid tumours using the rag2E450fs
(casper) ﬁsh.
Imaging ERMS heterogeneity at single-cell resolution. We next
wanted to dynamically visualize tumour cell heterogeneity at
single-cell resolution using a transgenic model of kRASG12D-
driven ERMS25. We have previously created primary ERMS
in triple transgenic myf5:GFP; myogenin-H2b:mRFP;
mylpfa:lyn-cyan zebraﬁsh, which enables the labelling of
tumour cells based on differentiation status18. To achieve direct
imaging of heterogeneous tumour cell populations in
adult zebraﬁsh, we engrafted these ﬂuorescent transgenic
ERMS by intra-muscular injection into 3-month-old adult
ﬂk1:mCherry; rag2E450fs (casper) strain zebraﬁsh (4 105 cells in
2 ml per animal, Fig. 3a,b). Confocal microscopic imaging
revealed that GFP-labelled TPCs and AmCyan-labelled
differentiated cells were largely conﬁned to distinct regions of
the tumour ( 100 magniﬁcation, Fig. 3c, left panel), consistent
with previous reports18. Remarkably, the vasculature transects
areas of regional tumour cell heterogeneity. We have also
noted that in this particular case, juxtaposition of speciﬁc
ERMS cell subtypes near vascular beds was not observed.
Higher magniﬁcation imaging of areas enriched with
differentiated ERMS cells revealed the presence of myf5-GFPþ
TPCs, albeit at reduced numbers when compared with other
regions of the tumour ( 400 magniﬁcation, Fig. 3c, right panel).
Our data suggest that ERMS cells largely reside in regionally
deﬁned niches based on differentiation status and are not
anatomically conﬁned by proximity to vessels. The
combination of ﬂuorescent transgenic labelling of tumour cell
subpopulations and subsequent cell transplantation will be
important for deﬁning how niche topology is established and
ultimately inﬂuences continued tumour growth in ERMS and a
wide range of cancers.
Detailing emergence of clonal dominance in T-ALL. We next
wanted to use our model to dynamically visualize the functional
consequences of tumour cell heterogeneity and emergence of
clonal dominance in T-ALL. It is well known that human
leukaemias and myelomas are oligoclonal at diagnosis; however,
relapse is often driven by emergence of an underrepresented
clone contained within the primary malignancy31–35. We have
previously created Myc-induced T-ALLs that express a variety of
ﬂuorescent proteins and then used cell transplantation to create
T-ALLs derived from single leukaemia cells36. Using these
monoclonal T-ALLs, our experiments sought to dynamically
visualize how individual T-ALL clones grow when combined
together, testing the hypothesis that inherent functional
differences between cells drive the emergence of clonal
dominance.
First, we assessed the kinetics of leukaemia regrowth in clones
that exhibited wide differences in leukaemia-propagating cell
(LPC) frequency and latency. Speciﬁcally, we mixed equal
numbers of AmCyan, ZsYellow and DsRED-labelled cells isolated
from three independent T-ALLs (Supplementary Fig. 2a–c).
Following transplantation into the dorsal musculature (3.3 104
of each clone, 1.0 105 total cells per recipient animal), engrafted
ﬁsh were imaged by confocal microscopy at 14 and 25 d.p.t.
Consistent with our expectations, ZsYellow-labelled T-ALL cells
with the highest LPC frequency and fastest growth outcompeted
the other clones at each of the time points analysed, making up
48.7% of the leukaemia by 14 d.p.t. and 72.3% by 25 d.p.t.
(Supplementary Fig. 2d,e). These data suggest that clonal
dominance can result from inherent functional differences
between clones.
We next wanted to examine emergence of clonal dominance in
T-ALL that had similar LPC frequency and growth kinetics,
exploring the notion that clonal dominance may also emerge
stochastically in vivo. For example, Lgr5þ intestinal crypt stem
cells exhibit a pattern of neutral drift, ultimately resulting in
Donor
Recipient
flk1:mCherry;
rag2E450fs
(casper)
TPC
Diff.
flk1:mCherry; rag2E450fs
myogenin-H2b-mRFPmylpfa-lyn-cyanmyf5-GFP
Figure 3 | Resolving tumour cell heterogeneity in ERMS at single-cell resolution following engraftment into ﬂk1:mCherry; rag2E450fs (casper) zebraﬁsh.
(a) Epi-ﬂuorescent images of primary ERMS in a 32-day-old myf5:GFP; myogenin-H2b:mRFP; mylpfa:lyn-cyan triple transgenic zebraﬁsh. (b) Epi-ﬂuorescent
images of ﬂk1:mCherry; rag2E450fs (casper)-recipient ﬁsh engrafted intra-muscularly with ﬂuorescently labelled ERMS at 28 d.p.t. (n¼4 animals). (c)
Confocal image with mCherry-labelled vasculature outlined by white dashed lines (left,  100 magniﬁcation). Higher magniﬁcation of boxed region (right,
400 magniﬁcation). Myosin-expressing, differentiated cells (Diff.) and less frequent myf5-GFPþ tumour-propagating cell (TPC) denoted by arrowheads.
Scale bar equals 2mm in a, 5mm in b, 100mm (c, left panel) and 25mm (c, right panel).
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regional dominance of a single clone within each villus37. In the
cancer setting, elegant cell lineage tracing experiments have
conﬁrmed that clonal drift can impart regional dominance of
Lgr5þ intestinal crypt stem cells in mouse intestinal
adenomas38. To assess if clonal drift may also account for
dominance of T-ALL clones over time, T-ALL clones that had
similar growth rates and LPC frequencies were transplanted into
recipient rag2E450fs (casper) ﬁsh (3.3 104 of each clone, 1.0 105
total cells per recipient animal). Despite these leukaemias having
similar growth rates, latency and LPC frequencies (Fig. 4a–c), the
AmCyanþ clone was consistently outcompeted over time,
comprising only 9.8±6.4% of the leukaemia by 22–24 d.p.t.
(Fig. 4d,e). By contrast, the remaining leukemias contained both
mCherryþ and ZsYellowþ cells and in some instances
dominance of one clone prevailed (Fig. 4f, n¼ 16 animals). To
rule out the potential effects of ﬂuorescent labelling may have on
the proliferation of leukaemia cells, we repeated the same
experiment with another combination of AmCyan, ZsYellow
and mCherry T-ALL clones that also shared similar LPC
frequency and latency. Interestingly, with this combination, the
ZsYellow-labelled cells was reproducibly outcompeted by the
AmCyan- or mCherry-labelled cells, with dominance of these
latter clones being observed in animals over time (n¼ 13 animals
total, 2 independent experiments, Supplementary Fig. 3). We
conclude that clonal dominance can result from inherent genetic
and epigenetic differences between different tumour clones,
which was not revealed using traditional limiting dilution cell
transplantation approaches that only analyse the growth of
individual clonal populations of cells. Moreover, our experiments
provided additional evidence that neutral stochastic drift can
account for emergence of clonal dominance over time.
Tumour evolution and metastasis in melanoma. Metastasis is a
major clinical challenge for those diagnosed with melanoma and
is associated with poor prognosis39,40. Not all cancer cells can
enter the circulation and seed new areas of tumour growth,
suggesting that heterogeneity and continued clonal evolution
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Figure 4 | Visualizing the emergence of clonal dominance in Myc-induced T-ALL. (a) Donor animals engrafted with monoclonal T-ALL arising in the CG1
background. (b,c) Monoclonal T-ALLs were implanted into the syngeneic CG1 strain ﬁsh and assessed for LPC frequency by limiting dilution cell
transplantation (b) or latency of regrowth (c). P-values are noted within each panel. Not signiﬁcant (NS). (d,e) Confocal imaging of engrafted rag2E450fs
(casper) ﬁsh at 10 d.p.t. (d) and 23 d.p.t. (e). White arrow denotes site of injection, and the location for confocal imaging. (f) Relative proportions of each
ﬂuorescent clone contained within leukaemias from individual engrafted animals (n¼ 16 animals). Imaging was completed on the same animals at 10–13
d.p.t. and 22–24 d.p.t. The ZsYellowþ clone dominates leukaemia regrowth in animals #1–3, whereas mCherryþ dominates in animals #13–16. Scale bars
equal 5mm in whole animal images and 50mm in confocal images.
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likely drive metastasis in a large subset of cancers41. Yet, to date,
zebraﬁsh models of bona ﬁde metastatic progression have not
been fully described. To recapitulate metastasis in adult zebraﬁsh,
we ﬁrst transplanted melanoma cells retro-orbitally into the
recipient rag2E450fs (casper) ﬁsh. Robust engraftment was
observed at the site of injection, followed by local inﬁltration
into structures adjacent the gill, head kidney and kidney marrow
(Fig. 5a,b). Yet, with a stringent deﬁnition of metastasis, we could
not document a single case where metastasis originated from
haematogenous spread or was delineated by growth clearly
separated from the primary site.
To further reﬁne methods to assess metastatic spread, we next
injected GFP-labelled, BRAFV600E, tp53 / melanoma cells into
the dorsal musculature of rag2E450fs (casper) zebraﬁsh, reasoning
that inﬁltration into muscle would be clearly distinguished
from seeding of distant sites within the visceral organs. Using
this approach, three out of six primary melanomas metastasized
to structures near the thymus and head musculature that
were clearly distinct from the primary lesion (Fig. 5c and
Supplementary Table 2). In total, 8 of 58 engrafted animals
harboured distant metastasis by 30 d.p.t. (Supplementary
Table 2). Metastatic growth was easily quantiﬁed over time
following serial imaging of the same animal (Fig. 5d). GFPþ
metastatic lesions were independently conﬁrmed by
histo-pathological analysis for morphology, pigmentation and
anti-GFP immunostaining on section (Fig. 5e). Using similar
approaches, we have also dynamically visualized metastatic
tumour growth in neuroblastoma and ERMS (Supplementary
Fig. 4), suggesting this approach will likely be broadly useful for
assessing the kinetics of metastatic colonization and growth in a
wide range of solid tumours.
We next wanted to assess how metastatic potential may change
in the same tumour over time and whether serial passaging of
individual melanomas could result in phenotypic changes,
including increased aggression, invasion and acquisition of
metastatic characteristics. Speciﬁcally, two non-metastatic
BRAFV600E, p53 / melanomas at the 1 passage were
implanted into the dorsal musculature of rag2E450fs (casper)
zebraﬁsh and animals assessed for local engraftment, invasion
and metastatic growth following serial passaging. Sectioning and
microscopic analysis conﬁrmed that early passaged melanomas
were not metastatic and tumours were conﬁned to the site of
injection (Fig. 6a and Supplementary Fig. 5a). Following serial
passaging, one melanoma continued to resemble the parental
tumour and did not change its growth rate or metastatic potential
(8 passages, total 191 days in vivo, Supplementary Fig. 5b,c).
By contrast, the second melanoma lost pigmentation, had
signiﬁcantly accelerated growth and harboured metastatic lesions
(7 passages, total 134 days in vivo, Fig. 6b,c). With this particular
tumour, GFPþ lesions were found to have metastasized to the
mesonephric trunk kidney by 6 d.p.t., which eventually spread to
the regions adjacent to the thymus and head kidney by 12 d.p.t.
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Figure 5 | Visualizing melanoma invasion and metastasis following engraftment into rag2E450fs (casper) mutant ﬁsh. (a) Invasion assays using retro-
orbital transplantation of a BRAFV600E, tp53 / pigmented melanoma. White arrow denotes the site of injection. Green arrow denotes spread to the
kidney marrow that is contiguous with primary tumour growth that has arisen adjacent to the eye. Histological examination conﬁrmed the presence of
pigmented melanoma cells at the site of injection (b, left panels) and contiguous with the trunk kidney (b, right panels). (c) Metastasis assays using
implantation of non-pigmented, GFP-labelled melanoma cells into the dorsal musculature of rag2E450fs (casper)-recipient ﬁsh. White arrow denotes the site
of injection. Yellow arrow denotes site of distal metastasis. (d) Quantiﬁcation of metastatic growth as assessed by epi-ﬂuorescence microscopy over time.
(e) Haematoxylin and eosin-stained sections of the same animal imaged in c, conﬁrming metastatic growth of melanoma adjacent to the thymus (top
panels) and conﬁrmed by anti-GFP immunostaining on section (bottom panels). Scale bars equal 5mm for whole animal images, 2mm in images of heads,
1mm in 40 histological images; 300 mm in  100 histological images and 100mm in 400 histological images.
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(n¼ 4 of 4, P¼ 0.003, two-tailed Fisher’s exact test). Confocal
imaging revealed seeding of GFP-labelled cells to distal sites
within the tail of the recipient ﬁsh, suggesting the formation of
micro-metastatic lesions adjacent to ﬂk1:mCherry-labelled
vasculature (n¼ 2, Fig. 6d). Our experiments conﬁrm that not
all melanoma cells have metastatic capacity and that evolution of
metastatic potential occurs in melanoma, consistent with that
have been reported for human melanoma42,43. In total, our model
provides a dynamic imaging platform to visualize the tropism of
metastasis.
Discussion
Imaging cancer cell heterogeneity and the hallmarks of cancer in
live animals has been a challenge. Many investigators have
developed imaging modalities and complex surgical approaches
in rodent models to gain optical access to developing tumours.
These approaches often require implantation of imaging
windows for repeated high-resolution IVM10,11. Using these
experimental platforms, investigators have successfully
imaged several hallmarks of cancer, including migration44,
intravasation45, extravasation46, invasion47 and metastasis12,14,
as well as responses to chemotherapies in vivo48. In hope of
bypassing the need for surgical intervention and overcoming the
limitation of visualizing cancer cells only within predetermined
imaging windows, we engrafted ﬂuorescently labelled cancers into
optically clear immune-compromised zebraﬁsh and directly
imaged tumours using confocal microscopy. Engraftment of
ﬂuorescent cancers into the rag2E450fs (casper) zebraﬁsh has
facilitated the direct visualization of single cancer cells, functional
differences between tumour cell clones and several hallmarks of
cancer including acquisition of elevated growth potential,
development of new vascular networks and acquired cell
motility leading to invasion and metastasis.
The functional consequences of tumour cell heterogeneity have
only recently begun to be explored using IVM, and a number of
interesting and unexpected tumour cell behaviours have been
revealed. For example, our group has utilized ﬂuorescent
transgenic approaches to label ERMS cells based on muscle
differentiation status18. Our experiments uncovered that
differentiated ERMS cells seed new areas of growth, followed
later by slow-moving, less-differentiated myf5þ TPCs,
challenging the notion that cancer stem cells drive invasion and
metastasis. Imaging approaches have not been limited to analysis
of primary tumours. Rather, Chapman et al. have used xenograft
cell transplantation of human melanoma cells into larval zebraﬁsh
to assess the effects of intra-tumoral heterogeneity on growth49.
They found that tumours with high invasive capacity could
impart migratory potential to poorly invasive cell types.
Moreover, the poorly invasive cells could also enhance
colonization by aggressive melanomas when co-implanted into
larval ﬁsh, suggesting cell–cell cross-talk and collaborative
signalling networks can enhance migratory and invasive
behaviour between melanoma subclones. Using differential
labelling of human melanoma cells with GFP and mCherry,
these authors were able to dynamically image these processes in
live engrafted ﬁsh. Here, we performed proof-of-concept
experiments to assess the utility of rag2E450fs (casper) zebraﬁsh
for visualizing engraftment of heterogeneous ERMS cells in live
animals. For example, we directly visualized niche partitioning
based on differentiation status using ﬂuorescently labelled ERMS
cells. These niches are not anatomically conﬁned by proximity to
vessels, in contrast to what has been observed in osteosarcoma50
and brain tumours13,51 where cancer stem cells lie in unique
niches adjacent vessels. Furthermore, cell transplantation into
orthotopic sites in the rag2E450fs (casper) zebraﬁsh permitted
imaging of cells at single-cell resolution in live animals. We
envision that similar strategies will likely aid in assessing stromal
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cell contributions to tumour growth. In total, our cell
transplantation and imaging approaches will likely facilitate
efforts in deﬁning how niche topology is established and
ultimately inﬂuences continued tumour growth.
Evidence for continued clonal evolution and selection follow-
ing treatment has now been seen in a wide range of human
cancers. For example, human leukaemias and myelomas are
oligoclonal at diagnosis; however, relapse is commonly driven by
an underrepresented clone contained within the primary
malignancy31–35. Similar dynamics of heterogeneity has also
been observed in solid tumours. For example, triple-negative
breast cancers are comprised of heterogeneous clones that
harbour a wide spectrum of mutations that can change from
the time of diagnosis to relapse52,53. Altering frequencies of
speciﬁc clones have also been observed during tumour
progression in pancreatic cancer54,55 and brain tumours56.
Elegant cell lineage tracing experiments in mice have shown
experimentally that stochastic clonal drift can contribute to
regional dominance of Lgr5þ intestinal crypt stem cells in
mouse intestinal adenomas38; yet it is unclear if this pattern
applies to a wider array of cancer subtypes. Here, we have
experimentally recreated tumour cell heterogeneity by implanting
equal numbers of ﬂuorescently labelled T-ALL clones into the
rag2E450fs (casper) zebraﬁsh. By competing these T-ALL clones
together, we ﬁnd that one clone was consistently outcompeted
over time despite having equal self-renewal potential and overall
growth kinetics. Our data suggest that subtle functional variations
can exist within clones that may not be uncovered using
traditional cell transplantation assays that assess tumour
regrowth of only single clones, likely underestimating
differences in latency and LPC frequency. Alternatively, these
data may suggest that clones actively suppress the growth of other
clones and/or secrete factors to enhance growth of only related
cells. This interpretation is consistent with recent ﬁndings in
breast cancer where paracrine factor signalling from one clone
can alter growth of unrelated clones within the tumour57. Taken
together, these in vivo competition experiments have uncovered
interesting and potentially new biology that could not have been
discovered using traditional limiting dilution cell transplantation
approaches, facilitating the dynamic emergence of clonal
dominance within the same animal overtime.
Metastasis can be experimentally assessed in mouse models by
engrafting tumour cells into the vasculature and then identifying
metastatic lesions at necropsy. Alternatively, luciferase biolumi-
nescent imaging and non-invasive, whole-body imaging methods
have also been developed, including computed X-Ray tomogra-
phy, positron emission tomography and magnetic resonance
imaging. These imaging modalities are limited to detection of
tumours that are 200mm in diameter, expensive and largely
inaccessible to many laboratories58–60. Here, we have optimized
cell transplantation into adult, immune-deﬁcient rag2E450fs
(casper) zebraﬁsh in order to dynamically visualize tumour cell
migration, invasion and metastasis at high resolution. We
performed cell transplantation of ﬂuorescently labelled zebraﬁsh
tumour into the optic vessels and dorsal musculature, establishing
that metastatic progression is best assessed following injection
into the dorsal musculature. Furthermore, we have been able to
visualize the dissemination of micro-metastatic lesions to sites
adjacent to the tail vasculature in ﬂk1:mCherry; rag2E450fs (casper)
zebraﬁsh using simple confocal imaging. Finally, using serial
transplantation, we were able to evolve melanomas with high
metastatic potential, providing a novel platform for identifying
driver mutations that are speciﬁcally correlated with progression.
We envision that facile genetic approaches including transgenesis
and genetic knock-out using CRISPR/Cas9 will quickly make
zebraﬁsh the choice experimental model for assessing gene
pathways that modulate tumour progression and metastasis,
especially in the transplantation setting.
Methods
Creation of rag2E450fs (casper) homozygous mutant zebraﬁsh. Zebraﬁsh stu-
dies were approved by the Massachusetts General Hospital Subcommittee on
Research Animal Care (protocol #2011N000127).
rag2E450fs (casper) homozygous mutant zebraﬁsh were created by crossing
rag2E450fs (rag2fb101) mutant ﬁsh into the casper background19. Animals were
maintained as rag2E450fs/þ ; roy / ; mitfa / lines and in-crossed to generate
triple mutant animals. Resulting progeny were ﬁn clipped and genotyped using the
same method as we previously published22. Speciﬁcally, genomic DNA was
extracted using the Hotshot method described by Meeker et al.61, and subjected to
PCR using forward primer 50-ACTGCTCTAGTTGCAATTCCT-30 and reverse
primer 50-AGCTGGGGTCATCTTCAGT-30 . PCR was completed using 94 C
denaturation for 30 s, 54 C annealing for 30 s and 68 C elongation for 45 s
(35 cycles). PCR-ampliﬁed products were then incubated at 37 C overnight with
XcmI, which created a single cut in the mutant allele. Finally, DNA products were
resolved either on a 2% agarose gel or using the Qiaxcel genotyping system. For
neovascularization studies, ﬂk1:mCherry transgenic ﬁsh62 were crossed with
rag2E450fs (casper) ﬁsh and in-crossed to create compound mutant animals.
Tumour creation and cell transplantation into zebraﬁsh. Primary and serially
passaged tumours were derived from established transgenic zebraﬁsh models. For
example, T-ALLs were created by co-microinjection of linearized rag2:cMyc and
ﬂuorescent transgenic reporters into one-cell stage CG1 ﬁsh36,63 (Figs 1 and 4 and
Supplementary Figs 1–3). GFP-labelled ERMS were created by co-microinjection of
linearized rag2:kRASG12D and rag2:GFP transgenes into one-cell stage CG1 ﬁsh64
(Fig. 2); double-ﬂuorescent ERMS were created by microinjection of linearized
rag2:kRASG12D into one-cell-stage stable transgenic myf5:GFP; mylpfa:mCherry
CG1 ﬁsh18 (Fig. 1 and Supplementary Fig. 4). Triple-ﬂuorescent transgenic ERMSs
were created by microinjecting the linearized rag2:kRASG12D transgene into
one-cell stage stable transgenic myf5:GFP; myogenin-H2b:mRFP; mylpfa:lyn-cyan
zebraﬁsh in the AB background (Fig. 3). Melanomas were created by
overexpression of MiniCoopR-EGFP in the embryos of Tg (mitfa:BRAFV600E);
mitfa / ; tp53 / or Tg (mitfa:BRAFV600E); mitfa / ; tp53 / ; alb /
zebraﬁsh27 (Figs 1,2,5 and 6 and Supplementary Fig. 5), and were a kind gift from
the Houvras laboratory. The ofﬁcial ZFIN designation for the tp53 / zebraﬁsh
line is zdf1M214K, originally reported by Berghmans et al.65. Neuroblastomas were a
kind gift from the Look laboratory24.
Cell transplantation experiments utilized both male and female rag2E450fs
(casper) homozygous mutant zebraﬁsh. Recipient animals were transplanted at 2–4
months of age. Tumour cell transplantations were completed by intra-peritoneal,
intra-muscular and retro-orbital injections66–68. Intra-muscular and retro-orbital
injections were completed using microinjection of 2–3ml of cell suspension.
Recipient ﬁsh were scored for tumour engraftment, growth, invasion or metastasis
by epi-ﬂuorescent microscopy every 3–4 days until 30 d.p.t. or when animals were
moribund.
Confocal imaging of neovascularization and micro-metastasis. rag2E450fs
(casper) animals were engrafted with GFP-labelled ERMS or melanoma. To
visualize tumour vasculature, animals were injected with Quantum dot 655 reagent
(Qtracker 655, 405–615 nm excitation, 655 nm emission, 2.0 mM, Life Technologies
Cat# Q21021MP). Speciﬁcally, animals were injected with freshly prepared 1:3
diluted reagent (1 volume Qtracker 655 solution diluted in 2 volumes of 0.9x PBS,
yielding a ﬁnal concentration of 0.66 mM) using a 26s gauge Hamilton syringe
(4 ml injected intra-peritoneally, and 2 ml directly into the dorsal aorta). After
30min, animals were anaesthetized using 168mg l 1 Tricaine (MS-222, pH¼ 7.5)
and placed onto a 12.0-mm glass bottom imaging plate (Thermo Scientiﬁc, Cat#
150680). Under anaesthesia, motor functions of the animal were greatly reduced
and operculum movements were signiﬁcantly slowed. Each animal was imaged
under anaesthesia for 1–2min, allowing enough time for z-stack imaging or
multi-position single plane imaging using confocal microscopy. To ensure optimal
survival of the adult zebraﬁsh being imaged, anaesthetized animals were simply laid
down on the side in the imaging dish, with the tumour facing towards the lens. No
agarose embedding of the sample was used. Imaging was completed using an
inverted Zeiss LSM 710 confocal microscope. For neovascularization (Fig. 2) and
micro-metastasis imaging (Fig. 6d), z-stack imaging at  100 magniﬁcation was
achieved with a  10 objective (numerical aperture¼ 0.45, coverglass
thickness¼ 0.17mm, working distance¼ 2.0mm). Image series were acquired in
the ZEN software (single pass point scanning atB10mm per step over 100–200mm
distances). Fluorescent imaging was completed using the following settings: GFP:
excitation¼ 488 nm, emission¼ 503–528 nm; mCherry/mRFP: excitation¼ 561
nm, emission¼ 602–624 nm; Qtracker 655: use AlexaFlour647 setting,
excitation¼ 633 nm, emission¼ 638–755 nm. Laser intensity percentages were set
to be between 10 and 20% depending on the brightness of the ﬂuorescent labels
used. The ‘Best Signal’ option in the ‘Smart Setup’ was used for easy modulation of
the gating of each colour. For imaging ﬂuorescent combinations, gate settings were
manually adjusted to avoid overlap of ﬂuorescent signals. For z-stack images,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10358
8 NATURE COMMUNICATIONS | 7:10358 | DOI: 10.1038/ncomms10358 | www.nature.com/naturecommunications
planes were merged based on maximum intensity in Fiji (ImageJ). After imaging,
ﬁsh were immediately transferred into recovery tanks that contained fresh system
water, and later returned to the facility.
Confocal imaging of heterogeneity in ERMS and T-ALL. Multi-colour confocal
ﬂuorescence imaging was completed in both ERMS and T-ALL. Speciﬁcally, in
ERMS (Fig. 3) and T-ALL (Fig. 4 and Supplementary Figs 2,3), we simultaneously
imaged using three-colour combinations including AmCyan (excitation¼ 458 nm,
emission¼ 472–508 nm), GFP (excitation¼ 488 nm, emission¼ 493–586 nm),
ZsYellow (excitation¼ 514 nm, emission¼ 521–547 nm), DsRED (excitation¼
561 nm, emission¼ 575–703 nm) and mCherry/mRFP (excitation¼ 561 nm,
emission¼ 602–623 nm). Laser intensity percentages were set to be 18%. For
imaging at single-cell resolution,  400 magniﬁcation was achieved with a  40
water emersion objective (NA¼ 1.3, coverglass thickness¼ 0.14–0.19mm, working
distance¼ 0.62mm for 0.17mm coverglass). The ‘Best Signal’ option in the ‘Smart
Setup’ was used for easy modulation of the gating of each colour. For T-ALL,
proportions of each clone were quantiﬁed in the Fiji (ImageJ) software by measure
of area covered by each ﬂuorescent colour (Fig. 4 and Supplementary Fig. 2,3f), or
manual cell counts (Supplementary Fig. 3g). Both quantiﬁcation methods produce
consistently similar results.
Histological examination. Tumour histology was performed on animals as
previously described22. Brieﬂy, animals were ﬁxed in 4% paraformaldehyde,
embedded in parafﬁn and step sectioned. Adjacent slides were stained with
haematoxylin and eosin or anti-GFP (Living Colors Monoclonal Antibody JL-8,
Clontech, 1:1,000 dilution).
Statistical methods. Leukaemia propagating cell frequencies were calculated
using the extreme limiting dilution analysis software (http://bioinf.wehi.edu.au/
software/elda/). Differences in the LPC frequency were reported with a 95%
conﬁdence interval. Differences of latency were assessed by log-rank (Mantel-Cox)
tests (Fig. 4 and Supplementary Figs 2,3). In the melanoma evolution experiments
(Fig. 6), increased metastatic potential was assessed by Fisher’s exact test,
comparing the number of animals with metastatic disease at 1 transplant with
those found after 7 transplant.
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